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Abstract
The peptide complexed with human leukocyte antigen (HLA) can be said to have a 
significant role in the generation of alloresponses, both in terms of cellular and 
humoral alloresponses. Previous researchers have identified minor histocompatibility 
antigen (mHAG) derived peptides such as HA-1, and their contribution to 
alloresponses. However, little  research has been performed regarding the contribution 
of peptides, which are themselves derived from HLA molecules. To redress this, this 
thesis focused upon identifying and assessing the function of endogenous peptides, in 
particular peptides which are themselves derived from HLA class I molecules, which 
may have a role in the alloresponses, within the context of clinical transplantation.
This research describes the creation of a database of HLA class I derived peptides 
predicted to bind to HLA-A*02 molecules, and then utilises this database to identify 
HLA class I derived peptides which are bound by the HLA-A*02 molecule, present upon 
the surface of the monocytic THP-1 cell line. This process identified two peptides, 
which were derived from one HLA class I molecule and presented by another (HLA- 
A*02). One of the identified peptides (VMAPRTLIL) belongs to a group of peptides, 
known as leader peptides, which have functions in both innate and adaptive immune 
responses. A clinical audit was performed to assess the effect of mismatching the HLA 
class I derived leader peptides within the context o f renal transplantation and 
identified a correlation with a poorer functioning allograft at 12 months post 
transplant, when the donor and recipient have 3 leader peptide mismatches (p=<0.05).
Further experimental work attempted to determine a functional role of the 
endogenous peptides. In particular seeking to establish if variation w ithin peptides 
bound by the same HLA molecule can influence the subsequent binding of HLA specific 
antibodies, and if so, seek to elucidate the mechanisms involved. Using a T2 cell line 
peptide binding assay, as a target for a HLA-A*02 specific antibody, a variation 
between the ability of the antibody to bind when alternative peptides were bound was 
observed. Through the use of structural modelling it was demonstrated that changes 
within HLA class I bound peptides can induce conformational changes to  epitopes,
which were previously described for HLA class I molecules as being the targets of HLA 
class I specific antibodies.
These findings suggest an important role for HLA class I derived leader peptides in the 
outcome of renal transplantation, which requires further study w ithin a validating 
cohort of patients. While the observation that peptides can induce conformational 
variation w ithin identified epitopes provides further insight into the complex nature of 
alloantibody binding, and aides the understanding o f this process.
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1.1.1 Organ Transplantation
The use of organ transplantation as a clinical therapy in modern medicine is the result 
of many successive advances within multiple disciplines including: advances in the 
available pharmacology, improved surgical and intensive care techniques, greater 
success in tissue preservation and a vital understanding of the immunology of 
transplantation. These advances have led to the ability to transplant an ever increasing 
range of complex organs and tissues into patients for their life saving function (for 
example in the cases of cardiothoracic, renal and liver transplantation) and the quality 
of life that is associated with successful transplantation (Neipp et a i,  2006).
Perhaps the first documented attempt at organ transplantation is depicted in the 
works of renaissance painters, who portrayed the patron saints of surgery, Cosmos and 
Damian, performing a transplant in the 3rd century (Figure 1.1). However without these 
saintly powers it would be many centuries before transplantation became a reality; 
indeed many early attempts at organ transplantation resulted in failure either 
immediately or shortly after transplantation. Consequently the modern era of 
transplantation can be argued to have begun in the 1950s with the success of renal 
allografts, which survived for longer than 6 months (Murray et a i,  1962). These were 
quickly followed by successful heart transplantation (Barnard, 1968) and orthotopic 
liver transplantation (Starzl eta l., 1968).
Understanding the immunology of transplantation was crucial to these successes, and
improvements to this understanding have helped lead to the remarkable success of
modern transplantation. The father of transplant immunology and founder of the
British Transplant Society, Sir Peter Medawar, first demonstrated allograft rejection as
having an immune cause using skin grafts in animal models (Figure 1.2) (Medawar,
1945) and created the start of a new field of science, which would ultimately become
known as histocompatibility and immunogenetics. Medawar's experiments
demonstrated that rejection of skin grafts on animal models were T cell mediated, had
immunological memory and could be transferred from one animal to another.
Medawar was unaware at the time of his experimentation that the phenomenon he
was witnessing was a response primarily directed against mismatched Major
Histocompatibility Complex (MHC) encoded antigens. Further work into
histocompatibility and immunogenetics over the decades following Medawar's work
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Figure 1.1 Twins Cosmos and Damian perform a miraculous leg transplantation in the 
3rd century.
As depicted by an artist in the 1500s. Image reproduced for research purposes 
courtesy o f the Wellcome Image Library.
3
A) Syngeneic skin graft, is tolerated
B) An allogeneic skin graft is rejected 
within 10-13 days. Medawar 
termed this a 1st response. A 
second allograft using the same 
murine model as B) results in 
rejection in 6-8 days, the kinetics 
referred to as a 2nd set response
C) The T lymphocytes were 
removed from the murine model 
displaying 2nd set kinetics D) and 
then innoculated into a different 
mouse (E)
D) T cells transferred
from yellow to green mouse
E) A skin graft from the 1st mouse 
(Grey), is now rejected with the 
second set kinetics (6-8 days) in a 
naive mouse (Green) after its 
innoculation with the T cells, i.e . 
the response kinetics were 
transferred with the T cells
Figure 1.2, An overview of the experiments performed by Medawar
(Adapted from Janeway, CA. Travers, P. Walport, M. (1999) Immunobiology, 4th 
Edition, Churchill Livingston, Edinburgh, p510)
4
revealed the complex nature of the genes and proteins which govern rejection 
reactions and have led to a greater understanding of immunology as a whole.
1.1.2 A basic overview o f the immune system
This increased understanding of immunology has led to the current view of the 
immune system as a complex network of organs, tissues, cells and subsets of cells, 
which function and cooperate together in the defence of the organism against foreign 
invasion, most usually in the form of attack from pathogenic bacteria and viruses. The 
organs of the immune system, referred to as lymphoid organs as they are host to 
lymphocytes, include the tonsils, adenoids, lymph nodes, thymus, spleen, Peyer's 
patches, appendix and the bone marrow. Lymphatic and blood vessels facilitate 
migration of cells around the body and between these lymphoid organs. Lymphoid 
organs have specialised roles, the bone marrow for example is the ultimate source of 
all blood cells, including lymphocytes. B lymphocytes mature within the bone marrow  
and once activated they develop into plasma cells and secrete antibody which provides 
an effective response against pathogens, while T lymphocytes migrate from the bone 
marrow to the thymus for further development and can provide a variety of functions 
from direct cellular cytotoxicity of infected cells and pathogens to aiding B 
lymphocytes and their responses (Paul, 2013).
Fluid is exchanged between the blood and lymphatic vessels enabling the lymphocytes 
to encounter any invading pathogens. In addition the lymph nodes, which are located 
throughout the body (specifically clusters of lymph nodes are present in the neck, 
armpits, abdomen and groin), enable the lymphocytes to encounter antigen.
Containing specialized anatomical structures, the lymph nodes concentrate T cells in 
the paracortex to facilitate their encounter with antigen, allow the formation of B cell 
germinal centres and aid the production of humoral responses by the formation of 
plasma cells within the medulla. The regions within the body which facilitate the 
encounter of lymphocytes, and indeed other immune cells with antigen, are too 
numerous to list as they can be said to consist of areas which act as gateways to the 
body, such as the linings of the gastrointestinal tract (Paul, 2013). However a crucial 
element of a competent immune system is the ability to differentiate between self and
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non self, in order to generate an appropriate response. It is this ability which is most 
pertinent to the setting of organ transplantation.
1.1.3 Histocompatibility and Immunogenetics
In order to distinguish between self and non-self, immune cells recognise antigens via 
specialised receptors, such as the pattern recognition receptors of the innate immune 
system or the B and T cell receptors of the adaptive immune system. In 
transplantation, in which cells, tissues or organs are transferred from one individual to 
another, recognition of non-self antigens from the transplanted material can occur, 
which can lead to damage and/or rejection of the transplant. As Medawar 
demonstrated this is best avoided by use of a syngeneic transplant (i.e. between a 
genetically identical donor and recipient), such as in the case of monozygotic twins, 
thus allowing 'self-recognition' of the transplant due to the expression of the same 
antigens, and therefore allowing histocompatibility (Afzali et ah, 2007). However as 
most individuals do not have a genetically identical twin this is rarely an option in 
clinical transplantation, and an allograft is performed (the transplant of genetically 
different material from an individual of the same species). An immune response 
against the differing antigens on the allograft can be formed, as a consequence of its 
lack of histocompatibility (Afzali et a l, 2007).
The genes expressing the antigens of the greatest significance in histocompatibility are 
encoded for on the short arm of chromosome 6, specifically 6p21.3, in a region known 
as the Major Histocompatibility Complex (MHC). In man, within the MHC it is the genes 
which encode the Human Leukocyte Antigens (HLA) which have the greatest impact in 
transplantation (Howell e ta lw 2010).
1.1.4 The Major Histocompatibility Complex
Our current understanding of the MHC has been pieced together from observations 
spanning several decades (Thorsby, 2009). The Nobel prize for Physiology or Medicine 
in 1980 being awarded to Benacerraf, Dausset and Snell for discovering the MHC. In 
the 1940s, Snell first discovered components of the MHC through their role in 
transplant rejection in murine models. This knowledge was added to in the 1950s as 
Dausset identified the first HLA molecules after observing immune reactions following 
blood transfusions between ABO compatible individuals and establishing the cause as
being white blood cell agglutination, this agglutination was a result of HLA specific 
antibodies, while Benacerraf provided the evidence that immune reactions are 
controlled by genes. Working alongside these three pioneers, were a host of other 
investigators who also identified HLA molecules. Through international collaborative 
efforts, facilitated by a series of International Histocompatibility Workshops (IHWS), 
these researchers exchanged sera and cells and identified that several locally identified 
HLA were identical (Thorsby, 2009). The sera used by these researchers to identify HLA 
molecules was obtained from multiparous women, whose immune system was 
exposed to the HLA molecules of their partners during their pregnancies, consequently 
their sera contained HLA antibodies, which were formed against the different HLA 
molecules of the foetus, which were paternally inherited. Through careful population 
and familial studies these investigators went on to establish different loci encoding the 
identified HLA. Leaping forward to present day, modern molecular biology techniques 
have revealed the exquisite polymorphism of HLA molecules and the complexity of the 
MHC. At the time of writing there are 8,794 HLA alleles identified on the IMGT/HLA 
sequence database (Robinson et ol., 2013), the nomenclature system for which is 
governed by the World Health Organisation (WHO) nomenclature committee and the 
MHC itself contains some 224 genes (Figure 1.3).
1.1.5 The diversity of the M ajor Histocompatibility Compiex
The remarkable polymorphism of the MHC has been revealed due to its significance in 
infection, autoimmunity and transplantation, which has led the MHC to be the most 
widely studied region of the human genome (Horton eta l., 2004). The primary 
function of the genes within the MHC is to confer protection from pathogens. It 
incorporates many of the genes which have a role in the processing and presentation 
of antigen, such as the transporter associated with antigen processing (TAP) genes, 
which are required for transporting peptides from the cytosol into the endoplasmic 
reticulum (ER) (Cresswell et a l, 1999), as well as the HLA genes.
HLA molecules are membrane bound heterodimer glycoproteins which bind, and then 
present, peptides to T lymphocytes (T cells). HLA Class I molecules, HLA-A, B and C, are 
expressed on almost all nucleated cells (as well as platelets) and present intracellular
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processed peptides (e.g. of viral origin) to cytotoxic CD8+T cells (Long and Jacobson 
1989). HLA class II molecules, HLA-DR, DQand DP, have a more restricted distribution, 
being expressed on cells of the monocyte/macrophage lineage, B cells and activated T 
cells. HLA Class II molecules can also be induced by the cytokine interferon-y (IFN- y) 
on some cell types, such as endothelial cells. HLA Class II molecules present 
extracellular derived peptides (e.g. bacterial peptides) to T helper CD4+ cells (Howell et 
a l, 2010).
The peptides bound by HLA molecules possess a set of anchor residues which fit 
specifically into pockets within the HLA molecule's binding groove (discussed in further 
detail later), this confers a specific set of characteristics upon the peptides bound by 
HLA molecules. These characteristics have been suggested as one of the key driving 
forces behind the extensive polymorphism of HLA molecules. Specifically referred to as 
the heterozygote advantage theory, which proposes that individuals who are 
heterozygous for HLA molecules, are able to respond to a greater number of pathogen 
derived peptides than homozygotes, due to their ability to present a greater range of 
peptides, as a consequence of the variation in the peptide binding characteristics of 
their greater range of HLA molecules (Spurgin and Richardson, 2010). Additionally 
another advantage can be seen in rare HLA alleles, whereby it is argued that the 
ongoing immune-evasion strategies of pathogens leads them to overcome the peptide 
presentation of the most common HLA molecules, therefore new HLA alleles which 
arise are able to provide a greater protection than common alleles, therefore offering 
a survival advantage (Spurgin and Richardson, 2010). Another interesting feature 
regarding the nature of MHC diversity can be observed within these common alleles, 
as some HLA haplotypes are seen with a far greater frequency than others. Indeed 
linkage disequilibrium, which refers to the characteristic of certain genes to be 
inherited together due their proximity to each other upon the chromosome, means 
that certain common haplotypes are observed in far higher frequencies than they 
would be if haplotypes were the consequence of a random formation. Furthermore 
the phenomenon of a founder effect can be observed within some HLA haplotypes. 
Whereby some genetic variation is lost when a sub population is established from a
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larger population by a limited number of individuals, this is seen within patients 
suffering from haemachromatosis (HFE), an iron overload disorder. The carrier of the 
original mutation on the HFE gene was believed to be of Celtic or Viking origin, and 
possessed the HLA haplotype HLA-A3; B7 or A3; B14. Although recombination events 
have led to new haplotypes which include the HLA-A3 molecule, linkage disequilibrium 
between HLA-A3 and the mutated HFE gene means a strong association between these 
two genes is still seen today (Olsson et al. 2009).
1.1.6 The association of transplant outcome and HLA
The significant effect of HLA upon outcome of transplant can be observed by looking at 
the survival of allografts in relation to HLA matching between donor and recipient 
pairs, as shown for kidney transplants (Figure 1.4). Non HLA genes within the MHC 
have also been linked to transplant outcome, including major histocompatibility 
complex related chain A (MICA) (Sanchez-Zapardiel etal., 2013) and B (MICB) (Hankey 
et al., 2002) and tumour necrosis factor (TNF) gene polymorphisms (Sahoo et al., 2000) 
amongst others.
The significance of HLA matching on transplant outcome is not uniform across all 
transplanted tissues, the effect of mismatches being profound in haematopoietic stem 
cell transplantation (HSCT), and less so in liver transplantation. The expression and 
distribution of the HLA antigens influences this effect, as well as various other factors 
such as the risk of graft versus host disease (GvHD) in HSCT and type and dose of 
immunosuppression utilised. To understand the mechanism by which HLA matching 
influences the outcome of allotransplantation, it is essential to understand how the 
immune system is able to distinguish between self and non-self and in particular the 
role which HLA plays within this process.
1.1.7 The role of HLA in distinguishing between self and non-self
The interaction of the T cell receptor (TCR) on CD4+ and CD8+T cells with peptide 
complexed HLA (pHLA), is central to the discrimination of self and non-self antigens in 
triggering adaptive immune responses (Huang etal., 2010; Zingernagal eta l., 1974). 
The ability of the TCR to recognise a pHLA as foreign or self is achieved via a process of 
positive and negative T cell selection of appropriately armed T cells in the thymus, as 
described in detail by
10
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Ziegler eta l., (2009). This process, referred to as central tolerance, allows the 
destruction of self-reactive T cells while retaining those T cells with appropriate 
peptide complexed HLA (pHLA) discrimination capabilities (Edelmann et al., 2011).
1.1.8 T cell development within the thymus
The presence of pHLA is thought to be crucial in the establishment of this central 
tolerance. Briefly, T cell education occurs within the thymus, pHLA is expressed upon 
cortical thymic epithelial cells (cTEC), if the TCR of the developing T cell does not 
recognise a pHLA on cTEC, or if the TCR reacts with high affinity to these pHLA 
molecules, then the T cells do not survive positive selection. If the TCR interacts with 
the pHLA with a low affinity then the T cell survives positive selection as self restricted 
(i.e. it recognises self pHLA with low affinity), but has the potential for self reactivity. 
These positively selected cells then migrate within the thymus via the cortico- 
medullary junction and into the medulla, where they interact with the medulla thymic 
epithelial cells (mTEC), where negative selection occurs. This mechanism involves the 
deletion of T cells whose TCR reactivity to self antigens is greater than an acceptable 
threshold, thus removing self reactivity (Ziegler et al., 2009).
The ability for T cells (and B cells) to distinguish between self and non self is vital for an 
appropriate immune response to develop. The consequence of a transplanted allograft 
expressing differing HLA to the recipient can be severe, as recognition of the 
transplanted antigens can occur in a process known as allorecognition and an immune 
response generated against the allograft, which can be both cellular and/or humoral in 
nature (Petra eta l., 2013).
1.1.9 The processes of allorecognition in transplant rejection
In order to understand allorecognition a basic understanding of 'normal' immune
recognition processes is required. Immunology text books tell us that for recognition of
an antigen and an immune response to occur, the response to foreign antigen is
initiated by antigen presenting cells (APC), which take up antigen in the periphery and
migrate to the secondary lymphoid organs, the spleen, lymph nodes and the gut and
mucosa-associated lymphoid tissue. Naive T cells, which constantly patrol through
secondary lymphoid tissues, engage and sample the foreign antigen, displayed by the
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APCs as pHLA complexes. A naive T cell, which recognises an APC displaying a pHLAfor 
which its TCR is specific, engages the APC in an interaction between the TCR and pHLA 
(as well as co-receptors and co-stimulatory molecules, which are essential for an 
effective immune response). This interaction leads to the generation of armed effector 
T cells, which express the necessary receptors for migration to the site of inflammation 
(Lakis, 2003).
In transplant immunology this process has the added complexity of donor APC and 
non-self HLA molecules. These complexities are described in the mechanisms of direct 
and indirect allorecognition and the concept of peripheral sensitisation (Figure 1.5). 
Peripheral sensitisation describes the process whereby donor endothelial cells, which 
line vascularised allografts, are capable of directly activating allospecific naive T cells 
(Al-Lamki e ta l,  2008). Direct recognition can be summarised asT cell recognition of 
intact donor HLA on donor APC, whereas, indirect recognition is the result of T cell 
recognition of allopeptides bound to self HLA on recipient (self) APC (Benchou and 
Thomson, 2009). Both the indirect and direct allorecognition pathways play an 
important role in the response to an allograft. Direct allorecognition is believed to be 
the driving force behind early acute allograft rejection episodes, due to the high 
frequency of T cells capable of recognising intact donor HLA on donor APC (Bolton et 
a l,  2008), whereas indirect recognition is thought to be responsible for later allograft 
damage when the source of donor APC has been exhausted (Afzali et al., 2008).
T cells are the principle effector cells of allorecognition and alloreactive T cells are 
readily detectable in humans, between 0.1% and 10% of T cells have been shown to 
react with alloantigens (Coif et a l,  2007), which is significantly higher than the less 
than 1/100,000 (0.001%) of T cells which are reactive towards nominal antigens 
(Heeger, 2003).
The relative simplicity of the direct and indirect pathways is complicated by the theory 
of semi-direct allorecognition (Afzali e ta l,  2008). Whereby instead of the traditional 
immune response 'cross-talk' between T cells, where CD4+ and CD8+T cells are 
stimulated by the same APC. Semi-direct recognition in transplantation requires cross­
talk between direct and indirect recognition. Where CD4+T cells with indirect
13
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allospecificity can amplify or regulate directly allospecific CD8+ T cells. This appears to 
require a Tour cell' or 'unlinked model' as the CD4+ indirectly allospecific T cells would 
be activated by self APC, whereas, the CD8+ directly allospecific T cells would be 
activated by donor APC. Such 'unlinked' help may not be required however, as 
dendritic cells have previously been shown as being able to acquire intact MHC peptide 
complexes from other dendritic cells (Afzali et al., 2008 and Brown et al., 2011). A 
potential consequence of the semi-direct pathway could be sustained stimulation of 
directly alloreactive T cells when donor APC has been exhausted.
In terms of which T cell lineages are responsible for specific graft damage induced via 
indirect and direct mechanisms, Ali and colleagues (2013) argue that indirectly 
stimulated CD8+ T cells are 'largely clinically irrelevant1 due to graft parenchyma 
remaining completely of donor origin in vascularised allografts, and thereby the  
cytolytic property of CD8+ T cells can only be activated through direct recognition of 
allogeneic class I HLA (the graft having no recipient HLA presenting donor antigen upon 
it therefore negating indirect recognition). This can be said to be true to some extent 
for CD4+ T cells as well, in that no recipient class II HLA will be present upon the 
allograft either. However CD4+T cells indirectly activated via recipient APC can, 
theoretically at least, help mediate a humoral response (and more controversially, a 
cellular effector response (Ali et al., 2013) if the semi-direct mechanism of 
allorecognition is assumed to be correct). In particular, evidence seems to show that 
memory CD4+T cells derived by indirect recognition can provide help to na'fve B cells 
responding to a new, secondary, target alloantigen. This would explain the observation 
of late developing de novo HLA alloantibody (Ali et al., 2013).
1.1.10 The categories o f transplant rejection
Allorecognition then, can generate both cellular and humoral responses to the 
allograft, and consequently rejection of an allograft can also be made up of both 
cellular and humoral responses, or indeed may be comprised of one response 
predominantly over the other (Petra et al., 2013). Transplant rejection episodes are 
categorised according to the time frame in which they occur post transplant, and are 
known as, hyperacute, accelerated acute, acute and chronic rejection episodes.
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1.1.10.1 Hyperacute allograft rejection
Hyperacute rejection occurs minutes to hours after the vascular clamp to the 
transplanted organ is removed allowing reperfusion (Nankiville and Alexander, 2010). 
The cause for hyperacute rejection was established in the 1960s (Patel and Terasaki, 
1969) as being due to preformed donor specific antibodies (DSA), specifically towards 
HLA antibodies (although donor specific ABO group antibodies are also a cause of 
hyperacute rejection this can be avoided be by ensuring ABO compatibility) which are 
present in the recipient due to previous exposure to HLA molecules, through previous 
transplant, pregnancy or transfusion, bind to their specific HLA target upon the 
allograft vascular endothelium, and mediate allograft damage, via activation of the 
complement cascade, a feature which can be observed in the biopsies of rejected 
allografts in the form of C4d deposition (Girnita et al., 2007). This process results in 
vascular thrombosis and ischaemic necrosis to the allograft, the consequence of which 
is nearly always removal of the allograft (Nankiville and Alexander, 2010).
1.1.10.2 Accelerated acute allograft rejection
In a similar fashion to hyperacute rejection, accelerated acute rejection is mediated by 
HLA antibodies, which were either at a low level and not detected by a pre-transplant 
crossmatch (XM), or due to an anamnestic response (Nankiville and Alexander, 2010). 
The rejection event occurs within the first few days post transplant and is caused by 
HLA antibody as with hyperacute rejection. The sudden increase in DSA is caused by 
activation of memory B cells post transplant. In other aspects, accelerated acute 
allograft rejection is comparable to hyperacute rejection.
1.1.10.3 Acute allograft rejection
Acute rejection occurs over the first months post transplant and is comprised of both 
cellular and humoral components (Nankiville and Alexander, 2010). Predominately 
caused by direct allorecognition (Bolton et al., 2008), acute rejection develops as intra­
allograft immature donor dendritic cells carry donor antigens to the draining lymph 
nodes and spleen, in the process of which they mature into APC (Nankiville and 
Alexander, 2010) and present their antigen to T cells. Activated T cells then migrate to 
the allograft and mediate allograft damage. In sites of acute rejection within an
allograft, interstitial mononuclear cells including CD4+ and CD8+ T cells can be seen to
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accumulate upon histological analysis of biopsies, where direct contact with tubular 
epithelial cells generates cell mediated cytotoxicity, and CD4+T cells can promote a 
humoral response (Nankiville and Alexander, 2010).
1.1.10.4 Chronic allograft rejection
Chronic rejection occurs in an ongoing process years post transplant, and is thought to 
be the result of indirect recognition (Afzali et al., 2008). However the contribution of 
this ongoing process to eventual allograft loss can be difficult to determine, as allograft 
damage is also caused by immunosuppressant toxicity as well as the patient's primary 
disease over the same time period. In the case of kidney transplantation for example, 
the term chronic rejection is often replaced with chronic allograft nephropathy, to 
highlight the contribution of these varied factors to damage to the allograft. The 
features of chronic rejection include: the gradual loss of allograft function over time, 
with T cell infiltration of the allograft parenchyma and deposition of T cells and 
macrophages in the interstitium (Nankiville and Alexander, 2010).
1.1.11 The role o f peptides in direct and indirect allorecognition 
The role of the direct allorecognition pathway in acute rejection seems to contradict 
the classic self restriction property of T cells, i.e. that T cells can only recognise foreign 
antigen when complexed with self HLA (Ziegler et al., 2008), as direct recognition 
involves the recognition by self TCRs of intact donor HLA on donor APC. Self restriction 
is a consequence of the establishment of central tolerance (previously discussed in 
section 1.1.7 and 1.1.8), and classically two models have previously been proposed to 
explain the mechanism by which a T cell is able to 'break' self restriction, and recognise 
donor HLA directly on donor APC, these are known as the high density determinant 
model and multiple binary complex theory (Afzali et al., 2007). The 'high density 
determinant' model proposes that directly alloreactive T cells recognise differences in 
the amino acids of the HLA molecules of the donor cells, and that the nature of the 
peptide within the groove is unimportant. This means all donor cells expressing HLA 
can act as a ligand for directly alloreactive T cells, creating a very high density of ligand. 
As a result of this high density, the affinity of the directly alloreactive T cell receptor is 
hypothesised to be lower than that of a self-restricted T cell receptor and can thus
overcome self restriction (Bharat and Mohanakumar, 2007).
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In the multiple binary complex theory however, the peptide has a key role in direct 
allorecognition. This model proposes that alloreactive T cells recognise specific 
peptides within the donor HLA grooves. These peptides are derived from homologous 
intracellular proteins which are also present within the recipient. However differences 
in the donor HLA groove due to HLA polymorphism, result in a different set of peptides 
being presented from the same intracellular proteins, when compared to the peptides 
presented by the recipient's HLA (Bharat and Mohanakumar, 2007). This model fits 
with the current understanding of TCR/pHLA interaction, which is discussed later, and 
assumes that a TCR is able to recognise the donor HLA due to the relative structural 
similarity of the molecule in TCR binding regions in comparison to the peptide binding 
HLA groove regions.
The indirect allorecognition pathway is perhaps a closer representation of the way a T 
cell recognises an antigen in a 'normal1 immune response. The donor antigens have 
been internalised, processed and presented in the context of self HLA on recipient 
APC. The role of the peptides is central to the recognition by TCR (as is the case with 
normal antigen recognition) and the generation of an alloimmune response in the 
indirect recognition pathway.
Most recently, the significance of the peptide within both direct and indirect
recognition is becoming clear, and many studies have now demonstrated the existence
of peptide specific alloreactive T cells, and the ability in some of these cases, for
distinct T cells to respond to multiple allopeptides (Felix et al., 2007). Recent reviews
have highlighted the fact that peptides are intrinsic to TCR recognition and that there
are many similarities between allorecognition and conventional recognition (Felix and
Allen, 2007). Indeed the ability of the TCR receptor to recognise multiple peptides
complexed within the same HLA molecule (which emphasizes the importance of the
peptide within recognition pathways) was recently reported by Wooldridge and
colleagues (2012) in an autoimmune context. They described a single CD8+T cell
derived from a patient with type I diabetes, which was specific for a preproinsulin
derived peptide, and was identified as pathogenic in this context. The autoimmune
TCR of this CD8+ T cell was identified as being able to recognise more than 106 different
peptides. The authors most significant finding is perhaps not the surprising extent of a
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single TCR to identify such a large array of peptides, but that the initial peptide antigen 
can be improved upon in terms of its stimulation of the TCR, the authors reporting an 
increase in the functional response of greater than 100 fold in a CD8+ T cell already 
established as pathogenic.
1.1.12 The effect of altering the peptidome through transplantation 
Peptides, according to the literature, play a key role in TCR recognition and, according 
to the multiple binary complex model, are crucial to direct recognition. Furthermore 
the peptides available to be bound by HLA, the so called peptidome (Milner et al., 
2013), are altered through allotransplantation, due to the presence of non-self 
antigens. This change within the peptidome can therefore allow an alloreactive T cell's 
TCR to recognise a target pHLA with a higher affinity than self pHLA, otherwise the T 
cell bearing the TCR would have been deleted during the establishment of central 
tolerance (if self reactivity was high, the T cell would have been deleted), and this 
change in affinity leads to a response from the T cell. The change of the peptidome it 
can be then argued, reduces in amount, degree and intensity, the effects of negative 
selection, or in more concise terms abates negative selection. A measure of this 
response can be observed in the high frequency of alloreactive T cells, although other 
factors influence this high number of alloreactive T cells, and include the number of 
pHLA complexes upon the surface of APC and the influence of co-stimulatory signals, 
as well as the number of TCR upon the surface of the T cell (Smith et al., 2012).
As an example of the influence peptides can have upon binding affinities of the TCR,
the minor histocompatibility antigen (mHAG), HA-1, demonstrates how the change of a
single amino acid within a peptide bound by HLA can significantly affect TCR
recognition and affinity. mHAGs result from the presence of different gene
polymorphisms between the donor and recipients, and can be encoded for by
autosomal genes, or from proteins encoded upon the Y chromosome in sex
mismatched grafts. These different polymorphisms result in the presence of different
peptides being bound by HLA molecules which then act as alloantigens and induce an
alloresponse (Roopeen eta l., 2002). The HA-1 mHAG results from the products of a
dimorphic gene, HMHA-1. HA-1 is an HLA-A*02 restricted peptide, only one of the two
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variants is known to cause alloreactivity, this being VLHDDLLEA, the other variant, 
VLRDDLLEA, differs at position 3 by a His(H)/Arg(R). Although both peptides bind to 
HLA-A*02, the allogenic H containing peptide allows greater structural stability when 
complexed with the HLA-A*02 molecule, and is presented at the cell surface in greater 
numbers than the R variant (Nicholls et oL, 2009). However, the R peptide is thought 
capable of forming complexes with HLA-A*02 and being expressed in the thymus 
during central tolerance. Consequently HA-1 can serve to highlight a process reducing 
the effect of negative selection. Whereby, if the immunogenic HA-1 H peptide was 
presented by HLA-A*02 upon thymocytes during the establishment of central 
tolerance and a TCR receptor was specific to this target above an appropriate 
threshold then it would have been deleted. However if HA-1 H was absent during 
central tolerance, and later introduced to the TCR (e.g. as a consequence of indirect 
allorecognition) then a response can be formed. In this concept a portion of the 
alloreactive T cells could be thought to be quasi autoimmune in nature, due to the 
'undoing' of central tolerance, Figure 1.7.
The HA-1 R peptide has not been shown to generate an immune response and appears 
to form a less stable structure with HLA-A*02. Studies using Surface Plasmon 
Resonance (SPR) to measure HA-1 specific TCR and HLA-A*02 complexed with H and R 
peptide show a decreased affinity for the HA-1 R, with extremely rapid off rates 
(Nicholls eta l., 2009), which most likely accounts for this observation. In a direct 
allorecognition situation, assuming the binary complex theory is correct; where donor 
and recipient combinations represent an HLA mismatch, the HLA polymorphism results 
in a different set of peptides being bound, to which an alloreactive TCR can have an 
inappropriate affinity for, thus also abating negative selection and allowing the 
generation of a T cell response.
Comparison of the binding affinities of T cell's TCR, between TCRs of T cells which are 
specific for viral antigens, cancer antigens, autoimmune antigens and alio antigens, 
demonstrates that there are similar and 'robust' affinities between alio, viral and 
cancer antigen specific TCR in measurements carried out by SPR, and greater affinities 
for alloreactive TCRs than the autoimmune specific TCR affinities (Smith et al., 2012).
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change in the peptide environment following transplantation allows inappropriately high affinity by the TCR to those peptides not 
experienced by the TCR during central tolerance, thus allowing a quasi-autoimmune response to the transplanted organ.
1.1.13 Factors that influence alloreactivity
The overall contribution to alloresponses of the TCR upon alloreactive T cells, which 
are the result of altering the peptidome is uncertain, and must vary greatly between 
different donor and recipient combinations. Indeed, alloreactivity is influenced by a 
number of variables such as the number of mismatched alleles (the alloreactivity of 
certain mismatches also varies, with some being permissive mismatches and others 
being strongly immunogenic, which is believed to be a function of structural 
similarities between certain HLA molecules) and gender; females generally exhibit 
higher alloresponsive T cell frequency. Additionally, in healthy individuals a proportion 
of viral specific memory T cells exist, which have been shown to be cross-reactive in an 
alloresponsive HLA class I specific manner. Considering that Epstein-Barr virus (EBV) 
and cytomegalovirus (CMV) specific CD8+T cell frequencies have been shown to be 
between 10%-40%, a significant pool of anti-viral memory T cells are available, some of 
which are capable of cross-reacting with donor antigens (Smith et al., 2012). Although 
the mechanism by which this cross-reactivity occurs remains to be elucidated, given 
the orthogonal binding mechanism of TCR to pHLA, the bound peptide is likely to play 
an integral role, due to its interaction with the TCR (see section 1.1.8), the 
complementary-determining regions (CDR)3 somatically rearranged variable- 
(diversity)-joining regions of the a(3 TCR, which are the most polymorphic regions (see 
section 1.1.15), being positioned at the binding interface with the HLA bound peptide 
(Garcia eta l., 2009).
1.1.14 The contribution of peptide to the mechanism ofTCR-pHLA interaction
Garcia and colleagues (2009) outlined the molecular bias of the TCR binding to pHLA,
where they describe how this binding interface is composed of four structurally
distinct components, which form composite surfaces. The portion of the TCR which
binds to the pHLA can be divided into the invariant germline variable (V) gene encoded
regions, which comprise the CDR1 and CDR2, and the junctions between the
somatically rearranged variable-diversity (J) gene encoded-joining regions, which form
the CDR3 region. The TCR binding region upon the pHLA is mostly comprised of
conserved regions of scaffold upon the a-helix of the groove, within which the
diversity of the peptide binding region of the HLA encloses a peptide. The binding of
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the TCR to pHLA allows the interaction of the TCR's most variable region, CDR3, to the 
centre of the pHLA, allowing interaction with diverse peptides (Coif et al., 2007), while 
the germ-line encoded CDR1 and CDR2 regions interact with HLA around the peptide 
binding region (Figure 1.8 and 1.9). Binding in this manner allows for 75-80% of the 
contact of the TCR and pHLA being achieved by CDR1 and CDR2, and this interaction is 
postulated as being a facilitator of the rapid TCR 'scanning' of pHLA, allowing 
identification of peptides within the pHLA which stabilize the half-life of TCR-pHLA 
interaction via CDR3 for a period long enough for signalling to occur (Garcia et al.,
2009).
This description highlights the intrinsic nature of the peptide in the activation of T cells 
via their TCR. In another paper, Corse and colleagues (2011) conclude that the stronger 
the interaction between TCR-pHLA, the more efficient the T cell response in vitro.
While they report that in in vivo responses, there are likely to be constraints upon high 
and low levels of T cell stimulation, for example attenuation of strong signals to 
prevent detrimental inflammation, or, following a time lag, similar levels of T cell 
reactivity can be seen for low potency pHLA, whereby interrogation of pHLA by TCR 
may involve multiple encounters prior to activation of T cells. In addition reports state 
that variability in TCR-pHLA interactions could lead to expansion and differentiation of 
different T cell clones (Corse et al., 2011 and Mirshahidi et al., 2004), such as memory 
cells, or regulatory T cells. Indeed low dose of pHLA has been shown to favour 
transient FoxP3 positive T regulatory cell formation above FoxP3 negative T effector 
cells (Long eta l., 2010).
1.1.15 The mechanisms of obtaining diversity within the TCR 
The TCR is unusual in being both highly diverse, consisting of an estimated 1015 
potential sequences, and yet being restricted to recognising its antigen in the context 
of HLA (Birnbaum et al., 2012). The mechanism of binding to the pHLA, as described in 
section 1.1.8, reveals a binding interface which consists of both highly diverse (CDR3) 
and more conserved (CDR1 and 2) regions, which facilitate these properties. The 
development of diversity within the TCR is achieved by recombination of the Variable 
(V), Diversity (D) and Joining (J) genes, so called V(D)J recombination, which is achieved
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through a single recombinase enzyme, encoded for by the lymphoid-specific 
recombination-activating genes 1 and 2 (RAG1 and RAG2) (Hewitt eta l., 2010). 
Specifically the CDR1 and CDR2 regions are encoded for by the germlineT cell receptor 
a-variable (TRAV) and (3-variable (TRBV) genes, while the highly diverse CDR3 is 
encoded for by V and J gene segments in the a-chain of the TCR, and the V(D)J 
segments in the (3-chain (Gras eta l., 2012). Furthermore additional variation can be 
generated within the CDR3 regions by the addition/deletion of non-nucleotide (N) 
templates at the V-(N)-J, V-(N)-D and D-(N)-J junctions (Gras et al., 2012).
1.1.16 The influence of HLA bound peptide on TCR mediated alloreactivity 
In support of the importance of the peptide in the binding mechanism and activation 
of alloreactive T cells, Morris and colleagues (2010) demonstrated that alloreactive and 
non-alloreactive T cells differed specifically at the CDR3 region of the TCR, supporting 
the hypothesis that CDR1 and CDR2 regions provide a germ line affinity for HLA, and 
offering an explanation for the ability for alloreactive T cells to recognise non-self HLA. 
In addition, there are at least two cases reported within the literature of the CDR3 
region of the TCR providing the majority of the binding energy due to TCR recognition 
of bulged peptides (Liu et al., 2012; Speir et al., 2001).
The orientation of the TCR in relation to pHLA also appears to have an influence upon 
the ability of a TCR to recognise pHLA, with the orientation of the most variable region 
of the TCR positioned such that it engages with the peptide, highlighting the 
significance of the peptide in its ability to generate TCR mediated immune responses. 
There is some variation described within the literature between the precise 
mechanisms, but generally an orthogonal docking angle is seen in reported TCR/pHLA 
crystal structures (Garcia eta l., 1996; Garcia eta l., 2009). The a-chain of the TCR 
alignment falling over the NH2-terminal end of the peptide, with the (3-chain over the 
COOH-terminal. In the reported structures, the variation that has been observed is 
seen in the degree of flexibility within the TCR binding of pHLA. Whereby the angle to 
which TCR engages pHLA can vary from between 22 to 84 degrees. It appears the TCR 
approaches the binding of HLA with a single binding conformation, it then flexes and 
readjusts the interaction with pHLA to allow the formation of the single binding 
conformation (Felix and Allen, 2007).
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Considering these findings the nature of the peptide presented by HLA in an 
alloimmune setting can induce a variety of effects upon the T cells which recognise 
them. This ranges from the generation of a response targeted to the allograft, resulting 
in allograft damage and/or rejection, to inducing allograft protection via the formation 
of FoxP3+ T regulatory cells (Sakaguchi et al., 2001). The significance of the peptide 
bound by HLA to the triggering of immune responses has led many investigators to 
study the processes of peptide processing and presentation by HLA, as well as 
attempting to characterise the properties of peptides bound by specific HLA alleles.
1.1.17 Peptide processing and presentation
Given the extensive impact that HLA bound peptide has been demonstrated to have 
upon TCR recognition, whether in the context of alloimmune, autoimmune or immune 
responses against pathogens, the nature of this peptide binding and its orientation 
within the HLA molecule is likely to be of consequence. As such, the structure of HLA 
molecules and their mechanism of peptide presentation have been extensively 
studied. The nature of peptide processing and presentation is dependent upon the 
peptide source, and the class of HLA molecule to which they are bound for 
presentation.
1.1.17.1 The source of peptides in the HLA class I processing pathway
Class I HLA molecules present peptides derived from endogenous proteins to cytotoxic
(CD8+) T lymphocytes. These peptides are generated via proteasome mediated
degradation of proteins at the end of their functional lives, as well as newly
synthesised proteins in the form of defective ribosomal products (DRiPs) (Schubert et
al., 2000), the source of these proteins can be derived from self proteins, or from
pathogens, such as viral proteins due to a viral infection. The functional life of different
proteins varies considerably and can range from minutes to hours, however a
significant proportion of proteins are degraded immediately post synthesis, prior to
the formation of functional proteins as a consequence of DRiPs. DRiPs being the result
of defective transcription or translation, alternative reading frame usage and failed
assembly into functional proteins via other mechanisms (Neefjes et al., 2011). The
DRiPS are degraded immediately to prevent aggregation of protein, this process
therefore allows peptides to be presented by HLA class I extremely rapidly. Indeed the
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influenza virus can be recognised by T cells, 1.5 hours post infection due to DRiPs, 
instead of 8 hours later when the first stable viral proteins are degraded by the 
proteasome of infected cells (Neefjes e ta l ., 2011). In addition to peptides being 
generated from proteins at the end of their functional life and from DRiPs, peptides 
which have been generated from non-continuous sequences which are a consequence 
of ligation have been observed (Neefjes eta l., 2011). Dalet and colleagues (2011) 
report the splicing of two protein fragments in the proteasome to form a peptide 
which is presented to CD8+ T cells by Class I HLA. In the transplant setting, this raises 
the intriguing theoretical possibility that alio and self protein fragments could be 
spliced to form a novel peptide.
The repertoire of peptides which can be bound by HLA class I molecules, known as the 
HLA class I peptidome (Milner et al., 2013), can therefore include peptides from  
proteins which are non functional, peptides which are not encoded for by the genome 
due to ligation, and peptides from proteins which have reached the end of their 
functional life, all of which have been shown to be capable of eliciting an immune 
response. In addition to this variety of peptide origin, a different degradation pattern 
has been observed between the constitutive and the immuno proteasomes 
(Eleftheriadis, 2012), which can also produce variety in the peptides generated. 
Regardless of this wide source of peptides, loading onto the HLA class I molecule for 
presentation is essential for effective immunity. In order to facilitate this, a peptide 
loading complex is formed.
1.1.17.2 The HLA class I antigen processing pathway
As the peptides for class I HLA molecules are generated within the cytosol their 
transport into the ER, where HLA molecules are assembled, is required. This access to  
the ER is granted by the transporter associated with antigen processing (TAP), which 
also forms a part of the peptide loading complex (PLC). TAP is formed from two gene 
products, TAPI and TAP2, and transports peptides of 8-16 amino acids in length into 
the ER. Once inside the ER, the peptides are processed to ensure their suitability for 
loading onto HLA molecules by the action of ER aminopeptidases, specifically ERAP1 
and ERAP2, which trim the N-terminal ends of peptides (Wearsch and Cresswell, 2008),
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These ER aminopeptidases are not however part of the PLC, and do not otherwise 
facilitate loading of peptides and assembly of HLA molecules.
The assembly of HLA and loading of peptides is achieved via a two stage process 
(Figure 1.10). Initially calnexin (CNX) and ERp57, which is a protein disulfide isomerase 
(promotes disulphide bond formation), facilitate early folding of the heavy chain (HC) 
and association with |32-microglobulin (p2M). After which, a second stage occurs 
whereby the HC and (32M are recruited into the PLC (Figure 1.11). The PLC is comprised 
of tapasin, which acts as a bridge between TAP and the HC, and is covalently 
associated with ERp57. ERp57 itself is also bound to calreticulin (CRT) and CRT is 
bound to a monoglucosylated AMinked glycan attached to the HC at Asn86 (Wearsch 
and Cresswell, 2008). In terms of PLC function, tapasin stabilizes the HLA molecule 
while it is empty (Elliot and Williams, 2005) and promotes high affinity peptide loading, 
in a process known as peptide editing. Interestingly the influence of tapasin upon 
peptide binding appears to be HLA allele specific, with peptide loading being heavily 
reliant upon tapasin in some HLA alleles, such as HLA-B*44:02, while others appear to 
be able to load peptide without the function of tapasin, for example HLA-B*27:05 
(Elliot and Williams, 2005). HLA molecules and peptides, which do not form a complex 
with each other, are transported back into the cytosol for further trimming or 
destruction via peptidases and the proteasome. This transport out of the ER is 
achieved via the ER-associated protein degradation (ERAD) system (Neefjes eta l., 
2011). Successfully complexed HLA class I and peptide is transported to the Golgi body 
and then transported from the Golgi to the cell surface with the aid of CD99, a 
leukocyte adhesion molecule. The absence of CD99 has been shown to result in a build 
up of MHC Class I within the Golgi (Bremond et a!., 2008).
1.1.17.3 The HLA Class II antigen processing pathway
HLA class II molecules are also assembled in the ER, where an a and (3 chain associate
with an invariant chain (li), the resulting heterodimer-li complex is then transported to
the late endosomal compartment known as the MHC Class II compartment (MIIC),
again via the Golgi. The li blocks the peptide binding groove thus preventing
endogenous peptide binding (Wolters and Chapman, 2000), the class II associated
invariant chain peptide (CLIP) region of the li chain occupies the binding groove
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(Neefjes et al., 2011) and the li undergoes stepwise proteolytic degradation so that 
only the CLIP region remains. This CLIP/HLA class II complex can now load peptide for 
presentation at the cell surface, as CLIP, unlike the larger li, rapidly dissociates from 
the HLA class II molecule and is replaced by an exogenous peptide from a protein 
degraded in the endosomal pathway (potentially an exogenous pathogen, or donor 
protein). This replacement of CLIP with exogenous peptide requires the presence of 
another HLA class II molecule, the HLA-DM protein (Neefjes e ta l., 2011). The 
successfully loaded class II HLA molecule is then displayed upon the cell surface. 
Crucially the polymorphism of both class I and class II HLA molecules provides a range 
of peptide binding characteristics upon different HLA molecules. To some degree this 
allows then, an ability to determine the likelihood of a specific peptide to be bound by 
particular HLA molecules using bioinformatic approaches (Helmberg, 2012), discussed 
in section 1.9.
1.1.18 The characteristics o f peptide binding by HLA molecules 
The genes within the MHC are highly polymorphic; indeed the HLA-B gene is believed 
to be the most polymorphic gene within the human genome (Yanover and Bradley, 
2011). The polymorphism within HLA molecules is at its greatest in the sequences 
lining the peptide binding grooves, specifically the greatest polymorphism is encoded 
for by exons 2 and 3 of the Class I a-chain (HLA-A, B and C) and exon 2 for the class II (3- 
chain of HLA-DR, DQand DP molecules, in addition polymorphism is also seen within 
the alpha chain of DQ and DP molecules. This polymorphism produces a selective 
peptide binding motif for each HLA molecule, which results in the ability to bind a 
specific set of peptides, referred to as the peptide repertoire or peptidome (Rao et al., 
2011). The peptide repertoire of different HLA molecules can overlap, as a 
consequence the same peptide can be presented by numerous HLA molecules. Indeed 
this promiscuous binding of peptide maybe as high as 60% (Rao et al., 2011). This 
promiscuity of binding may be a disadvantage in terms of the immune response, due 
to the principles of the heterozygous advantage theory. Whereby, individuals who are 
heterozygote are able to present a wider range of peptides than homozygotes, due to 
the potential ability to display a wider peptide repertoire. The promiscuous binding of 
peptide by some HLA molecules will obviously reduce this effect for those peptides.
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Indeed, individuals with HLA molecules which have unique peptide binding motifs have 
a lower chance of transmission of a pre-adapted virus (Rao et al., 2011).
In the transplant setting these properties could have various effects, which are 
dependent upon the uniqueness of the peptide binding motifs of HLA mismatches, and 
the promiscuity of donor and recipient peptides. A promiscuous peptide could be 
bound by a donor or recipient HLA molecule and may or may not initiate an 
alloimmune response, depending upon the state of tolerance to the epitopes 
generated. Use of structural simulations to investigate peptide binding landscapes for 
HLA-A* and B* alleles have revealed that the HLA-B locus encoded antigens are, on 
average, able to bind a greater range of peptides, although this is not uniform for all 
alleles, some HLA-A* alleles being able to present a greater range of peptides than 
some HLA-B* alleles (Yanover and Bradley, 2011).
HLA alleles which share similar peptide binding characteristics are grouped into HLA 
supertypes, which has allowed the development of 'immunological hotspots' whereby 
regions of some antigens (such as the SARS coronovirus nucelocapsid) have regions of 
promiscuous T cell epitopes (Zhang et al., 2011) i.e. they contain peptides which bind 
to multiple HLA molecules, these have therefore been used as potential targets for 
vaccine development. For HLA-Class I, nine supertypes have been identified, based 
upon overlapping peptide binding repertoires and groove structures, these being HLA 
class I supertype A l, A2, A3, A24, B7, B27, B44, B58 and B62 (Zhang et al., 2011).
1.1.19 Predicting peptide binding to HLA
In order to allow a greater understanding of the relationship between peptide and HLA 
encoded molecules, several bioinformatic tools have been generated to provide an in 
silico assessment of peptide binding, such tools include the SYFPEITHI and the immune 
epitope databases (Helmberg, 2012). These tools utilise the described properties of 
peptide binding to the groove of HLA encoded molecules, and include bioinformatic 
systems for prediction of peptide binding to the HLA class I and class II molecules.
In the peptide binding groove of the HLA class I molecules, six binding pockets have
been identified, A-F, which have allele specific characteristics, towards specific peptide
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side chains, known as anchor residues (Fagerberg eta l., 2006). The six binding pockets 
allow amino acids, which have similar physicochemical properties, to be bound in a 
specific maner. The contribution to peptide binding is not uniform across all binding 
pockets, and peptide residues can be bound in pockets which are highly specific for 
that residue, these residues are termed primary or main anchor residues, the less 
specific residues are termed secondary anchor residues. The greatest contribution to 
peptide binding within HLA class I molecules comes from the N and C terminals of the 
peptide which are usually bound firmly by the ends of the binding groove, by pockets A 
and F respectively (Fagerberg et al., 2006). Further binding energy is produced by 
hydrogen bonds between the HLA and backbone of the peptide. This concept of 
binding pockets has been broadened more recently, with some evidence suggesting 
the ability to predict peptides, which will bind to less well structurally documented 
alleles, such as the HLA-B*41 variants, requires a fine understanding of the amino acids 
present within the groove and each pocket (Bade-Doeding etal., 2007).
Assessing peptide binding within HLA class II is more complex than that of HLA class I. 
Indeed state-of-the-art performance in peptide prediction reaches an AUC ROC (area 
under receiver operator curve) of 0.85-0.95 for HLA class I but only 0.70 to 0.85 for 
HLA class II (Zhang et al., 2012), indicating a higher accuracy for HLA class I binding 
prediction than class II. The increased complexity of predicting HLA class II peptide 
binding is due to various differences to the class I binding. The binding groove in HLA 
class II molecules which accommodates peptide is open at the terminal ends, allowing 
longer peptides to bind, and also allowing peptide to bind at multiple sites. In addition, 
peptide residues which fall outside the peptide binding groove can interact with the 
HLA molecule and enhance its structural stability (Liao and Arthur, 2011).
An interesting feature of peptides eluted from HLA class II molecules and subsequently 
sequenced, is that a significant fraction of them are derived from intracellularly 
synthesised proteins, between 70-90%, depending upon the HLA allele from which the 
peptides were eluted (Leddon and Sant, 2010). This observation demonstrates that in 
the absence of a pathogenic challenge, HLA class II molecules present peptides which 
are most likely sourced from APC derived intracelluar proteins, and not, in the main, 
extracellular derived proteins. Furthermore, it has been reported that 10-60% of these
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peptides are themselves derived from HLA molecules themselves (Leddon and Sant,
2010). This is an interesting finding, considering the higher risk of mismatching HLA-DR 
over HLA-A and B in renal transplantation (Opelz 1997), and the role of endogenous 
peptides in allorecognition, described in section 1.1.20.
1.1.20 The role of endogenous derived peptides in allorecognition
The evidence for peptide dependent alloreactivity is increasing within both solid organ 
transplantation and HSCT. Within the limited number of structural models of this 
phenomena it is interesting to note that, where the peptide has been identified, the 
evidence suggests that alloreactive T cells recognise endogenous peptide (D'Orsogna 
et al., 2013). Indeed in an investigation into 50 different alloreactive T cell clones, 
which were generated in a GvHD response in vivo, they were not only peptide specific, 
but led the authors to conclude, 'that the alloreactive T cells exert a high-avidity 
recognition for a single endogenously processed and presented peptide' (Amir et al.,
2011).
1.1.21 The importance of peptides in the alloresponse
The evidence then that peptides bound within HLA molecules have a significant 
influence upon allorecognition is incontrovertible. These peptides can be of MHC 
origin, or minor histocompatibility antigen (mHAG) derived, and can be from both the 
donor and the recipient depending upon the context in which they are presented.
The alloresponse can be generated by a change in the peptidome, or the HLA 
molecules expressed, to which the recipient has not previously been exposed to during 
the establishment of central tolerance, which results in a change in the affinity to  
which T cell's TCR recognise pHLA, and results in a response from the T cell.
Given the effects of pHLA upon T cell clone formation by differential engagement of 
the TCR, it is not surprising that carefully selected peptides have been investigated as 
potential therapies for use in vaccination (Lovgren et al., 2012), cancer therapy 
(Goulmy, 2004), preventing autoimmunity and tolerance induction (Mirshahidi et al., 
2004). In one such paper which examines the impact of peptide dose upon CD8+ T cell 
responses (Lovgren etal., 2012), the authors conclude that low dose peptide
vaccination generated stronger CD8+T cell responses than high dose peptide, and
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showed a lower dependence upon CD8 co-receptor. This is an intriguing finding 
considering the observation that alloreactive T cells have shown TCR cross-reactivity 
for MHC class I and II molecules (Smith etal., 2012), and offers the potential 
explanation that this cross-reactivity is as a result of low frequency peptides.
In the transplant setting, intrathymic injection of allopeptide has been shown to induce 
acquired systemic tolerance (Oluwole et al., 2001), a process which re-establishes the 
central tolerance lost due to transplantation.
Recently the generation of a chimeric state in renal transplant recipients by 
simultaneous HSCT has been shown to be capable of providing an environment 
suitable for renal allograft survival, without maintenance immunosuppression (Kawai 
et al., 2008). This work was carried out following the hypothesis of the 
interrelationship of chimerism and transplant tolerance outlined by Starzl and 
Demetris (1998). The proposed mechanism of achieving tolerance following chimerism 
has been postulated to be the elimination of 'reactive cells within the thymus which 
are reactive to donor antigen1 (Kawai et al., 2008), this would again restore central 
tolerance. Intrathymic deletion was found to be the 'dominant tolerance induction 
mechanism' through mixed chimerism, reviewed by Pilat and Wekerle (2010).
However central tolerance is certainly not the only player in such events (Pilat and 
Wekerle, 2010). Indeed administration of allopeptides, or cells which express single 
donor class I HLA, has been reported to result in down regulation of alloantigen 
specific cell-mediated responses by Tregs (Wood and Sakaguchi, 2003), the authors 
called for further characterisation of the allopeptides involved. The phenomena of 
Treg cells being critical for the maintenance of central tolerance is well reported, and 
can be seen in the development of severe autoimmune disease in regulatory T cell 
transcription factor Foxp3 deficient individuals (Kim eta l., 2011). Given the ability of 
changes within pHLA to alter the affinity of TCR-pHLA interactions, and that the affinity 
of the TCR for pHLA can influence T cell clone formation, the pHLA environment will 
have an impact upon this event. The differentiation of specific T cell clones will also be 
dependent upon the environment within which the pHLA is displayed, with a 
significant role for costimulation (Kim eta l., 2011). Therefore the pHLA can be said to
have a significant role in both the generation of the alloresponse, due to the
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phenomena of reducing or abating negative selection, and to achieve transplant 
tolerance through re-establishing central tolerance, via appropriate introduction of 
donor peptide antigens. Of particular interest is the role of endogenously sourced 
peptides within these phenomena.
1.2 Thesis aims
This thesis will seek to increase the understanding of the role of the peptide bound by 
HLA molecules in the context of alloreactivity in transplant recipients.
This will be achieved by identifying and assessing the function of endogenous peptides, 
which may have a role in the alloresponse within the context of clinical 
transplantation.
The key research approaches include:
In chapter 2 the research attempts to identify potential endogenously derived 
peptides, which may provide targets for allorecognition. Given that HLA class II 
molecules have been shown to present peptides derived from HLA class II molecules. A 
method for assessing this phenomena in HLA class I molecules will be investigated, 
specifically:
•  A bioinformatic database of potential HLA class I derived peptides, which may 
bind to HLA-A*02, will be generated using peptide binding software
•  Peptides bound by HLA-A*02 will be isolated from the HLA-A*02 molecule and 
characterised by mass spectrometry
•  The characterised peptides will be searched within the bioinformatic database 
to determine whether they are derived from HLA class I molecules.
Research described in chapter 3 will seek to assess the role of peptides, identified from  
the research undertaken within chapter 2, in the context of clinical transplantation in 
relation to outcomes, specifically:
•  HLA class I derived peptides, which are of particular interest in the alloresponse 
setting, will be identified and a 'key' showing the HLA alleles which encode these 
peptides will be generated
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•  This key will be utilised in a cohort of renal transplant recipients, which will be 
assessed for the effect of matching/mismatching these peptides, in relation to the 
performance of the allograft within the first 12 months post transplant.
In chapter 4, the experimental work will attempt to determine a functional role of the 
endogenous peptides identified in chapter 2, and seek to establish if variation within 
peptides bound by the same HLA molecule can influence the subsequent binding of 
HLA specific antibodies, and if so, seek to elucidate the mechanisms involved.
•  A cell line which expresses HLA-A*02 will be loaded with peptides identified in 
chapter 2
•  An HLA-A*02 specific antibody will be used to assess the influence of these 
peptides on the ability of an antibody to bind to its target
•  Structural modelling with be utilized to examine the influence of peptide upon 
antibody binding, using the current understanding of electrostatic potential energy 
upon an antibody target and the antibody binding characteristics.
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Chapter 2 - Identifying HLA Class I derived peptides as 
potential ligands in inducing alloreactivity
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2.1.1 Introduction
This chapter will seek to create a database of peptides which can theoretically be 
derived from HLA-Class I molecules and then presented by another HLA-class I 
molecule. The database will then be utilised to identify any HLA derived peptides 
eluted from an HLA molecule.
2.1.2 Bioinformatics within transplant immunology and HLA peptide binding 
predictions
Within the field of transplant immunology there are a wide range of frequently used 
bioinformatic tools (Helmberg, 2012), which provide both a collection of experimental 
data, such as the HLA/IGMT database (Robinson et al., 2013) or allele frequency 
database (Gonzalez-Galarza eta l., 2010). These allow access to information 
contributed to by the entire transplant immunology community. There are also 
bioinformatic tools which allow analysis of an investigator's own data, using the 
described properties of the bioinformatics tool in question, such as the use of 
HLAmatchmaker (Duquesnoy et al., 2011), to ascertain permissible epitope 
mismatches between donor and recipient pairs.
The use of bioinformatics to predict peptide binding to HLA molecules dates back to 
the late 1980s, and essentially three approaches to determining the probability of 
binding are used, these being: (1) position specific scoring matrices (PSSM), (2) artificial 
intelligence (Al) systems and (3) structural based methods (Liao and Arthur, 2011). 
Some systems utilise a combination of these techniques. Both PSSM and Al use the 
sequences of previously eluted peptides from specific HLA molecules to predict the 
ability of peptides to bind to a given HLA molecule. As the particular binding pockets of 
an HLA allele will favour certain amino acid characteristics (acidic, basic, polar, non­
polar, etc.) a likelihood of favourable binding can be established. The Al component 
allows for subtle relationships between amino acids within the peptide to be 
considered, most commonly PSSM and Al systems are used in parallel (Liao and Arthur,
2011). Structural based systems use the ever increasing number of crystal structures 
(Bjorkman et al., 1987) to estimate the stability and strength of binding of a peptide to 
a particular HLA molecule, determining the free energy. A review of the peptide
predicting bioinformatics tools available conclude that PSSM and Al combined systems
41
currently provide the best predictions (Liao and Arthur, 2011). Of these systems, 
perhaps the most widely reported within the literature is that of the SYFPEITHI 
database, first reported by Rammensee and colleagues (1999). The SYFPEITHI database 
was named after the sequence of the first peptide eluted from an MHC molecule, and 
contains a repository of such sequences combined with PSSM and Al peptide 
prediction. SYFPEITHI peptide binding prediction is based upon published peptide 
sequences, and only includes sequence prediction for HLA molecules for which a large 
amount of data is available. In line with all such bioinformatics tools, careful 
judgement regarding appropriate use of the data generated is required and, in the 
case of peptide prediction, certainty regarding actual binding of a peptide requires 
confirmation within the laboratory, either by eluting peptides from selected HLA 
molecules, or by assessing the binding of HLA molecules, by particular peptides, 
experimentally.
2.1.3 Confirmation of HLA peptide binding and sequencing of isolated peptides.
Various approaches within the literature are reported for isolating peptides from HLA
molecules and their subsequent characterisation (Castellanos et al., 2001; den Haan et
al., 1998; Bade-Dodingeta l., 2011; Heinhold eta l., 2010; Harndhal eta l., 2009).
Typically peptides are eluted from HLA by acid elution following the isolation of the
HLA molecule itself (if not produced in a pure soluble form). Often High Performance
Liquid Chromatography (HPLC) is used to separate the peptides prior to their sequence
characterisation. Recently, sequence characterisation by mass spectrometry (MS) has
been favoured within the literature, whereas previously Edman end terminal
sequencing was the methodology of choice (Hoppes et al., 2010). The combination of
separation of HLA from a target cell (if not in a soluble form), isolation of peptide from
the HLA itself, and then sequencing of the peptide makes this a time consuming
process. However new approaches such as those reported by Heinhold and colleagues
(2010), have demonstrated the utility of a two-step sequential immunoprecipitation
and Matrix-Assisted laser desorption/ionization Time of Flight (MALDI-TOF) method to
identify HLA-B bound peptides. The increasing use of MS for peptide characterisation is
largely due to the increased sensitivity of mass spectrometers, and has led to the
identity of the characteristics of large pools of peptides derived from different HLA
grooves to be determined, this has aided the development of the previously described
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PSSM (Falk eta l., 1991). However, it is often difficult to determine between self­
peptides and non-self-peptides (either of pathogen or donor origin) when eluted from 
HLA, and consequently further characterisation of the identified peptides are often 
performed by measuring functional responses, meaning the overall process of 
identifying allogenic peptides can be time consuming (Hoppes et al., 2010).
2.1.4 Mass spectrometry sequencing of HLA eluted peptides 
Mass spectrometers ionise compounds (i.e. generate a positive (cation) or negative 
(anion) electrical charge), this generally causes fragmentation of the compound, some 
of these fragments can in-turn fragment further (Hoffmann and Stroobant, 2007). The 
ions, which are thus generated, are separated within a mass spectrometer according to 
their mass-to-charge ratio and detected in accordance with their relative abundances.
The visual representation of the data generated is a plot of the mass-to-charge ratios 
of the detected fragments and their abundances, and can be displayed as a table 
showing mass-to-charge ratio (m/z) vs relative abundance (%) or most commonly the 
data is plotted as a mass spectrum, with m/z plotted upon the x axis and relative 
abundance upon the y axis. The ions generated and displayed within the mass 
spectrum provide information regarding the nature and structure of the precursor 
compound. Where a pure compound has been ionised and is still present in an 
unfragmented form, it is referred to as the molecular ion. The molecular ion is present 
at the highest m/z value, giving the molecular mass of the compound, while fragments 
from the molecular ion will be of a lower m/z ratio. For example, if methanol is 
analysed the molecular ion appears at m/z 32 of the spectrum (methanol's molecular 
mass is 32), while there is also a peak on the spectrum at 15 m/z. Therefore there has 
been a loss from the methanol molecular ion of 17 (32-15=17). This equates to the loss 
of a hydroxyl group and is the m/z of methanol minus a hydroxyl group (Hoffmann and 
Stroobant, 2007). These principles are also used to study proteins and peptides, not 
only with the capability to detect complexes of linked amino acids, but also post- 
translational modifications (Hoffmann and Stroobant, 2007). In terms of peptide 
sequencing, as is appropriate here, the peptide must undergo fragmentation in the 
same manner as a chemical compound. In simplistic terms, fragmentation causes the 
bonds between adjoining amino acids to break, this allows the amino acids, and
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fragments of amino acids which remain joined together, to have their molecular mass 
determined by the m/z ratios produced. In cases where a residual amount of the 
unfragmented peptide still remains, the molecular mass of the peptide itself can be 
determined. Two mass spectrometry techniques which are most often used in the 
study of peptides and proteins are electrospray ionization (ESI) and the previously 
mentioned MALDI. These two techniques are particularly suitable to the study of 
peptides and proteins as they do not require the analyte to be in a volatile state, a 
requirement which limited the study of non-volatile biological molecules prior to the 
introduction of ESI and MALDI (Hoffmann and Stroobant, 2007).
In previous reports of HLA derived peptide sequencing, MALDI has been used to great 
effect (Heinhold eta l., 2010). MALDI tandem mass spectrometry (MS/MS) peptide 
sequencing relies upon the peptide being dissolved in a matrix of small organic 
molecules, which is then dried and placed under vacuum conditions within the MALDI 
MS and pulsed with a laser. The organic compounds within the matrix have a strong 
absorbance at the wavelength of the laser, causing ablation of the matrix and also the 
peptide, generating an ionised gas phase (Hoffmann and Stroobant, 2007) which can 
then be separated within the MS, based upon the m/z of the peptide. In addition, 
through the use of tandem mass spectrometry (MS/MS) it is possible to isolate a 
particular peptide by identifying it through its m/z ratio in the first MS, then the 
peptide either undergoes spontaneous or induced fragmentation to yield peptide 
fragments for analysis within the second MS. In this way it is possible to select a 
peptide of a particular molecular weight from a mixture of peptides and then fragment 
and sequence that peptide (Hoffmann and Stroobant, 2007). MS/MS has been used in 
this way specifically for the purpose of characterising MHC class I peptides (Escobar et 
al., 2011), the data produced however, is complex. Fortunately various Tree to use7 
bioinformatic data analysis tools are available, which can provide likely peptide 
fragmentation products given a known sequence (Steen and Mann, 2004), or allow 
comparison to previously characterised sequences.
2.1.5 Roepstorff-Fholmann-Biemann nomenclature and describing peptide fragments
When fragmentation of a peptide is induced, the fragments generated are comprised
of different components of the peptide. In order to allow an accurate description of
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these peptide fragments, a system known as Roepstorff-Fohlmann-Biemann 
nomenclature (Figure 2.1) is used to describe the fragmentation products (Steen and 
Mann, 2004). Essentially the fragmented peptide ions are referred to as an, bn and cn 
ions, when the amino terminus group remains, and zn, yn and xn ions, when the 
carboxyl group remains (n equals the number of amino acid residues). The assigned a, 
b or c (or z, y and x) is dependent upon the position within the peptide to which the 
peptide is fragmented. As the 20 common amino acid residues have known masses, 
the mass difference between consecutive ions produced allows deduction of the 
peptide sequence (Table 2.1). The fragmentation of the peptide can produce a 
complex array of ions derived from the peptide, as stated earlier, various bioinformatic 
tools are available to help decipher this data and allow the sequence to be derived. 
Those bioinformatic tools most pertinent to this thesis, calculate the likely fragment 
ions of a given peptide, allowing the interrogation of a mass spectrum for those 
fragments. Such bioinformatic tools include the MS Product resource from the 
University of California mass spectrometry bioinformatics suite 
(www.prospector.ucsf.edu).
2.1.6 Assays to assess the binding of peptide by HLA
The ability of HLA to bind particular peptides can be investigated experimentally. 
Investigations of peptide binding are often used in conjunction with the bioinformatic 
tools discussed in section 2.1.1, or as a measure of the strength of binding peptides 
identified through those techniques discussed in section 2.1.3. Techniques assessing 
the binding of peptides to HLA and currently reported within the literature include: 
binding measurements assessed by the ability to inhibit binding of a fluorescently 
labelled reference peptide to HLA (Baxter eta l., 2004; Haan eta l., 1998), refolding of 
HLA molecules with test peptides (Harndahl etal., 2009), surface plasmon resonance 
(Chen eta l., 1994) and TAP deficient cell line binding of specific peptides (Gatfield et 
al., 1998; Wang et al., 1998; Gricks et al., 2001; Stuber et al., 1995; Castellanos et al., 
2001). One advantage of the TAP deficient cell line approach to assessing peptide 
binding is that subsequent to successful binding, the cell line loaded with the bound 
peptide can be utilised in various functional assays (Castellanos et al., 2001) or as 
targets for HLA antibody binding.
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here for completeness. Adapted from Hoffmann & Stroobant (2007).
The T2 cell line is one such cell line. T2 is a hybrid of T and B lymphoblasts and was first 
described by Salter and colleagues in 1985. As described in chapter 1 (section 
1.1.17.2), TAP forms an essential component of the antigen processing and peptide 
loading pathway. Consequently cell lines deficient in TAP have reduced (Salter et al., 
1985) or absent (Gatfield et al., 1998) expression of HLA at the cell surface. It should be 
noted that where encoded, HLA synthesis continues within TAP deficient cell lines, but 
when presented at the cell surface, without the stabilizing effect of bound peptide, the 
HLA dissociates rapidly. This has led to the discovery that incubating these cell lines 
with a peptide fitting the binding characteristics of the HLA molecule, allows 
stabilization of the HLA molecule at the cell surface (i.e. peptide binding is not 
achieved via traditional routes and is taken up at the surface). This can be measured as 
an increase in surface expression levels of HLA by the use of an HLA specific antibody, 
commonly the antibody used is specific to a conformational dependent epitope, to 
ensure correct structural orientation of the HLA detected (Gatfield eta l., 1998).
2.1.7 Aims of chapter 2
The work undertaken within chapter 2 will seek to establish a database of peptides 
derived from HLA-A*, B* and C* encoded alleles, which are theoretically capable of 
binding to HLA-A*02 encoded molecules. This database will then be assessed by 
obtaining peptides from an HLA-A*02 molecule and searching for matching peptide 
ligands within the database. This will provide information which will give an insight 
into the nature of HLA molecules binding HLA derived peptides, and allow the 
identification of specific combinations of HLA molecules and HLA derived peptide 
complexes. This insight will further the understanding of the allorecognition process.
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2.2 Materials and Methods
A flowchart overview of all the methods described here is given at the end of this 
section on page 56, to provide an overview of the work flow.
2.2.1 Creating a bioinformatic database of peptides derived from HLA-A*, B* and C* 
encoded alleles with theoretical HLA-A*02 binding potential.
The SYFPEITHI database was used to generate peptides which have a high probability 
of binding to HLA-A*02 (Rammensee et al., 1999; Liao and Arthur, 2011). Amino acid 
sequences of HLA Class I encoded alleles were obtained from the HLA/IGMT database 
(Robinson et a l, 2013) and entered into the SYFPEITHI database, to generate potential 
peptides theoretically capable of binding to HLA-A*02, which were derived from HLA- 
Class I encoded alleles. SYFPEITHI has a reported minimum reliability of retrieving the 
most 'apt' peptide in 80% of all predictions, identifying a naturally presented peptide 
within the top 2% of all peptides predicted in 80% of cases (Rammensee et a l,  1999). 
Thus for a protein sequence of 400 amino acids in length, the correct peptide will be in 
the top 8 scoring peptides in 80% of cases. The HLA-Class I a-chain is less than 400 
amino acids in length, but to ensure the utility of the bioinformatic database 
generated, the top 10 scoring peptides were recorded in the order of their binding 
score. Briefly the SYFPETHI binding score system examines every amino acid within a 
peptide, giving a value of 1 for an amino acid only slightly preferred at its respective 
position, while amino acids which are optimal anchor residues are given the value of 
15. Amino acids are then scored depending upon their frequency within natural 
peptides previously eluted and characterised from the HLA molecule of interest. The 
scoring ranges from 1-15 based upon these frequencies, while negative values are also 
assigned when an amino acid has been shown as being disadvantageous in a particular 
position (Rammensee e ta l,  1999).
The molecular weight was calculated for each peptide generated, and the position of 
the peptide within the HLA class I a-chain was also recorded. This process generated a 
database containing peptides derived from the amino acid sequences of all HLA-A*, B* 
and C* encoded alleles (>6000) listed upon the HLA/IGMT database, which were 
predicted to match the binding characteristics of HLA-A*02.
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2.2.2 Identification of HLA-A*02 expressing THP-1 cells and recovery of their membrane 
fragm ent
The monocytic cell line THP-1 (ATCC TIB-202) was used as a source of HLA-A*02, as the 
previously reported HLA expression included HLA-A*02 (Tsuchiya eta l., 1980). THP-1 
cell line authentication was performed by HLA typing according to the PCR sequence- 
specific primers (SSP) phototyping method (Bunce eta l., 1995), and through 
commercially available short tandem repeat (STR) cell line authentication (LGC 
standards, UK). THP-1 cells were cultured in R PM I1640 medium (5% Fetal Calf Serum 
(FCS), 200mM L-Glutamine, 100 pg/ml penicillin/streptomycin (Life Technologies, 
Fulton, UK), until confluent. Cells were washed twice in 0.85 % phosphate buffered 
saline (PBS) (Life Technologies, Fulton, UK) (pH 6.8-7.2,) with 5% FCS and then 
resuspended in PBS. A confluent flask of THP-1 cells provided approximately lg  of cells 
post washing. A 3ml glass homogeniser was used to lyse the resuspended THP-1 cells, 
(5 plunges on ice), the resultant lysed cells were centrifuged at 5000g at 4°C for 10 
minutes, to remove the nuclear and mitochondrial components from the lysed cells. 
The pellet containing the nuclear and mitochondrial components was discarded, while 
the supernatant was retained and centrifuged at 100,000g at 4°C for 1 hour to isolate 
the membrane fraction. The supernatant was discarded and the pelleted membrane 
fraction was resuspended in 0.5M TRIS-HCI (pH 7.2).
2.2.3 Dynabead isolation of HLA-A*02 encoded molecules from the isolated membrane 
fraction
HLA-A*02 molecules were isolated from the membrane fraction using a Dynabeads co- 
immunoprecipitation kit (Life Technologies, Fulton, UK), this kit allows a pure protein 
isolate, without contamination from the isolating antibody. To obtain HLA-A*02 
molecules from the cell membrane fraction, monoclonal mouse anti-HLA-A*02, BB7.2 
(Abeam, Cambridge, UK), was coupled to M-270 magnetic dynabeads according to the 
kit protocol. Briefly, lOmg of M -270 magnetic dynabeads were washed in 1ml of kit C l 
wash buffer by pipetting, the magnetic beads were placed upon a Dynamag (Life 
Technologies, Fulton, UK) for 1 minute. This allowed attraction of magnetic beads to 
the Dynamag and therefore to move to the side of the separation tube, the C l wash 
was then aspirated and discarded. 14pg of BB7.2 antibody was transferred to the
separation tube with the addition of C l wash buffer to give a total volume of 500pl. An
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equal volume of C2 kit coupling reagent was added to this solution and gently mixed 
by pipetting, and placed on a rotating mixer for 24hrs at room temperature (RT). Post 
incubation, the separation tube was placed upon the Dynamag for 1 minute and the 
supernatant was aspirated. 800pl of HB kit wash reagent was added, and the beads 
were mixed by gentle vortexing and place upon the Dynamag for 1 minute, the 
supernatant was then removed. Subsequent washes using LB and then SB kit reagents 
repeated this process, the final SB wash buffer included a 15 minute incubation period 
on a rotating mixer at RT, prior to placing on the Dynamag and subsequent removal of 
the supernatant. The BB7.2 coupled M -270 dynabeads were then resuspended in 1ml 
of kit SB wash, giving a final concentration of lOmg/ml BB7.2 conjugated M-270  
dynabeads.
lm l of BB7.2 coupled dynabeads at lOmg/ml concentration was added to a tube 
containing the separated cell membrane fraction and placed upon a rotating mixer, 
ensuring the dynabeads remained in suspension for 40 minutes at 4°C. After this time 
the tube was placed upon the Dynamag, drawing the dynabeads to the side of the tube 
and the remaining liquid removed. The dynabeads were then washed using 200pl of kit 
extraction buffer by gentle pipetting, before placing upon the Dynamag and aspirating 
the supernatant as before, this was repeated three times. A final wash using kit LWB 
buffer consisted of the addition of 200pl of LWB buffer and a 5 minute incubation on a 
rotating mixer at RT, before aspiration post Dynamag incubation as before. After these 
washing stages, the BB7.2 captured protein was eluted by means of a glycine elution 
buffer, via a 5 minute incubation at RT on a rotating mixer and then placing on the 
Dynamag for 1 minute, the aspirated supernatant, containing the isolated HLA-A2, was 
transferred to a clean 1.5ml Eppendorf tube. Protein concentration of the eluted 
product was measured using the NanoDrop (Thermo Scientific, Wilmington, USA) 
spectrophotometer by measuring absorbance at 280nm, with the elution buffer being 
used to correct for background.
2.2.4 Confirmation of protein capture via Dynabead isolation
Following precipitation of HLA by BB7.2 anti-HLA coupled Dynabeads as described
above, the HLA protein was obtained while the capture antibody remained bound to
the Dynabeads. To confirm the presence of the protein purified by BB7.2 anti-HLA
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antibody, the elutant containing the protein was separated on a 12% Bis-Tris 1.6mm 
gel (Life Technologies, Fulton UK), in conjunction with a Novex sharp protein standard 
(Life Technologies, Fulton UK) protein size marker, via MOPS SDS (3-(N- 
morpholino)propanesulfonic acid, sodium dodecyl sulfate) (Life Technologies, Fulton 
UK) electrophoresis and then stained using silver staining (ProteoSilver Plus Pro Silver 
stain, Sigma-Aldrich, Dorset, UK) according to the manufacturer's instructions, with the 
single exception being within the stage of the silver staining assay termed sensitisation 
(whereby pores within the gel are generated to allow silver staining of the protein 
within the gel to occur). Briefly, the protocol fixes the gel, post electrophoresis, using a 
50% ethanol, 40% acetic acid with 10% H20 solution, followed by washing, firstly with a 
30% ethanol solution and then with distilled H20. The sensitisation stage was then 
performed using the kit sensitisation solution. As the 12% Bis-Tris gels used were of a 
greater thickness (1.6mm) than those recommended by the manufacturer (1.0mm) of 
the silver staining kit, optimum staining was obtained when the incubation time for the 
sensitising stage was increased to 20 minutes as opposed to the manufacturers7 
recommended 10 minutes. Further washing was performed using distilled H20, post 
sensitisation, before the kit silver stain solution was added for 10 minutes, and then 
decanted. The gel was then washed briefly (90 seconds) with distilled H20, the H20 was 
decanted and a kit developer solution was added. A constant visual inspection was 
maintained during gel development, when bands became visible upon the gel, a kit 
stop solution was added for 5 minutes to stop the reaction, before a final wash and 
storage in H20. The stained bands on the gel were excised using a scalpel and de­
stained according to the silver staining kit protocol, by addition of gel destaining 
solution until the band disappeared and then washing with H20. An 'in-gel7 digest was 
performed upon the excised destained fragments to release the peptides bound by 
HLA captured by BB7.2 for analysis via MALDI MS/MS.
2.2.5 7In-gel7 digestion of excised gel fragments
Each excised and destained gel fragment was placed in a 1.5ml Eppendorf tube with 
75pl of lOOmM ammonium bicarbonate : acetonitrile (ACN) (1:1), vortexed and 
incubated for 15 minutes at room temperature, the solution was then aspirated and 
the process repeated once. 75pl of 100% ACN was then added for 30-60 seconds until 
the gel fragments had shrunk and turned white, the ACN was then aspirated and
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discarded. The gel fragments were then rehydrated in digestion buffer, containing 
50mM NH4HC03; 5mM CaCI2, 12.5ng/ml proteomic grade trypsin (Sigma-Aldrich, 
Dorset, UK), ensuring the gel fragments were covered and then incubated on ice for 15 
minutes. The supernatant was then removed and replaced with 70pl 50mM NH4HCO3, 
5mM CaCI2solution and incubated at 37°C overnight. The gel fragments were briefly 
centrifuged for 60 seconds at 500g to pellet the fragment and allow aspiration and 
transfer of the supernatant into a new 1.5ml Eppendorf tube. The resultant 
supernatant was concentrated and desalted using an Amicon Pro 3kDa filtration device 
(Millipore, Maine, USA) and then analysed via MALDI MS immediately.
2.2.6 Alternative method of peptide isolation using Superdex 75 column
An alternative protocol to obtain peptides from the HLA-A2 molecules isolated in 
section 2.2.3 utilized an Akta purifier (Amersham Biosciences, UK) coupled with a 
Superdex 75 column (GE Healthcare Lifesciences, Buckinghamshire, UK), to achieve 
liquid chromatographic separation based upon size in a 0.05M PBS (Life Technologies, 
Fulton, UK) 0.15M NaCI pH7.0 buffer run at 0.5ml/min. Protein isolated with an 
approximate size of 500-1500 Da was predicted to contain peptide which was derived 
from the protein bound by the BB7.2 isolated HLA and was utilized for MALDI MS/MS. 
The protein separation characteristics of the column are determined for known RMM  
standards separated upon the column. Bovine Serum Albumin (BSA) (67,000 kDa) 
8mg/ml, Ovalbumin (43,000 kDa) 25mg/ml, Ribonuclease (13,700 kDa) 5.0mg/ml, 
Aprotinin (6,512 kDa) 0.5mg/ml and Vitamin B12 (1,355 kDa) 0.1 mg/ml were used for 
this purpose, protein standards were filtered through a 0.45pm filter to remove 
aggregates. As fractions were eluted from the column, protein was detected by 
absorbance at 280nm. All fractions from the column were collected in 1ml aliquots 
directly from the column and were retained. Fractions predicted to contain the 
isolated peptide based on size were concentrated and desalted using an Amicon Pro 
3kDa filtration device (Millipore, Maine, USA) before MALDI MS analysis to remove any 
aggregates.
2.2.7 MALDI MS/MS and bioinformatic database assessment of isolated fragments 
As recommended for protein and peptide analysis of targets <10kDa, a MALDI matrix 
constituting lOmg/ml a-cyano-4-hydroxycinnaminic acid (CHCA) in 50% ACN, 50% H20
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and 0.1% trifluoroacetic acid (TFA) (Hoffmann and Stroobant, 2007) was pipetted 
(0.5pl) onto a MALDI OPTI TOF 192 target plate (Applied Biosystems, CA, USA) and left 
to dry for 20 minutes. The proteins isolated as described in 2.2.5 and 2.2.6 were 
pipetted (0.5pl) directly onto the dried MALDI matrix and left to dry for 10 minutes. 
After drying, the MALDI plate was loaded onto a QSTAR mass spectrometer for protein 
analysis. Any resultant peaks upon the mass spectra were searched within the 
bioinformatic database generated within 2.2.1 of this section for corresponding 
molecular weights of the predicted peptide ligands. For example if an m/z ratio of 1115 
was observed within the mass spectra, then a search for a peptide within the database 
corresponding to this molecular weight was performed. If any hits within the database 
were observed, MALDI MS/MS was performed upon the specific identified peptide to 
derive its sequence. The sequence described within the database was entered into the 
MS product peptide fragment calculator (www.prospector.ucsf.edu) to aide this 
process. In addition, the potential sequence as described within the database were 
commercially synthesized (ThinkPeptides, Oxford, UK and Pepceuticals, Enderby, UK) 
and reconstituted from lyophilised powder via a step wise addition of dimethyl 
sulphoxide (DMSO) (Sigma-Aldrich, Dorset, UK). These commercially synthesized 
peptides were analyzed by MALDI MS/MS therefore allowing direct comparison with 
the peptides generated from the HLA-A*02 molecules isolated from THP-1 cells. Thus, 
if a peptide was identified within the isolated HLA-A*02 elutant, which corresponded 
to the molecular weight and sequence of a peptide within the database then it could 
confidently be stated to be identified as an HLA-class I derived peptide, which is 
presented by HLA-A*02. In a final step however a binding assay was performed to 
assess the ability of the identified peptide to be bound by HLA-A*02.
2.2.8 HLA-A*02 peptide binding assay using the T2 cell line.
Previously described minor histocompatibility antigens (mHAG), shown to bind to HLA- 
A*02 (Spencer et al., 2010) were used as positive controls. These were HA-1, HA-2 and 
SMCY mHAG, with the following sequences VLHDDLLEA, YIGSVLISV and FIDSYICQV 
respectively. The positive controls were synthesized as outlined for the test peptides 
in section 2.2.7. Optimal concentration of peptide (25pg/ml) for the binding assay was 
established via titration with the HA-1, HA-2 and SMCY peptides at 5pg/ml -  200pg/ml 
concentrations.
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The binding assay was performed as previously described (Pinilla-lbraz eta l., 2006). 
Briefly 1 x 106 T2 cells were washed in serum free R P M I1640, and incubated overnight 
at 37°C 5% C02/95%  air with lOpg/ml |32-microglobulin (Sigma-Aldrich, Dorset, UK) and 
optimal test peptide concentration (25pg/ml). T2 cells were then washed to remove 
peptide not bound to HLA-A*02, in serum free RPMI 1640 (Life Technologies, Fulton, 
UK) media and stained with mouse monoclonal anti-w6/32 (w6/32 is the name of the 
cell line first used to produce the antibody) lgG2a conjugated to Phycoerythin (PE) 
(Abeam, Cambridge, UK) for 30 minutes, followed by washing (x3 in RPMI 1640 at 
500g) to remove unbound antibody and fixing with 0.5% paraformaldehyde (Sigma- 
Aldrich, Dorset, UK)/0.05M PBS (Life Technologies, Fulton, UK). Analysis was 
performed using a FACSCalibur (BD biosciences, Oxford, UK) flow cytometer and 
fluorescence measured upon the FL-2 channel. Negative controls of DMSO alone and 
Class II derived peptides in DMSO, previously described as being able to be bound by 
HLA class II molecules (Costantino et o i, 2012) which were a kind gift from Dr Aravind 
Chekuri (St James University Hospital, Leeds, UK) were also used. Gates were set using 
a monoclonal isotype lgG2a PE conjugate control (Abeam, Cambridge, UK). Positivity 
was calculated by means of a fluorescence Index (FI), this being:
FI te s t  p e p tid e  -  FI n e g a tiv e  c o n tro l 
FI n e g a tiv e  co n tro l
A FI >0.5 was considered positive, which corresponds with the previously reported 
methods of determining positive reactions within this assay (Zhu eta l., 2003; Stuber et 
a!., 1994)
2.2.9 Reproducibility of assays described in section 2
All experiments described within this chapter were set up in triplicate, and repeated 
on at least three occasions unless otherwise stated.
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peptides bound by HLA- 
A *02 molecules
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Confirm  binding to  HLA- 
A*02 via peptide binding 
assay using the  T2 cell 
line
v; .
•  O b t a in  a m in o  a c id  s e q u e n c e s  f r o m  th e  H L A / I M G T  d a ta b a s e  f o r  a l l  
H L A  c la s s  I  a -c h a in s  l is t e d
• E n t e r  s e q u e n c e s  in t o  th e  S Y F P E I T H I  p e p t id e  p r e d ic t io n  s o f t w a r e  a n d  
c a lc u la te  p r o b a b i l i t y  o f  b in d in g  to  H L A - A *02
•  F o r  th e  to p  10 r a n k e d  p e p t id e s  f o r  e a c h  H L A  c la s s  I  a - c h a in s  e n te r e d ,  
re c o r d  th e  s e q u e n c e  in  th e  b io in f o r m a t ic  d a ta b a s e  a lo n g  w i t h  th e  
c a lc u la te d  m o le c u la r  w e ig h t ,  s e q u e n c e  p o s it io n  a n d  S Y F P E I T H I  s c o re
•Lyse THP-1 cells w ith  a glass homogeniser and isolate m em brane 
frac tion  by u ltracentrifugation
• Perform  dynabead isolation o f membrane frac tion  to  obtain HLA-A*02 
molecules
•Separate isolated HLA-A*02 molecules via SDS MOPS, o r using AKTA 
pu rifica tion
•Com pare m /z ra tio  o f peptides obtained to  those p redicted in the 
peptide database
•Investigate any peptide 'h its ' w ith in  the database and pe rfo rm  MS/MS 
peptide sequencing upon the isolated peptide, and a synthetic 
peptide which possesses the same sequence as th a t iden tified  in the 
database fo r  comparision
• Confirm any peptide fo r  which the  same mass spectra is observed fo r  
the synthesized peptide as th a t obtained from  THP-1 cells can bind to  
the T2 cell line
Figure 2.2 An overview of the work flow for experimental methods utilised within Chapter 2.
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2.3 Results
2.3.1 Generation of the HLA-A*02 specific HLA class I derived peptide database 
The peptide database currently contains nearly 3000 peptides, with sequences derived 
from HLA class I molecules, which are predicted to bind to HLA-A*02 encoded antigens 
with a high affinity, according to the algorithm utilized within the SYFPEITHI program.
A screenshot of the database is shown in Figure 2.3. The database groups peptides into 
the 10 top scoring peptides for each HLA allele, these alleles in turn are grouped into P 
groups (i.e. they contain the same protein sequence within their peptide binding 
region). The database was structured in this way to keep the data as concise as 
possible to aide in searching. For each peptide sequence recorded, the HLA alleles 
encoding the peptide are shown, along with the position of the peptide sequence 
within the HLA allele encoding it, followed by the score assigned by the SYFPEITHI 
program and then the calculated molecular weight. This allows the database to be 
searched for peptide sequences which match a particular molecular weight, or to 
search for peptides derived from particular regions within the amino acid sequences of 
the HLA-class I a-chain. This is achieved by using the 'find' function within the 
Microsoft excel program. For searching for a peptide of a molecular weight of 999 Da, 
for example the user would enter 999 in the 'find' function, and any peptide with this 
molecular weight can be viewed and searched through, recording the alleles encoding 
the peptide, the peptide sequence and position of the peptide as the user progresses 
through the search.
2.3.3 Obtaining peptides from HLA-A*02 molecules
In order to validate the database, peptides were obtained from HLA-A*02 molecules 
expressed by the THP-1 cell line. Figure 2.4 shows the eluted products of the Dynabead 
isolation of HLA-A*02 by the HLA-A*02 specific BB7.2 monoclonal antibody, from the 
membrane fraction of THP-1 cells. The gel was stained via the sensitive silver staining 
method, and the images reveal three distinct bands obtained by the 
immunoprecipitation, this corresponds to previously described properties of BB7.2 
(Peace-Brewer et al., 1996; Brady et al., 2000). The three bands visible have been 
described as a result of different sialic acid /  glycosylation states by these authors. 'In 
gel' digests were performed upon all three excised bands and multiple common
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peptides were identified within the bands as would be expected from a single HLA- 
A*02 encoded antigen.
Separation of the BB7.2 purified product from the Superdex 75 column reveals several 
protein peaks, as determined by measurement of absorbance at 280nm, as fractions 
were eluted from the column (Figure 2.5). The reported optimum separation capacity 
of the Superdex 75 column is between 70,000-3,00008, as a consequence the fractions 
most likely to contain the peptide, which were obtained from bound HLA-A*02 
(approximately 500-1,500Da), would be expected to be eluted off within the last 
fractions from the column. The last fractions collected showed a corresponding 
estimated size of approximately lOOODa, according to the characteristics of the column 
in terms of the elution time for the protein standards.
2.3.4 MALDI MS fo r preliminary identification of peptides 
The MALDI MS of the peptides produced by both methods, produced MS spectra 
containing peptides, which were within the size range of peptides which expected to 
be bound by HLA class I molecules (approximately 500-1500Da) (Figures 2.6, 2.7 and 
2.8). MALDI MS analysis of the matrix only, aided determination of the m/z peaks 
which were associated with the matrix, allowing analysis of true peptide m/z data only. 
The m/z ratios of the peptides were entered into the peptide database, as described in 
section 2.2.7. Hits within the database are marked on the MS spectra. Figure 2.6 shows 
8 peptides with m/z ratios ranging from 1013.66 to 1098.01. When these were entered 
into the peptide database, 1013.66,1050.12,1066.08 and 1098.01 produced a hit with 
potential sequences of VMAPRTLIL and/or VMAPRTLLL (1013.66), QLRALEGT (1050.12), 
YLENGKETL (1066.08) and YWDGETRKV (1098.01) being given, these were shown to be 
encoded for by various HLA molecules by the peptide database.
In terms of the size of the peptides within the final fractions eluted from the Superdex 
75 column, the MALDI MS analysis determined their size to be within 900 and 1200Da 
as expected by the determined characteristics of the column (Figure 2.5[B]). 
Furthermore, MALDI MS/MS established the sequences corresponded with those 
peptides obtained from the excised gel fragments and 'in gel' digests, and those from  
the column separation.
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2.3.5 Determination of HLA type fo r THP-1 ceils and characterisation o f HLA derived 
peptides bound to HLA-A*02
The cell line validation of THP-1 included the determination of the HLA type, this 
identified a discrepancy with the previously reported HLA type for THP-1 (Tsuchiya et 
al., 1980), allowing a higher resolution revised THP-1 HLA type, HLA-A*02; B*15; C*03; 
DRB1*01, DRB1*15; DRB5*01/02; DQB1*05, DQB1*06, to be determined (Battle e ta l ,
2012). The previous type being reported as HLA-A2, A9, B5, DRwl and DRw2 (Tsuchiya 
eta l., 1980) (the nomenclature used here corresponds to the contemporary system at 
the time of THP-1 cell line establishment), specifically the reported higher resolution 
type now includes alleles at the additional HLA-C*, DRB5*, and DQB1* loci, and 
identifies HLA-A as being homozygote for HLA-A*02 rather than co-expressing HLA-A9. 
The HLA-B* alleles were shown to be B*15 rather than those encoding for the B5 
antigen, and finally the reported DRw2 serological antigen is split into the DRB1*15 
alleles which encode for the DRw2 antigen.
The HLA type of THP-1 included those antigens which encoded the peptides identified 
as hits within the database from the MALDI MS data in Figure 2.6 VMAPRTLIL (1013.66) 
being encoded for by HLA-C*03, QLRALEGT (1050.12) by HLA-A*02, YLENGKETL 
(1066.08) by HLA-A*02 and B*15, and YWDGETRKV (1098.01) encoded for by HLA- 
A*02.
VMAPRTLLL (1013.66) was not encoded for by HLA molecules expressed upon THP-1. 
The peptide database identified VMAPRTLLL as being encoded for by HLA-A*01, A*03, 
A* 11, A*29, A*30, A*31, A*32, A*33, A*36, A*74; C*02, C*15 molecules.
All the HLA alleles which are capable of encoding the peptides identified in Figure 2.6 
and producing hits within the peptide database are shown in table 2.2. In addition the 
table catalogues all peptides identified as hits within the database within figures 2.7 
and 2.8. Showing a total of thirteen peptides, seven of which produced hits within the 
database. The MALDI MS spectrum in Figure 2.7 reveals a single peptide hit,
ALGFYPAEI (M W  980 Da) which is encoded by HLA molecules which include HLA-B*15 
antigen on THP-1. Two other peptides did not produce a hit within the database. In 
Figure 2.8 two further hits were observed, with peptides SMRYFTTSV (M W  1137 Da) 
and SMRYFYTSV (M W  1153 Da), both of which are encoded by various HLA molecules
(see table 2.2) including HLA-A*02, which is expressed by THP-1 cells.
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Those peptides which did not produce a hit within the peptide database are also 
shown within table 2.2 which include masses of 1002 ,1018 ,1029 ,1031 ,1060  and 
1082 Da. Other peaks within the MS spectra shown within figures 2.6, 2.7 and 2.8 
represent those associated with the MALDI matrix used within the method to aid the 
ionisation of the proteins. The m/z ratio of 1013.66 was the only result which provided 
two hits within the database, all other peaks resulted in a single, or no hit within the 
database. In addition the 1013.66 m/z ratio was the only peak which resulted from a 
HLA molecule which was not encoded for by THP-1 cells. Albeit this was in conjunction 
with a peptide hit which did have a HLA molecule encoding it, which was 
demonstrated as being expressed upon THP-1 cells, VMAPRTLIL (1013.66), being 
encoded for by HLA-C*03 on THP-1 cells. The identification of peptides in this manner 
produced a tentative identification, which required further analysis to confirm that the 
sequences of the peptides identified by their MW , have the same amino acid 
sequences as those within the peptide database.
2.3.6 MALDI MS/MS sequencing of peptides identified in 2.3.4 
In order to confirm the identity of the peptide sequences MALDI MS/MS was 
performed. Table 2.3 and 2.4 shows the predicted fragmentation products of the 
peptides identified with a M W  of 1013Da. These being VMAPRTLIL and VMAPRTLLL, 
which were obtained using the MS product peptide fragment calculator 
(www.prospector.ucsf.edu). Tables 2.3 provides the M W  of the b, c, y and z ions (as 
per Roepstorff-Fohlmann-Biemann nomenclature described in section 2.1.5) which 
would be expected to be produced if the peptide was in fact VMAPRTLIL, while table
2.4 contains a more comprehensive list of potential peptide fragmentation products, 
which includes fragmentation products which have lost H20 , NH2 and COOH groups 
(amongst others) during the MS/MS analysis. Unfortunately, as VMAPRTLIL and 
VMAPRTLLL differ only by the presence of amino acids leucine and isoleucine, at the 
same positions within the peptide, and both of these amino acids have the same 
molecular weight (131.18 Da), their fragmentation patterns are identical. This 
confounds the ability to determine between them in this manner and only the 
presence of both of these peptides should be considered. The fragmentation pattern 
observed during MALDI MS/MS does however match the expected patterns of these 
two peptides (Figure 2.9).
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In an additional confirmation step, a synthetic peptide commercially synthesized to 
have the same sequence as VMAPRTLIL was also subjected to MALDI MS/MS. This also 
shows the same peptide fragmentation products induced through collision induced 
dissociation (CID) during MS/MS (Figure 2.10). This reveals a MS/MS spectrum that 
matches the predicted peptide fragmentation patterns of VMAPRTLIL given in tables
2.2 and 2.3, and the peptide fragmentation pattern seen within the MS/MS spectrum 
of the peptide identified by the M W  of 1013 Da. Confirming that this is most likely 
either peptide VMAPRTLIL or VMAPRTLLL. As the MALDI MS/MS was able to confirm 
the presence of either VMAPRTLIL or VMAPRTLLL, but not determine between them, 
the flow cytometry T2 peptide binding assay was used to establish if both of these 
peptides could in fact be bound by HLA-A*02, the source of the initial bound peptides. 
Figure 2.11 presents this data as overlaid flow cytometry histograms, demonstrating 
assay validity via the positive and negative controls and then showing the overlaid 
VMAPRTLIL peptide result over the negative control. This demonstrates this peptide 
binds to FILA-A*02 on the T2 cells. However, the VMAPRTLLL peptide does not appear 
to stabilize the HLA-A*02 molecules present on T2 cells. This can be seen in the 
histogram showing the VMAPRTLLL peptide laid over the negative control. Comparison 
of the histograms shows VMAPRTLIL strongly stabilizes the HLA-A*02 molecules, while 
VMAPRTLLL closely resembles the negative control.
Interestingly the peptide database reveals that both the VMAPRTLLL and VMAPRTLIL 
peptides are found at a common site of their respective HLA antigens, both being 
present at position 3 of the HLA-class I a-chain. This region contains the leader peptide 
sequences of HLA class I molecules, and was investigated further in chapter 3.
However, since the leader peptides appear to have common characteristics, an 
analysis was performed to determine if any other leader sequences could be bound by 
HLA-A*02. Commercially synthesized leader peptides were subjected to the same T2 
binding assay as the VMAPRTLLL and VMAPRTLIL peptides.
This reveals that VMAPRTLIL (identified as leader peptide 7 and highlighted yellow) is 
the only leader peptide which is capable of binding to HLA-A*02 as this is the only 
peptide stabilizing HLA-A*02 at the surface, all the other leader peptides, shown in 
Figure 2.12 as leaders 1, 2, 3, 4, 5, 6, 8, 9 and 10 (with their sequences also given), have 
a FI of less than 0.5.
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This includes the VMAPRTLLL peptide (also highlighted yellow to enable easier 
comparison with VMAPRTLIL), this again confirms that VMAPRTLIL is able to be bound 
by HLA-A*02 and VMAPRTLLL is not.
Considering that THP-1 cells do not express the HLA molecules which include a 
VMAPRTLLL peptide, and that the VMAPRTLLL peptide cannot be bound by HLA-A*02, 
the molecule used as a source of these peptides, then the VMAPRTLLL peptide is 
extremely unlikely to be the potential 1013 M W  peptide identified in the peptide 
database. The VMAPRTLIL peptide however, which was also identified within the 
database, can be bound to HLA-A*02 and is also present in one of the HLA molecules 
which is expressed upon THP-1, specifically the HLA-C*03 molecule.
MALDI MS/MS of the other peptides identified as hits within the peptide database did 
not suffer the potentially confounding problems of two identical peptide masses being 
identified within the peptide database. Of those other peptides tentatively identified 
by the peptide database and MALDI MS, the peptide with the ALGFYPAEI (M W  980) 
sequence was the only other peptide which was present within the HLA molecules 
present upon THP-1 cells, which was also not present in the HLA-A*02 molecule (table 
2.2), ALGFYPAEI being present in the HLA-B*15 molecule on THP-1 cells. Again to 
confirm its identity MALDI MS/MS sequencing was performed.
The fragmentation products which would be expected from the ALGFYPAEI (M W  980) 
peptide are shown in table 2.5 for the b, c, y and x ions and table 2.6 for other 
potential fragmentation products.
The MALDI MS/MS spectrum for ALGFYPAEI (Figure 2.13) reveals a fragmentation 
pattern which matches that predicted for ALGFYPAEI, confirming the presence of this 
peptide. Therefore both ALGFYPAEI and VMAPRTLIL are confirmed as being bound by 
HLA-A*02. Neither of these peptides sequences are present in HLA-A*02 molecules, 
indicating that they are a result of peptides being bound by HLA-A*02. The ALGFYPAEI 
peptide is found within the HLA-B*15 molecule (table 2.2) present upon THP-1 cells, 
and this peptide is then presented by HLA-A*02. Interestingly ALGFYPAEI is present in 
several other HLA alleles according to the peptide database, these being HLA-A*01, 
A*03, A* 11, A*23, A *24, A*30; B*15, B*18, B*27, B*35, B*38, B*39, B*40, B*41, B*42, 
B*44, B*45, B*46, B*47, B*48, B*49,
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B*50, B*51, B*52, B*53, B*54, B*55, B*56, B*57 (table 2.2), incorporating both HLA-A 
and B alleles. The VMAPRTLIL peptide in comparison is present in several HLA-C 
molecules, specifically HLA-C*01, C*03, C*04, C*05, C*06, C*08, C*12, C*14, C*16,
C* 17:02 (table 2.2).
2.3.7 Assessing peptide binding to HLA-A*02 via the T2 peptide binding assay 
As with peptide VMAPRTLIL, to ensure peptide ALGFYPAEI was capable of being bound 
to HLA-A*02, the T2 binding assay was performed for ALGFYPAEI. The results of this 
experiment are shown in Figure 2.14 and reveal ALGFYPAEI has a FI of 1.5, 
demonstrating binding, highlighted in yellow and identified as peptide 19. In addition 
to this data, Figure 2.14 also contains the T2 binding assay data of 8 peptides 
commercially synthesized from sequences contained within the peptide database. 8 
peptides within the database were selected at random. The T2 binding assay of these 
peptides, reveals two peptides had a FI of greater than 0.5 demonstrating they are 
correctly predicted as being able to bind to HLA-A*02. The remaining six did not bind 
with FI of less than 0.5.A final peptide with the sequence of SMRYFYTSV, identified as 
peptide 20 in Figure 2.14, is also shown as not binding to HLA-A*02 (Fl<0.5). This 
peptide is present in one of the HLA antigens expressed by THP-1 cells, HLA-A*02 and 
also by six other HLA-A allele groups which are not present on THP-1 cells, HLA-A*11, 
A*25, A*26, A*34, A*66  and A *68. The SMRYFYTSV peptide was tentatively identified 
within the peptide database after a providing a hit from the MALDI MS (Figure 2.8) 
with a M W  of 1153 Da, and was speculatively synthesized for the T2 binding assay. The 
lack of binding within this assay however means it is unlikely to be the correct 
sequence. In order to confirm this, MALDI MS/MS analysis was performed upon the 
identified M W  1153 Da peptide. The fragmentation products for SMRYFYTSV predicted 
to be present are given in table 2.7 and 2.8, while the MS/MS spectrum for the M W  
1153 Da peptide is shown in Figure 2.15. The MS/MS spectrum does not correspond to 
the predicted fragmentation products, with the only fragmentation product observed 
being that of arginine, as indicated on the spectrum. Demonstrating that the peptide 
with the M W  of 1153 Da, is not the SMRYFYTSV peptide which produced a hit within 
the database, although it does contain arginine. A summary of these experiments is 
shown in table 2.9, which provides the sequences of all the potential peptides 
tentatively identified as hits within the peptide database, followed by the results of the 
MALDI MS/MS analysis and the T2 peptide
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binding assay. This summary table includes three peptides which, as with the 
SMRYFYTSV peptide, were demonstrated as not corresponding to those providing a hit 
in the peptide database when analysed by MALDI MS/MS. These peptides have the 
following sequences and MW , SMRYFTTSV (1137 Da), TLLLLLLGA (926 Da) and 
YLENGKETL (1066 Da). Because the peptides were not confirmed as present by MALDI 
MS/MS they were not commercially synthesised to perform the T2 binding assay in 
order to reduce costs, with the exception of the TLLLLLLGA (926 Da) peptide, which 
was included in the random selection of peptides analysed in Figure 2.14, for their 
ability to bind to FILA-A*02 in the T2 assay, this produced a negative result.
In total, two peptides were confirmed as being bound by an FILA-A*02 molecule, these 
being ALGFYPAEI and VMAPRTLIL (highlighted in yellow in table 2.9), which were 
present in the FILA-B*15 and FILA-C*03 molecules respectively, expressed on the TFIP-1 
cell line.
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2.4 Discussion
The creation of a peptide database, which contains those sequences which are 
predicted as likely to be bound by HLA-A*02, and are themselves derived from HLA 
class I molecules, has provided a mechanism for identifying two peptides, which are 
encoded for by one HLA class I molecule and bound and presented by another (HLA- 
A*02). Specifically the ALGFYPAEI and VMAPRTLIL peptides, which are encoded for by 
HLA-B*15 and HLA-C*03 alleles within the THP-1 HLA type (Battle et a i,  2013) 
respectively. In addition to these alleles, several other HLA alleles encode these 
peptides, ALGFYPAEI is encoded for by HLA-A*01, A*03, A * l l ,  A*23, A*24, A*30;
B*15, B*18, B*27, B*35, B*38, B*39, B*40, B*41, B*42, B*44, B*45, B*46, B*47, B*48, 
B*49, B*50, B*51, B*52, B*53, B*54, B*55, B*56, B*57 and VMAPRTLIL by HLA-C*01, 
C*03, C*04, C*05, C*06, C*08, C*12, C*14, C*16 and C*17:02.
In terms of allorecognition this finding is of some significiance. If an allograft recipient 
has an HLA type which includes the HLA-A*02 molecule, but does not include include 
any of the other HLA molecules containing the ALGFYPAEI and VMAPRTLIL sequences, 
then the recipient will have had no experience of these peptides when central 
tolerance was established, although they will have been selected to recognise HLA- 
A*02 molecules.
As a consequence if the organ donor's HLA type included both the HLA-A*02 molecule 
as well as one (or more) of the HLA alleles encoding the ALGFYPAEI and VMAPRTLIL 
peptides, then the allograft recipient will be able to recognise the donor's HLA-A*02 
and then form a response to the ALGFYPAEI and/or VMAPRTLIL peptide which is bound 
within it. This is a similar mechanism to that of mHAGs allorecognition, with the 
exception that instead of a non-HLA polymorphism encoding the protein being 
presented, it is another HLA antigen.
Extending this concept further, the HLA type of donor and recipient pair could be
considered not only as being matched or mismatched in terms of their shared HLA
molecules, but when they are mismatched, the extent to which their mismatches are
able to generate peptides capable of being bound by the matched antigens could also
be considered. In some situations permissible mismatches may be possible in this
context. Whereby the HLA antigens which are mismatched contain either peptides
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which cannot bind to the matched antigens, or have peptide sequences which are 
shared with other HLA antigens which the donor does possess.
The concept of matching of peptides in this manner would require a significant amount 
of time and effort to become fully realised. The work described here provides a proof 
of principle and includes only 3000 peptides within the peptide database, and only in 
the context of binding to the HLA-A*02 molecule. Both of these limitations would need 
to be expanded further to generate any realistic utlity. However the proof that 
alloresponses are derived from mismatching of peptides can be seen in the role of 
mHAG in HSCT cases, and via the concepts such as the binary complex theory.
In terms of the location of the peptides which were identified within chapter two, it is 
interesting to note that two peptides which were predicted as likely to bind to HLA- 
A*02 were leader peptides, and present at postition 3 of the a-chain. Analysis of the 
leader peptides is performed in greater detail within chapter three, which discusses 
the role which these peptides have within the immune system. However in terms of 
being able to be bound by HLA-A*02 only one of the leader peptides tested produced a 
postive HLA-A*02 T2 peptide binding assay result, the VMAPRTLIL peptide.
Chapter 2 provides a proof of principle of this approach to identifying the different 
peptides which are derived from one HLA molecule and presented by another.
In summary the work described includes:
•  The creation of a peptide database, which contains peptides derived from HLA 
molecules predicted to be bound by HLA-A*02
•  The utility of this peptide database in characterising peptides derived from one 
HLA molecule and presented by another
•  The identification of peptides within this context, ALGFYPAEI and VMAPRTLIL, 
and demonstration of which HLA molecules these peptides can be derived from
•  Evidence that only one HLA class I leader sequence peptide can be bound to 
HLA-A*02.
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Chapter 3 -  Endogenous derived class I leader 
peptides and renal transplant outcome
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3.1.1 Introduction
In chapter 2 an endogenous HLA class I leader peptide was identified which bound to 
HLA-A*02 molecules. Specifically the leader peptide from HLA-C*03 molecule was 
detected on HLA-A*02 molecules expressed on THP-1 cells, which was used for the 
BB7.2 (anti-HLA-A*02) antibody targeted magnetic bead purification. Although there is 
variable interpretation of the use of the term leader peptide (Molhoj and Degan,
2004), in the cases of HLA class I derived leader peptides, which are reported within 
the literature (Lee e ta i,  1998; Braud eta l., 1997), the definition of a peptide which 
'directs the ribosome to the ER, and initiates the growing protein across it before being 
cleaved and secreted into the external environment', is appropriate here. These 
proteins are of potential significance within alloresponses, as they can clearly be 
presented at the cell surface by HLA, therefore they could be potential targets for 
recognition by CD8+ T cells if bound by HLA-Class I. The leader sequences would be 
present at high levels due to their secretion into the cytosol whenever HLA is 
synthesized, thus potentially providing an abundant target for alloreactive T cells in 
accordance with the principles discussed in chapter 1. Furthermore HLA class I leader 
sequences have been shown to have novel roles regarding non-classical HLA-E 
expression and function, which may have an influence upon the alloresponse (Petrie et 
al,, 2008).
3.1.2 HLA class I leader peptides and HLA-E
Expression of HLA-E has been shown to rely significantly upon the binding of HLA class 
I leader sequences in a TAP dependent manner (Lee et a i, 1998). This expression is 
crucial for HLA-E to act as a ligand for the CD94/NKG2 family of receptors, which are 
expressed upon Natural Killer (NK) cells (Petrie e ta lw 2008). Furthermore HLA-E has 
been shown to act as a presenter of antigen to the a-(3 TCR on T cells, via the 
presentation of cytomegalovirus (CMV) derived peptides in a HLA-E restricted manner 
to the cx-p TCR of CD8+ T cells (Tamouza et al., 2006; Allard et al., 2012). Thus HLA-E 
mediated immunity spans both innate and adaptive immune responses. Currently the  
HLA/IMGT database lists 13 HLA-E alleles which encode for 5 proteins, however the 
reports within the literature regarding HLA-E focuses upon alleles HLA-E*01:03 and 
01:01, as these are the only two widely represented alleles (Hosseini et al., 2013).
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The importance of HLA-E within the transplantation setting has received a relatively 
small amount of interest in comparison to classical HLA molecules. However several 
studies now suggest that HLA-E polymorphisms are associated with a lower incidence 
of GvHD and transplant related mortality (TRM) following HSCT (Hosseini e ta l., 2013; 
Tamouza e ta l., 2006; Danzer eta l., 2009). In particular a better overall survival was 
seen in patients homozygous for HLA-E*01:03, post HLA matched HSCT (Tamouza et 
al., 2006; Danzer eta l., 2009). The influence of HLA-E within solid organ 
transplantation is relatively unreported; however HLA-E expression has been shown to 
be significantly increased within renal biopsy specimens undergoing a rejection event 
(Crispim et al., 2008).
A comparison of the two most common alleles, HLA-E*01:01 and 01:03, reveals that 
they differ by a single amino acid at position 107, which is found within the a2 domain 
of HLA-E (Danzer et al., 2009). This variation allows HLA-E*01:03 to bind the HLA class I 
derived leader peptides with a greater affinity than HLA-E*01:01, and consequently 
HLA-E*01:03 molecules are expressed at significantly higher numbers at the cell 
surface (Danzer et al., 2009). Once at the cell surface, HLA-E interacts with the 
CD94/NKG2 family of receptors, which comprise both inhibiting (NKG2A and B) and 
activating receptors (NKG2C, E and F) on NK cells (Heatley eta l., 2013). Interaction of 
HLA-E with these activating and inhibitory receptors results in an activating or 
inhibitory signal to the NK cell, dependent upon the balance of these stimuli (Vales- 
Gomez et al., 1999).
Interestingly the NKG2 inhibitory receptor, NKG2A, which prevents NK cell dependent
cell lysis after activation, has been exploited by certain pathogenic viruses in an
immunoevasive mechanism (Heatley et al., 2013). As variation in the leader sequences
bound by HLA-E affects the ability of CD94/NKG2 receptors to recognise their HLA-E
target (Hoare et al., 2008), certain CMV strains have evolved to take advantage of this,
by mimicking HLA-class I leader sequences themselves. The human CMV strain AD169
for example, contains a nonomer sequence exactly homologous to a leader peptide
sequence from HLA-C, which has been shown to upregulate HLA-E surface expression
and inhibit NK mediated cell lysis (Tomasec eta l., 2000). This mimicry presumably
evolved due to evolutionary pressure induced by the viral strategy of down regulating
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classical HLA class I surface expression to avoid CD8+ cytotoxic T cell immunity 
(Mazzarino et al., 2005). Due to this down regulation of HLA class I, the virus becomes 
susceptible to NK mediated lysis mechanisms, which result from the detection of a 
reduction in surface expression in HLA. One such mechanism being a lack of HLA-E 
expression as a result of reduced leader peptide availability (a consequence of down 
regulating the classical HLA expression); by providing a homologous HLA-E leader 
sequence, AD169 maintains HLA-E surface expression (Mazzarino eta l., 2005) and thus 
avoids the NK cell mediated lysis. Demonstrating the specificity of this mechanism, 
CMV specific effector memory cells, which target infected cells in an HLA-E restricted 
manner, are detectable only within those patients who do not have the leader peptide 
sequence mimicked by CMV within their HLA type (Mazzarino et al., 2005), i.e. patients 
who possess a different leader sequence to the one CMV is mimicking can effectively 
target and kill the viral infection. This finding has potentially profound implications in 
the setting of organ transplantation. Transplant recipients who possess CMV-specific 
effector memory cells, which are HLA-E restricted, and receive an allograft which 
expresses HLA class I molecules encoding the leader peptide mimicked by CMV, will 
form an alloresponse via the CMV specific memory effector cell recognition of leader 
peptide (mimicked by the CMV strain) and bound by HLA-E expressed on the allograft.
3.1.3 Allorecognition and HLA class I derived leader sequences
It is interesting to note that of the reports on HLA-E polymorphism and transplantation 
outcome, it is the HLA-E*01:03 allele, which encodes a surface antigen expressed at 
higher levels than its equally common counterpart HLA-E*01:01, that is associated 
with reduced TRM post HSCT, the explanation for this being the increased availability 
of HLA-E*01:03 to bind to inactivating CD94/NKG2 receptors (Hosseini et al., 2013). 
Given this observation, the finding that changes within the leader peptide bound to 
HLA-E, can profoundly affect recognition by CD94/NKG2 receptors on NK cells in a 
discriminatory manner (Hoare et al., 2008), and that they can be peptide specific 
(Lampen et al., 2013) leads to the question of whether differences between donor and 
recipient leader sequences, due to classical HLA mismatches, would influence the post 
transplant outcome. This would result in alternative HLA-E/leader peptide 
combinations, which may prevent interaction with inactivating CD94/NKG2 receptors 
and lead to a cytolytic response.
91
Additional evidence for a potential influence of HLA class I derived leader sequences 
was provided by Allard and colleagues (2012), who showed that HLA-E restricted CD8+ 
T cells, responding to CMV infection in a renal transplant recipient, can be alloreactive 
when the CMV and mismatched donor class I antigens contain the same sequence, i.e. 
the HLA class I derived leader sequence and the CMV homologue for this sequence. 
Therefore evidence exists that HLA Class I derived leader sequences can influence both 
innate alloresponses through the change of recognition by CD94/NKG2 receptors, and 
adaptive alloresponses through HLA-E restricted CD8+ T cells.
3.1.4 Assessing the effect of endogenous HLA-Class I derived leader peptides upon 
transplant outcome
Given that it is clear that HLA-class I derived leader sequences can affect 
allorecognition, and that currently there is a lack of clinical data regarding any 
influence of differences, between the HLA class I derived leader peptides expressed 
between transplant donors and recipients on transplant outcome, this chapter will 
specifically assess matching levels of HLA class I derived leader sequences, between 
renal transplant donors and recipients, and relate the level of matching to transplant 
function, during the first 12 months post transplant.
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3.2 Materials and Methods
A flowchart overview of all the methods described here is given at the end of the 
section on page 97, to provide an overview of the work flow.
3.2.1 Renal transplant recipients
A retrospective study of consecutive renal transplants carried out at St James 
University Hospital, Leeds, was undertaken in the form of a clinical audit. Ethical 
approval for the study approval was granted by Leeds central ethics committee and 
the local NHS research ethics committee. Approval letters are provided in the 
appendix.
3.2.2 Data collection
The data for over 300 renal transplant recipients was retrospectively analyzed for 
patient demographics, recipient sex and age, and transplant related variables: donor 
type (donation following brain stem death (DBD), donation following cardiac death 
(DCD) or live donation), presence of anti HLA IgG and whether it was donor specific 
(DSA), recipient HLA type, donor HLA type and recipient creatinine levels at 3, 9 and 12 
months post transplant. When the laboratory data was incomplete e.g. no 12 month 
serum creatinine levels recorded, then the transplants were not included in the audit. 
This resulted in a total cohort of 139 renal transplant patients with complete datasets 
for analysis. Data was collected from the laboratory database at the Transplant 
Immunology Department, at St James University Hospital in Leeds. Where data was 
incomplete within these records the raw data was obtained from the patient's renal 
file, also held within the Transplant Immunology Department. With the exception of 
creatinine levels, which were obtained from the Proton database within the Renal unit 
at St James University Hospital.
3.2.3 Analysis of HLA class I leader sequence matching
To ensure a complete record of the currently defined HLA class I derived leader 
sequences, the HLA/IMGT database was searched for all recorded HLA-A*alleles 
(n=2365 alleles encoding n=1695 proteins), B* alleles (n=3005 alleles encoding n=2277 
proteins) and C* alleles (n=1848 alleles encoding n=1321 proteins), and the amino acid 
sequence of the leader peptide encoded by each of these alleles was recorded.
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Specifically, the leader sequence is located within the HLA-Class I a-chain at amino acid 
residues at position 3-11 (Braud et al., 1997), this sequence was recorded along with 
the HLA type encoding it in a spreadsheet. This allowed for a comparison of the leader 
peptides between the recipient and donor pairs, by using their HLA typing data to 
establish the leader peptides encoded within their HLA types and then assessing the 
level of leader peptide matching between them.
3.2.4 Post transplant renal function analysis
Although serum creatinine level measurements taken at a single time point post 
transplant have previously been utilized, and validated, as an approach to assess post 
transplant outcome (Hariharan eta l., 2003), it can be influenced by a variety of factors, 
including sex, age and patient size. Therefore to accurately utilize the serum creatinine 
level data for renal function in this retrospective analysis, the change of serum 
creatinine level between 3 and 12 months post transplant was calculated for each 
recipient, by using data obtained from serum samples collected from the recipient post 
transplant. This approach has previously been reported, and has been shown to have 
utility as a predictor of long-term renal allograft survival (First, 2003; Hariharan et al., 
2003). A decrease in serum creatinine levels between 3 and 12 months indicates an 
improvement in renal allograft function, while an increase indicates deterioration, this 
change in serum creatinine is referred to as A creatinine within this thesis from this 
point forward. To allow confirmation of any trends observed within the data set, 
serum creatinine was recorded at 3, 9 and 12 months.
3.2.5 HLA matching
In order to assess the impact of HLA matching within the cohort of patients, the HLA 
matching grade was calculated for each donor and recipient pair. HLA matching is 
recorded by the number of mismatches at the HLA-A locus, followed by the HLA-B 
locus, and then the HLA-DR locus, giving a three number matching level, 000 indicating 
no mismatches at HLA-A, B or DR, while 222 indicates the maximum 2 mismatches at 
HLA-A, B and DR. A single mismatch of HLA-A, two mismatches at HLA-B and no 
mismatches at HLA-DR would be represented as 120.
This information was used to determine which category of NHS Blood and Transplant
Organ Donation and Transplantation (NHS BT ODT) renal allocation matching group the
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pairs would fall into, thus allowing patients to be grouped according to similar levels of 
HLA match and mismatch. In the interest of clarity the NHS BT ODT HLA matching level 
groups are given in Table 3.1.
3.2.6 Summary o f data collected
In summary the following data was collected in the audit.
•  Recipient age and sex
•  Presence of anti-HLA-IgG
o Whether this was DSA
•  Source of donor kidney
o Donation following brain stem death 
o Donation following cardiac death 
o Live donation
•  Post transplant serum creatinine
o 3 months post transplant 
o 9 months post transplant 
o 12 months post transplant
■ 3 and 12 month levels were used to generate A creatinine
•  HLA type of recipients and donors
o Used to determine HLA matching
o Used to determine NHS BT ODT matching groups for transplant pairs
o Used to determine HLA class I leader sequence
■ And therefore HLA class I leader sequence match status
3.2.7 Statistics
The Welch t-test, also known as the unequal variance t-test, a variation on the  
student's t-test, was used for statistical analysis. The Welch t-test was selected due to
its appropriate use in analysis of groups which have underlying variance. The Welch t-
test does not assume equal variances between groups (Ruxton, 2006).
An analysis of variance was performed using the SPSS (IBM, Armonk, NY) statistical
software package, in order to assess the variation within groups. Specifically analysis of
A creatinine within sex v leader peptide mm groups; donor source v leader peptide
groups and NHSBT ODT match level and leader peptide mm groups were analysed.
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000 -N o  HLA 
mismatches at HLA- 
A,B or DR
000 (The level of HLA A mm is given in 
the first number, HLA-B in the second 
number and HLA-DR in the third)
0 HLA-DR and 0 /o r l 
HLA-B
100, 010, 110, 200, 210
(0 HLA-DR and 2 HLA- 
B) or (1 HLA-DR and 
0 /o r l HLA-B)
020, 120, 220, 001, 101, 201, 011, 111, 
211
(1 HLA-DR and 2 HLA- 
B) or (2 HLA-DR)
021, 121, 221, 002, 102, 202, 012, 112, 
212, 022, 122
Table 3.1 The NHSBT ODT matching levels used for grouping renal patients according 
to HLA type in the retrospective clinical audit.
These matching levels are used by NHSBT ODT for categorising patients into HLA 
matching levels fo r the national allocation of deceased donor kidneys. The matching 
levels comprise part of an algorithm, which incorporates many variables not pertinent 
to this study (such as wait time upon the list for kidney offers). Additionally, as part of 
the NHSBT ODT allocation scheme a system of default HLA antigens are currently used. 
For clarity this system refers to the practice of ensuring potential renal recipients who 
possess rare HLA antigens, are not disadvantaged by defaulting to a common 
equivalent which is structurally similar to the rare antigen. No default antigens were 
used in assigning HLA matching levels fo r this study. Where appropriate a split 
resolution o f HLA type was also used to determine matching level.
96
The HLA/IMGT database was searched to identify all 
recorded HLA class I leader sequences
♦
Leader sequences were recorded, assigned a number 
and grouped with the HLA alleles which encode them
♦
Renal transplant donors and recipients were assigned 
the leader sequence numbers encoded within their 
HLA types
Mismatch between leader sequences 
for renal transplant donors and 
recipients was calculated
*
The leader 
sequence numbers 
mismatches were 
calculated in the 
graft to host 
direction -  
including total 
number of 
mismatches and 
HLA loci encoding 
the mismatch
Relationship of leader sequence matching to A 
creatinine level was analysed
Figure 3.1 A flow diagram overview of the collection of HLA class I leader 
sequence data in a cohort of kidney transplant patients and relationship to A 
creatinine
97
3.3 Results
3.3.1 Cohort demographics and variance within groups
Complete data was collected on 139 renal transplant patients, with a mean age of 41.8 
years. The cohort comprised slightly more males than females (58.3% (n81) v 41.7%  
(n58). The number of previous transplants, if any, was not recorded. However 35.97%  
(n50) had anti-HLA-IgG detected at the time of transplant, 2% (n3) of which was DSA. 
The donor organs were predominantly from DBDs (55% (n77)), live donation 
accounted for 30% (n42) of the donor organs, while 14% (n20) of donor organs were 
from DCDs. A range of NHS BT ODT matching levels were observed, with 11% (n l6) 
level 1, 28% (n40) level 2, 40% (n57) level 3 and 19%(n26) level 4 matches. The mean 
serum creatinine level post transplant was comparable between 3 and 12 months, 
being 135 (+/- 60.9 SD) mmol/L and 131 (+/- 54.4 SD) mmol/L respectively. The patient 
demographics and variance within groups are summarised in Table 3.2.Analysis of 
variance demonstrated no statistical significant difference between groups. However it 
should be noted that a reduction of statistical power in groups containing low numbers 
may contribute to this finding.
3.3.2 Identification of HLA class I derived leader peptides and their frequencies
The search of the HLA/IGMT database identified 11 HLA class I derived leader peptide
sequences, and their corresponding encoding HLA allele groups, identified in table 3.3.
Each leader peptide is identified with a number (leader 1, leader 2,..etc) along with the
leader peptide sequence and the HLA allele groups which encode the leader peptides.
The amino acid sequences of the identified HLA class I leader peptides corresponded
to those previously reported (Romagnani et al., 2004), although the alleles which
encode the leader peptides reported here is more comprehensive, incorporating HLA-
A *68; B*48, B*55 and B*46 allele groups, which have not been previously reported,
making this the most comprehensive list of documented HLA class I derived leader
peptides, and the alleles which encode them currently reported. The frequencies with
which the leader peptides were observed within the cohort of renal patients and their
donors (table 3.4), shows leader peptide 3 to have the lowest observed frequency
(0.06%), while leader peptides identified as leader peptides 4 and 11, were not
observed within this cohort of patients at all. Leader peptide 10 was also seen with a
98
low frequency (0.45%) within this cohort. All the other identified leader peptides were 
observed with a frequency of between 10-20%
3.3.3 Number of HLA class I derived leader peptide mm observed
In analysis of the level of HLA class I leader peptide mismatches between donors and 
recipients (table 3.5) 32.4% of renal transplants were shown to have no leader peptide 
mismatches, while the most common number of leader peptide mismatches observed 
was a single leader peptide mismatch, observed within 38.8% of the transplants, two  
leader peptide mismatches and three leader peptide mismatches were observed in 
23.7% and 5% of transplants respectively.
3.3.4 HLA matching levels observed within the cohort
In terms of the HLA matching levels observed, those patients which received an 000 
mismatched renal allograft and are therefore grouped into NHSBT ODT matching level 
1, comprised 11.5% of patients (table 3.6), while NHSBT ODT matching levels 2, 3 and 
4, were seen in 28.8%, 40.3% and 19.4% of patients respectively. Demonstrating a 
range of HLA matching within these patients.
3.3.5 Relationship between leader peptide mm and creatinine level
The comparison of the number of HLA class I leader peptide mismatches and their
relationship to A creatinine levels (figure 3.2), reveals a striking relationship between
the number of leader peptide mismatches to A creatinine. A reduction in A creatinine
approaching 20 mmol/L was found where no leader peptide mismatches were
observed, this reduction in A creatinine indicates the allograft performance has
improved from 3 to 12 months post transplant. Where three leader peptide
mismatches were identified, an increase in A creatinine was observed, with levels
approaching 20mmol/L, indicating the allograft performance had decreased from 3 to
12 months post transplant. The change in A creatinine was a statistically significant
association, p<0.05 (table 3.7), for the three leader peptide mismatches group.
A stepwise increase in A creatinine was seen depending upon the number of leader
peptide mismatches, zero leader mismatches showing a decrease in A creatinine, one
leader mismatch a more modest decrease, two leader peptides mismatches producing
little change in A creatinine, and three leader peptide mismatches an increase. This
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5
increase in A creatinine, associated with an increased number of leader peptide 
mismatches, demonstrates a relationship with an R2 value of 0.9999 (figure 3.2).
The association between leader peptide mismatch and creatinine levels was also 
performed so that it included creatinine levels at 9 months post transplant (figure 3.3). 
With zero leader peptide mismatches showing a stepwise decrease in creatinine levels 
between 3, 9 and 12 months, the single leader peptide mismatches showing a 
consistent decrease between 3, 9 and 12 months, while the data for three leader 
peptide mismatches showing a stepwise increase in creatinine levels between 3, 9 and 
12 months. The two leader peptide mismatches however showed an initial decrease in 
creatinine levels from 3 to 9 months, and then a marked increase from 9 to 12 months. 
This increase from 9 to 12 months for two leader peptide mismatches was not as steep 
as that seen for three leader peptide mismatches. The two leader peptide mismatches 
creatinine level decrease from 3 to 9 months then recovered with an increase from 9 
months to 12 months, so that the creatinine levels returned to their 3 month level. 
Interestingly the three leader peptide mismatch groups creatinine levels, rose 
modestly between 3 and 9 months and then more sharply between 9 and 12 months. 
Furthermore this group had the lowest 3 month creatinine levels, which may be 
explained by the higher number of live donors within this group (Table 3.2).
3.3.6 NHSBT ODT matching levels and relationship to creatinine
The data representing the effect of NHSBT ODT matching levels and relationship to A
creatinine, figure 3.4, shows the effect of the increasing levels of mismatch and A
creatinine. With the level 1 group (the best matched group), associated with a
decrease in A creatinine of 20 mmol/L, while the level 4 group (those with the worst
matches), being associated with a more modest decrease in A creatinine, approaching
5 mmol/L. All the NHSBT ODT matching levels were associated with a decrease in A
creatinine, which is in contrast to the leader peptide mismatch analysis described
earlier, whereby the three mismatched (mm) group was shown to produce a
statistically significant change from a negative to positive A creatinine. Unlike the
leader peptide analysis, none of the NHSBT ODT groups were shown to be statistically
significant, table 3.8, nor was a positive A creatinine observed. The relationship
between NHSBT ODT levels and A creatinine was also shown, however the R2 value
equalled 0.9233. Indicating that the relationship between NHSBT ODT
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Effect of ODT matching levels and A A creatinine level (3 to 12 month) and 
creatinine level (3 to 12 month) relationship to ODT matching levels
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levels and creatinine did not fit the polynomial regression model as well as that of the 
leader peptide mismatches, where the R2 value was closer to 1, being 0.9999.
3.3.7 Effect of leader peptide mm within NHSBT ODT matched groups 
In an attempt to determine between the effect of leader peptide mm upon A 
creatinine levels and the effect of NHSBT ODT matching levels, an analysis was 
performed on the effect of leader peptide mm within NHSBT ODT 
matching levels was made. This analysis revealed the association between an 
increasing number of leader peptide mm and an increase in A creatinine was occurring 
within NHSBT ODT matching levels, for ODT levels 1 and 2 (figure 3.5) and ODT level 4 
(figure 3.6). In the NHSBT ODT level 1 matched group only matched (zero leader 
peptide mm) and single leader peptide mm were observed. With the matched group 
showing a reduction in creatinine, with a A creatinine of 20mmol/L, while the single 
leader peptide mm group showing an increase, with A creatinine 20mmol/L. The 
NHSBT ODT level 2 group was again associated with an increase in A creatinine 
associated with the number of leader peptide mm, however unlike level 1, all leader 
peptide mm levels were associated with a reduced A creatinine. Neither NHSBT ODT 
level 1 or 2 leader peptide mm analysis produced statistically significant observations 
(table 3.9). The NHSBT ODT level 4 group demonstrated the stepwise increase in A 
creatinine as the number of leader peptide mm increased (figure 3.6), it should be 
noted the 3 leader mm group only had 2 patients within it.
In the NHSBT ODT level 3 matched group, the data appeared to deviate from the 
stepwise increase in A creatinine level observed within the other NHSBT ODT groups. 
Whereby the 0 leader mm group appeared to show the poorest performance in terms 
of reduction of A creatinine, with a level of -6mmol/L, while one and two leader 
peptide mm had levels of -15mmol/L and -lOmmol/L respectively. Analysis of the raw 
data revealed a possible explanation for this observation, in that the zero leader 
peptide mm group, within the NHSBT ODT level 3 matched analysis, contained data 
from two allografts which exhibited a significant deterioration in A creatinine which 
may skew the data, these two allografts went on to require allograft nephrectomy
n o
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within 24 months post transplant. However it was important to include all the data 
collected in this study to prevent any bias.
Attention should also be drawn to the reduction in statistical power when analysing 
the individual NHSBT ODT groups in this way, with the numbers of patients within the 
four NHSBT ODT matching levels being low, ranging from 16-54 patients.
3.3.8 The effect o f specific HLA ciass I derived leader peptide mm 
To assess if there was any difference when the leader peptide from different HLA class 
I encoded molecules was mismatched, a comparison of leader peptide encoded just by 
HLA-A, HLA-B and HLA-C alleles was made (figure 3.7).
This demonstrates that HLA-B encoded leader peptides, identified in table 3.3 as 
leader peptides 5, 6 and 7, were associated with an increase in A creatinine in a 
stepwise fashion, dependent upon the number of leader mm observed (2 leader 
peptide mm were only observed twice so a statistical analysis was not performed due 
to their low frequency) (table 3.10). HLA-C encoded leader peptides, incorporating 
leader peptides identified as leader peptides 8, 9 ,1 0  and 11 (table 3.3), also 
demonstrated the association of an increase in A creatinine with an increase in leader 
peptide mm, only zero leader peptide mm and single leader peptide mm were 
observed within this group however, and this change was not statistically significant.
In contrast to the HLA-B and C encoded leader peptides HLA-A encoded leader 
peptides did not demonstrate an association with a decrease in A creatinine, instead 
there was an increase for zero and one leader peptide mm.
In an attempt to clarify this further, an analysis of the effect of mm of specific leader
peptides was performed. This demonstrated that mismatching leader peptides 1 and 2
(HLA-A encoded peptides) resulted in similar A creatinine levels as no leader mm at all
(figure 3.8), confirming that HLA-A leader peptides do not influence A creatinine levels
(leader peptide 3, which is also encoded for by HLA-A alleles was only observed once,
and is shown in figure 3.9 for clarity). Mismatching of leader peptides 5, 6 and 7 (HLA-
B encoded peptides), demonstrated a modest decrease in A creatinine levels for
peptide 6, a modest increase in A creatinine for peptide 7 and more marked increase in
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A creatinine peptide 5. Comparison to the zero leader peptide mismatches confirmed 
an influence of HLA-B encoded peptides, with the association for peptide 5 
approaching statistical significance (p=0.08) (table 3.11). Mismatches for the HLA-C 
encoded leader peptides, peptides 8 and 9, also showed an influence of mismatches 
and relationship to A creatinine levels when compared to the zero mismatched group, 
however this was not statistically significant (table 3.11), which may be due to the low 
numbers in the cohort with peptide 8 (n=8) and 9 (n=5).
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3.4 Discussion
The 11 leader peptides identified within this data set, using the HLA/IMGT database, 
contains the most complete list of HLA class I alleles and their encoded HLA alleles 
currently available, according to a search within the literature (as of May 2014). The 
accurate record of the sequences of HLA class I derived leader peptides, and their 
encoding HLA alleles has been demonstrated o f utility within this work, and would also 
aide those researchers whose work includes the role of HLA class I derived peptides in 
HLA-E induced responses, such as NK cell mediated cell lysis and HLA-E restricted CD8+ 
T cell activation. Indeed, the data previously published in the context of CMV infection, 
NK and CD8+ T cell responses and HLA class I derived leader peptides does not report 
the leader peptide sequences of HLA-A*68; B*48, B*55 and B*46 alleles (Romagnani et 
a i, 2004), making the data reported here more complete. Furthermore, Romagnani 
and colleagues (2004) assign a leader sequence of VTAPRTLLL for the HLA molecules 
encoded fo r by HLA-B*58 alleles, while the data here identifies the sequence as 
VTAPRTVLL. Cross checking upon the IMGT/HLA database (Robinson et a i, 2013) 
confirms the data reported here as accurate.
The frequencies of the 11 identified leader peptides, within the cohort o f 139 renal 
transplant patient and donors, was representative o f the frequencies of the HLA class I 
alleles which encoded them. Leader peptides 4 and 11 were not observed at all and 
were encoded for by HLA alleles which have a low frequency within the UK population. 
Leader peptide 4 being encoded fo r by HLA-A*80, which is seen in less than 1% of 
10,000 UK deceased donors according to NHSBT ODT data 
(http://www.odt.nhs.uk/transplantation/histocompatibility-and- 
immunogenetics/handi-informa tion/), while leader peptide 11 is encoded fo r by HLA- 
C*08:09, a rarely seen allele listed as unconfirmed upon the HLA/IGMT database 
(Robinson et a i, 2013), which has only been observed within a specific ethnic 
population, a group of Kolia Amerindians (Little et a i, 2001). Hence these two leader 
peptides were unlikely to be observed within the cohort of renal patients reported 
here. The low frequencies of the observed leader peptides 3 (0.06%) and 10 (0.45%), 
was also due to correspondingly low HLA encoding allele frequency, being encoded fo r
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by HLA-A*34:01 seen in individuals of Asian pacific islander origin (Robinson et a i,  
2013; Gonzalez-Galarza e ta i ,  2010), and HLA-C* 17:01/02 respectively.
The analysis of the number of mismatches between the identified HLA class I derived 
leader peptides and A creatinine demonstrated a stepwise relationship, with an 
increase in A creatinine associated with an increase in the number of leader peptide 
mismatches. This indicates that a poorer performance is seen in those allografts which 
have a greater number of leader peptide mismatches. This relationship was shown to 
be more pronounced than the relationship observed between A creatinine and NHSBT 
ODT matching levels (R2 value of 0.999 vs 0.9233). Furthermore the A creatinine levels 
in those patients who received an allograft with 3 leader peptide mismatches was 
shown to have statistically significant (p=0.05) poorer performance than the matched 
counterparts in terms of A creatinine levels. However a larger cohort of patients 
should be assessed to validate this data, particularly since no statistical significant 
association was seen within the analysis of variance within the assessed groups.
Analysis of the effect of leader peptide mismatches within NHSBT ODT HLA matching
groups shows that this effect appears independent of HLA matching grade. The
influence of HLA class I derived peptide mismatch and A creatinine being observed
within NHSBT ODT level 1, 2 and 4 matched groups. NHSBT ODT level 3 matched
patients however did not concur with this finding, specifically the zero leader
mismatched group appeared to perform the worst, as determined by A creatinine. This
may be explained by the confounding influence of two poorly performing allografts
within the zero leader peptide mismatched group within the NHSBT ODT level 3
matches (as described within section 3.3.8), this hypothesis would be supported by the
observation that the stepwise increase in A creatinine associated with an increase in
the number of leader peptide mismatches, returned for the single and two leader
peptide mismatches within the level 3 group. This data then shows a relationship
between the number of leader peptide mismatches and the post transplant outcome
of renal allografts as assessed by A creatinine (Battle et a i, 2013). However the exact
mechanism of this influence cannot be determined from this data.
Previously researchers have examined the role of HLA class I derived leader sequences
and their ability to bind to HLA-E, showing that not all peptides bind with equal affinity,
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and that a consequence of this is the alteration of HLA-E recognition by the 
CD94/NKG2 receptors upon NK cells (Hoare et a i, 2008). A comparison between the 
reported affinities of the leader peptides and HLA-E (Vales-Gomez e ta l., 1999), and 
the data presented here, in terms of the effect of mismatches of individual peptide, 
reveals some interesting observations. Reports within the literature upon the binding 
affinities of those leader peptides encoded for by HLA-B alleles demonstrate that the 
leader peptide, identified here as leader peptide 5, containing methionine at position 2 
of the peptide sequence binds with the highest affinity to HLA-E, while those peptides 
with threonine at position 2 (identified here as leader peptides 6 and 7) bind less well 
(Hoare eta l., 2008; Lee eta l., 1998; Lemberg etal., 2001; Vales-Gomez eta l., 1999).
The ability to be bound by HLA-E has a direct impact upon the expression level of HLA- 
E (Vales-Gomez et aI., 1999), and therefore changes within peptides which have 
different binding affinities would be expected to alter surface expression of HLA-E, and 
alter the ability of HLA-E to interact with the CD94/NKG2 activating/inhibiting 
receptors. It is interesting to note that mismatches at the HLA-B encoded leader 
peptides 5, 6 and 7 (figure 3.7) are associated with a poorer A creatinine level post 
transplant (indeed leader peptide 5 mismatches are approaching statistical significance 
p=0.08), while HLA-A encoded leader peptide mismatches appear to exert no influence 
upon A creatinine levels post transplant. This is particularly interesting when 
considering the reported observation that all HLA-A encoded leader peptides bind to 
HLA-E with the same affinity (Hoare et a i,  2008; Lee et a i, 1998; Lemberg et a i,  2001; 
Vales-Gomez e ta i,  1999).
In terms of the leader peptides encoded for by HLA-C, the majority of which observed 
here comprised leader peptides 8 and 9 (due to the frequencies of the respective 
encoding HLA-C alleles), variation is also seen between the binding affinities reported. 
Peptide 8 showed extremely good binding kinetics (Hoare e ta i,  2008; Lee e ta i ,  1998; 
Lemberg et a i, 2001; Vales-Gomez et a i, 1999) while peptide 9 extremely poor 
binding kinetics (Vales-Gomez et a i, 1999). The A creatinine level for these peptides 
also revealed an increase in comparison to the zero mismatched group, however this 
was not statistically significant.
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These findings, in conjunction with the reported binding affinity for HLA-E, lead to the 
hypothesis that a change in the peptides available to bind to HLA-E, results in a 
differential expression of HLA-E at the cell surface, as a consequence of individual 
peptide binding affinities. Changes in the levels of HLA-E expression could then lead to  
NK responses which are detrimental to the allograft, this would then be anticipated to 
be observed in the A creatinine levels as seen here. Clearly, functional data is required 
to support this hypothesis, however it is interesting to note that a reported 
immunoevasion strategy of CMV is to maintain HLA-E expression at the cell surface by 
mimicking HLA class I leader peptide sequences (Mazzarino et a i, 2005) and those 
utilized by CMV have a high affinity for HLA-E (Hoare et al., 2008; Lee et al., 1998; 
Lemberg et al., 2001; Vales-Gomez et al., 1999), which would increase the level of 
expression of HLA-E. In addition, in the reports on HLA-E polymorphism and HSCT 
outcome, it is the HLA-E*01:03 allele, which encodes a surface antigen expressed at 
higher levels than its equally common counterpart HLA-E*01:01, that is associated 
with reduced TRM post HSCT, the explanation for this being the increased availability 
of HLA-E*01:03 to bind to inactivating CD94/NKG2 receptors (Hosseini eta l., 2013). An 
analysis of CMV was not undertaken here, but would be an interesting area for further 
work, which is discussed in further detail in chapter 5. This work strongly suggests that 
mismatches between the HLA class I derived leader peptides influence A creatinine, a 
marker for renal allograft outcome. However, the exact mechanism requires further 
elucidation, with changes within the leader peptides which result in changes with 
affinity for binding to HLA-E, and therefore HLA-E expression a potential mechanism. In 
addition this work was hampered by the relatively small cohort of patients examined, 
and a larger validating cohort of patients is required to confirm these findings.
In summary, chapter 3 demonstrates that endogenously derived HLA class I peptides, 
in this case specifically their leader peptides, can influence the post transplant function 
of renal allografts (Battle et al., 2013). However a larger validating cohort of patients 
should now be assessed to validate this data and confirm the findings within chapter 3.
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Chapter 4 - Functional analysis of HLA-class I derived 
peptide influence upon the alloresponse
125
4.1.1 Introduction
In chapters 2 and 3, peptides were identified which were derived from one HLA class I 
molecule and presented by another. Subsequently clinical data was analysed to 
measure the influence of mismatching some of these peptides, within the context of 
renal transplantation. In this chapter, an investigation to assess a mechanism by which 
peptides may exert their influence upon humoral alloresponses was undertaken. The 
thesis introduction outlined the mechanisms by which peptides can generate 
alloresponses, describing the processes of direct and indirect allorecognition and the 
peptide involvement within them. In addition to the mechanisms described within the 
introduction, peptides may also influence the ability of preformed donor HLA specific 
antibodies to bind to their target epitope.
4.1.2 HLA antibodies and transplant outcome
HLA antibodies are formed in response to exposure to HLA antigens, a phenomena
known as sensitisation, this exposure can be generated as a result of transfusion,
pregnancy or transplantation (Resse eta l., 2013). The detection of donor specific HLA
antibodies (DSA) present within the serum of a renal transplant recipient prior to
transplantation by complement-dependent cytotoxicity (CDC) crossmatch (XM), has,
for many years been an absolute contraindication to transplantation, due to the
association of a positive CDC XM with hyperacute and accelerated acute rejection
(Girnita et al., 2007). While a positive T cell CDC XM remains a contraindication to
transplantation, technical developments within various methodologies used in the
detection and identification of HLA antibodies, such as the introduction of solid phase
assays, have led to highly sensitive approaches to HLA antibody detection, and
consequently the clinical impact of detected antibodies is not completely understood
in some circumstances (El-Awar et al., 2009). Current approaches to understand the
clinical impact of detected HLA antibodies aim at providing a stratification of risk,
based upon the results of XM and antibody identification assays, while considering the
type of organ to be transplanted, available immunosuppression strategies, clinical
urgency of transplant and various donor factors (Opelz et al., 2013). Currently H&l
laboratories utilize HLA antibody screening technologies in those patients who are
awaiting transplantation, to determine unacceptable HLA antigen mismatches due to
HLA sensitisation (Howell etal., 2010). By using this information, it is possible to
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predict the likelihood of a XM to return a negative result for a particular patient and 
donor combination, when the donor's HLA type is known. This process can prevent the 
shipment of an organ to a potential transplant recipient, who would produce a positive 
XM result. In addition, the resultant HLA antibody data allows for an indication of the 
likelihood of a patient to be offered a kidney to which they would be expected to 
produce a negative XM result. This is achieved by calculating the patient's HLA 
antibody reactivity to a panel of HLA antigens, whereby the HLA antibodies detected 
within a potential transplant recipient are assessed for matches to corresponding HLA 
types of the previous organ donors offered via NHS BT ODT, giving a percentage of 
reactivity to these donors. This process is sometimes referred to as calculated reaction 
frequency (CRF) or calculated panel reactive antibody (cPRA), and aids understanding 
of how long a patient is likely to wait for a transplant, given the percentage of donors 
that they would have been expected to have antibody reactivity to, and consequently 
would not have been offered, those with a cPRA >85% are classified as highly 
sensitised and are likely to have to wait significantly longer than unsensitised patients 
(Chang and Kobashigawa, 2012).
Recently, the ability to remove DSA through antibody desensitisation protocols to 
achieve a negative CDC XM result prior to transplantation, has led to an opportunity to 
transplant patients previously denied access to a transplant due to DSA . The reported 
success of desensitisation protocols varies, depending upon a number of factors such 
as: titre and specificity of DSA and the desensitisation protocol utilised (Marfo et al., 
2011). The graft survival in HLA antibody desensitisation protocols remains impaired in 
comparison to control groups (Becker et al., 2013), while still providing an important 
clinical option for transplantation for some patients. Those patients who have the best 
long-term survival, post DSA desensitisation transplant, are those who lose their DSA 
after their successful desensitisation and transplantation, whereas DSA persistence, 
recurrence or de-novo formation, all affect longterm allograft survival negatively 
(Becker et al., 2013). The development of de-novo DSA is also associated with reduced 
graft survival in non desensitisation cases (Fehr and Gaspert, 2012), even in cases 
where no antibody mediated rejection is identified (Roelen et al., 2012).
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A detailed understanding of the HLA antibodies present in a potential transplant 
recipient is vital, not only to prevent an unexpected positive XM result, but also to aid 
post transplant patient management, due to the de-novo formation of HLA antibodies 
against mismatched HLA antigens on the transplanted organ.
Such de-novo antibodies do not always occur when an HLA antigen is mismatched 
however, as the distinct sites which HLA antibodies bind to on HLA antigens, termed 
epitopes, are shared between some HLA antigens (Duquesnoy, 2011b). Consequently 
an HLA antigen could be mismatched, but the epitopes upon the mismatched HLA 
antigen may be present upon the mismatched HLA antigen, or upon other HLA 
antigens present within the transplant recipient's HLA type. Therefore the epitopes are 
matched and consequently HLA antibodies are not formed. In order to understand this 
process better, various mechanisms of characterising the epitopes have been 
proposed, the two most successful systems are the epitopes identified as 'eplets' by 
the HLAMatchmaker bioinformatic software (Duquesnoy, 2011a) and the TerEps 
identified by PaulTerasaki (El-Awar eta /., 2007).
4.1.3 HLA antibodies and epitopes
It was not long after the discovery of HLA specificities that serological crossreactivity
between certain HLA antigens was observed. To define this crossreactivity, HLA
antibodies were utilized to assess their binding to different HLA antigens, using this
process it was possible to identify groups of cross reacting epitopes, so called CREGs
(table 4.1) (cross reacting epitope groups) (Rodney et al., 1994; Fuller et al., 1990).
These groups helped categorise epitopes, which are shared between HLA antigens and,
as structural understanding of HLA molecules became defined, it could be
demonstrated that the crossreactivity of specific antibodies was likely to be the result
of common molecular structures between different HLA molecules (Duquesnoy,
2011b). It is these common molecular structures, which are referred to as epitopes
when antibody is capable of binding to them, and which are identified by various
systems, such as eplets or TerEps. It was Duquesnoy etal., (2011a/b) who initially
suggested that the epitopes themselves consisted of three consecutive amino acid
residues, and later revised this to identify epitopes via his eplet system, which used
stereochemical modelling of protein antigen-antibody complexes, to identify
polymorphic amino acid configurations on HLA antigens,
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A1C A l, A3, A l l ,  A19(A29, A30,A31), A36, A80
A2C A2, A9 (A23, A24), A28 (A68, A69), 
B17(B57, B58)
A10C A10 (A25, A26, A34, A66), A32, A33, A43, 
A74
Bw4 A9 (A23, A24), A25, A32, B13, B27, B37, 
B38, B44, B47, B49, B51, B52, B53, B57, 
B58, B59, B63, B77
B5C B5 (B51, B52) B18, B35, B53
B5C2 B5 (B51, B52) B15 (B62, B63, B71, B75, 
B76, B77), B17 (B57, B58), B21 (B49, B50), 
B35, B53, B73, B78
Bw6 B7, B8, B18, B35, B39, B40 (B60, B61), 
B41, B42, B45, B46, B48, B50, B54, B55, 
B56, B62, B64, B65, B67, B71, B72, B73, 
B75, B76
B7C B7, B8, B13, B27, B41, B42, B47, B48, B54, 
B55, B56, B60, B61, B81
B8C B8, B18, B38, B39, B64, B65
B12C B12 (B44, B45), B13, B37, B41, B47, B21 
(B49, B50), B40 (B60, B61)
Table 4.1 Cross-reactive epitope groups (CREG) (Reproduced from Laux and Pelz, 
2004; Mckenna and Takemoto 2000). HLA antigens enclosed within parentheses 
identify 'splits' o f broad HLA specificities although this may not include all splits w ith in  
the broad antigen, due to the possession of different epitopes w ithin certain splits.
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which were within a 3.5A radius, in positions within regions accessible to antibodies 
(Marrari eta l., 2010).
4.1.4 The use of HLAMatchmaker to define epitopes
The most frequently used mechanism of defining epitopes upon HLA antigens is the 
HLAMatchmaker bioinformatic system, which defines the epitopes on an HLA antigen 
as a series of eplets. This then allows for a comparison of eplets present on different 
HLA antigens, to see if any or all eplets are shared. This approach has led to a greater 
understanding of how antibodies are generated to HLA antigens, to which an individual 
does not appear to have been sensitised to, for example the observation of an HLA- 
DR1 antibody in response to an HLA-DRw51 antigen was explained by a shared eplet, 
identified as 96EV (Marrari eta l., 2011). Traditionally, HLA antibody identification has 
been achieved by describing a specific HLA antigen to which the antibody is detected 
as being capable of binding to, such anti-HLA-A2 or anti-HLA-B7. The HLAMatchmaker 
system has led to a greater understanding of the actual epitope targets of such 
antibodies, and can reveal them to be specific to single eplets or eplet pairs (discussed 
below).
The HLAMatchmaker derived eplets are identified via sterochemical modelling, which 
assesses each HLA antigen as a string of amino acid configurations in antibody- 
accessible positions (Duquesnoy and Marrari, 2009). Antigenic proteins have structural 
epitopes of 15-22 amino acid residues within an antibody binding surface of 700-900A, 
within these structural epitopes are 'hot spots' of 2-5 highly energetic residues, which 
contribute to the strength and specificity of antibody binding. Within HLAMatchmaker, 
eplets are derived from a 3A radius of a polymorphic residue upon the surface of a HLA 
antigen, which define these 'hot spots'. These eplets bind antibody as an individual 
eplet or as an eplet pair, with eplets in a pair being approximately 6-15A apart, and at 
least one of the pair being non-self (Duquesnoy and Marrari, 2009). The amino acid 
residues outside the hot spots contribute augmenting interactions, which contribute 
interactions which increase antibody-antigen stability.
The nomenclature of these eplets is derived from the polymorphic residues within the
eplet, and the position of the polymorphic amino acid residue within its chain of amino
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acid residues. The standard letter code is used to identify the amino acids. Using this 
system Duquesnoy has defined 199 eplets from 75 polymorphic positions within Class I 
HLA-A, B and C antigens, of which 110 were positioned on the a-helices, 60 on the side 
of the surface and 29 in the regions which are less accessible to antibodies such as 
underneath the molecule and under the peptide binding groove (Duquesnoy, 2011a). 
While the number of polymorphic regions within HLA Class II molecules consist of 44 
DRB, 33 DQB, 29 DQA, 20 DPB and 9 DPA chain polymorphic sites, which were shown 
to deliver 146 DRB, 74 DQB, 58 DQA, 45 DPB and 19 DPA individual eplets (Duquesnoy, 
2011a). As previously mentioned, the HLAMatchmaker program views an HLA antigen 
as a group of the identified eplets present upon an HLA molecule, these eplets are 
capable of inducing HLA specific antibodies, but an individual cannot generate HLA 
antibodies against eplets which are also present in their own HLA type, so called self 
eplets.
Using these principles, HLAMatchmaker can be used to assess the degree of mismatch 
in terms of eplets. In some cases, a transplant donor and recipient may be mismatched 
in terms of the HLA antigens they express, but matched in terms of the eplets present 
in their HLA antigens. This gives an indication of the likelihood of generating a humoral 
response to HLA mismatches as a consequence of transplantation. Furthermore the 
eplet system allows for the analysis of sensitisation pattern induced by an HLA 
mismatch, accounting for unexpected reactivity patterns such as the HLA-DR1 antibody 
induced by sensitisation to DRw51 (Marrari et o i, 2011). (figure 4.1).
The use of HLAMatchmaker has greatly improved the understanding of the HLA 
antibody sensitisation status of patients who are awaiting transplantation, as well as 
helping to minimise sensitisation, by allowing eplet matching in certain situations, 
when a HLA mismatch is unavoidable. Currently use of the HLAMatchmaker program 
has been described in various forms of transplantation, including, kidney, cornea, 
haematopoietic stem cell transplantation (Duquesnoy, 2011b) and cardiac 
transplantation (Resse et o i, 2013), as well as in the allocation of platelets. Despite the 
use of HLAMatchmaker in these clinical settings, no assessment of the generation of 
eplets caused by different peptides bound within the HLA groove has been made.
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2
Theoretically at least, changes within HLA bound peptide may alter the epitopes 
generated, both by generating new epitopes, and by altering the affinity of an antibody 
to an existing epitope. For example, a change within the peptide could alter the affinity 
of an antibody to an epitope present upon regions proximal to the peptide binding 
groove, such as the a-helices; altering the peptide bound within the groove may cause 
variation between the interaction of the amino acid residues of the a-helices and the 
bound peptide. As a consequence of this change, the ability of an epitope to be bound 
by an antibody maybe reduced or increased. Various modelling software is available to 
assess stereochemical structures in order to investigate the effect of peptide bound 
upon epitopes (Guex and Peitsch, 1997; Kosmoliaptsis eta l., 2011).
4.1.5 The evidence fo r the peptide influence on HLA antibodies binding to their epitopes 
In their assessment of a recombinant human Fab fragment for the investigation of 
tumour associated HLA-A1 melanoma associated antigen (M AG E-l)-A l complex, 
Hulsmeyer and colleagues (2004) crystalized the MAGE-1 peptide (EADPTGHSY) bound 
by HLA-A1 and complexed with the Fab fragment. This work demonstrated that several 
regions of the CDR of the Fab fragments were in direct contact with the MAGE-1 
peptide. Indeed the authors concluded that, in this case, the Fab fragment binds the 
HLA-A1 in a similar manner to a TCR. Indeed after comparing the Fab fragment's 
binding to HLA-A1 complexed to another MAGE peptide, MAGE-3, the authors stated 
that the Fab fragment 'does not bind', demonstrating clear evidence that changes 
within the peptide bound influences the ability of some antibodies to bind. 
Furthermore, altering the amino acids at specific regions within the peptide was 
determined to alter antibody binding ability, from 'weakly' binding to 'strongly' binding 
to its target.
Although this complex work clearly showed the ability of changes within the peptide 
bound by HLA to alter the ability of antibody to bind, it should be pointed out that the 
antibody fab fragment was a recombinant antibody, specifically selected for the 
purpose of investigating MAGE-1. It does however serve to demonstrate that 
antibodies can be HLA peptide complex specific, and can have their affinity altered by 
changing the peptide which is bound by HLA. An image of HLA-A1 complexed with
MAGE and interacting with the Fab fragment is shown in figure 4.2.
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PdbViewer (Guex & Peitsch 1997).
4.1.6 Structural modelling software
The original article describing the creation of the HLAMatchmaker bioinformatic tool 
(Duquesnoy, 2006), identifies the use of Cn3D (see in 3D) structure and sequence 
alignment software program, to identify the location of specific residues in crystallized 
HLA molecular models, which were obtained from the NCBI website 
(www.ncbi.nlm.nih.gov/protein). The Cn3D program allows a 'select by distance1 
function, which Duquesnoy applied around polymorphic residues to the distance of 
3.0A and 3.5A in order to identify eplets. However Cn3D is by no means the only 
structural modelling program available, with different modelling programs offering 
variation within their functionality. One such popular modelling program is Swiss- 
PdbViewer, which offers many of the functions within Cn3D, including the ability to 
measure the distance between residues, but with the addition of a mutation function 
(Guex and Peitsch, 1997). This mutation function allows the user to alter an amino acid 
residue, for example within a peptide, such as is seen within several minor 
histocompatibility antigens, such as HA-1 as previously described (section 1.1.12). The 
mutation function allows for an assessment of how a change of an amino acid would 
alter the possible structures of the molecule, including the formation of new hydrogen 
bonds. While the use of Ramachandran plots, which describe the torsion angles of 
amino acids within proteins (Hollingsworth and Karplus, 2010), incorporated within the 
Swiss-PdbViewer software, allows for the mutation to be assessed in terms of its 
correct orientation within a molecule (Guex and Peitsch, 1997). The Swiss-PdbViewer is 
an ideal tool for the assessment of a change in an amino acid of a peptide bound 
within an HLA molecule, and how this change may impact upon epitopes which are 
proximal to the peptide binding groove.
The ability of a peptide to alter the epitopes to which an HLA antibody binds, has 
several implications within the transplant setting (Mulder et al., 2005). Broadly 
speaking, this phenomena could affect the ability to detect clinically relevant 
alloantibodies, if different peptides are bound by HLA molecules used within detection 
assays to those bound to HLA antigens upon the allograft. While changes within the 
energy of an epitope as a consequence of peptide variation could potentially alter the  
function of an antibody which does bind (Kosmoliaptsis eta l., 2011).
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4.2 Materials and Methods
4.2.1 Purification of an HLA antibody to assess the influence of peptide upon antibody 
binding
A human antibody specific to HLA-A2, obtained from a patient undergoing a 
desensitisation protocol was a kind gift from Dr David Lowe (Royal Liverpool and 
Broadgreen University Hospital, Liverpool, UK), who provided the HLA-A2 antibody in an 
unpurified form, containing other human plasma proteins. The antibody was purified to 
remove plasma proteins using Montage antibody PROSEP-G purification kits (Millipore, 
Maine, USA) according to the manufacturer's instructions. All processes were carried 
out at 4°C. Briefly the HLA-A2 antibody (300ml) was filtered through a 0.22pm filter 
(Millipore, Maine, USA) to remove any aggregates and debris. The resultant sample was 
diluted in a kit binding buffer (1:1) and loaded onto a spin column (10ml per column) 
containing a protein G plug. Protein-G was selected due to its binding affinity for human 
IgG 1,2,3, and 4, while having no affinity for human IgA, IgD, IgE and IgM, unlike the 
alternative, protein-A, which does not bind human lgG3and does bind human IgA, IgD, 
IgE and IgM (Akerstrom et ai., 1985). The spin column was centrifuged at 150g for 20 
minutes to allow the HLA-A2 antibody to bind to the protein-G column. The column was 
then washed by loading the column with kit binding buffer (20ml) and by centrifuging 
the column for 5 minutes at 500g, to remove any unbound protein. The bound HLA-A2 
antibody was eluted from the protein-G column via pH elution, by addition of a kit 
elution buffer (10ml) to the column and placing a collection tube containing a kit 
neutralization buffer (1.3ml), beneath the protein-G column to capture the eluted 
protein, prior to the centrifugation of the column for 5 minutes at 500g. The 
neutralisation buffer adjusted the pH of the eluted protein from the column to pH 7.2- 
7.6, to avoid denaturation of the captured antibody upon storage in elution buffer.
The resultant sample was desalted and concentrated using a centrifugal 30,000 M W  
Amicon Ultra-15 filtration device (Millipore, Maine, USA) by loading 15ml of the eluted 
protein and centrifugation at 4000gfor 15 minutes, giving a final concentration of 0.30 
mg/ml of purified protein. (As determined by NanoDrop (Thermo Scientific, Wilmington, 
USA) spectrophotometer, by measuring absorbance at 280nm, with the elution buffer 
being used to correct for background).
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4.2.2 Assessment o f the epitope specificity of the HLA-A2 antibody 
The specificity of the isolated HLA-A2 antibody was assessed by the Luminex platform 
(Luminex, Austin, USA) and Labscreen single antigen HLA Class I HLA beads (referred 
herein as SAB, single antigen beads) (OneLambda, California,USA). The use of the 
Luminex platform and SAB for the detection of HLA antibodies, and their subsequent 
analysis for epitope specificity is highlighted within the 2014 British Society of 
Histocompatibility and Immunogenetics (BSHI) and British Transplant Society (BTS) joint 
guidelines for the detection and characterisation of clinically relevant antibodies in 
allotransplantation
(http://www.bshi.org.uk/BSHI_BTS_Ab_Guidelines_Revision_June_2014.pdf)
4.2.2.1 Luminex solid phase immunoassay basic principles
The Luminex is a solid phase immunoassay (SPI), which utilizes polystyrene beads which 
contain two fluorescent dyes, which emit light at different wavelengths, and are present 
within the beads at different ratios, the use of the dye ratio allows for up to 100 
individual distinguishable bead populations. The surface of the polystyrene beads is 
coated with different recombinant HLA molecules, which act as a target for any HLA 
antibodies in a test serum. Antibody bound to the HLA molecules upon the surface of 
the bead can then be detected by an anti-human IgG antibody conjugated with a third 
fluorescent dye, phycoerythrin (known as a reporter dye). Analysis of the beads upon 
the Luminex platform simultaneously assesses the bead in terms of its internal dye ratio 
and the presence (or otherwise) of the reporter dye, thus allowing the bead identity, 
which was coated with a known HLA antigen/s, and the reactive HLA antibody detected 
by the reporter dye, to be determined. The SAB used within this chapter were coated 
with HLA class I antigens, covering reactivity against HLA-A, B and C antigens.
4.2.2.2 Luminex solid phase immunoassay protocol
Briefly the LABScreen beads (OneLambda, California, USA) were resuspended by repeat
pipetting, then 5pl of LABScreen beads were incubated with 20pl of the purified HLA-A2
antibody in a 96 well filter plate (N.B. the filter plates were pre-wet with kit wash buffer
(OneLambda, California, USA) prior to use) for 30 minutes in the dark (with gentle
shaking on a plate shaker). Post incubation, the 96 well tray was washed by adding kit
wash buffer (150pl per well), sealing with a tray seal and centrifuging at 1300g for 5
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minutes. Wash buffer was removed by vacuum aspiration. This process was repeated 3 
times with 200pl per well of wash buffer for all subsequent washes. lOOpI of PE 
conjugated anti-human IgG was added to each well, which was then covered with a tray 
seal, gently vortexed and incubated in the dark for 30 minutes at room temperature 
with gentle shaking as above. Post-incubation, the 96 well tray was centrifuged at 1300g 
for 5 minutes and the supernatant removed by vacuum aspiration. 200pl of wash buffer 
was added and the tray was sealed and vortexed prior to centrifuging at 1300g for 5 
minutes, the wash buffer was removed by vacuum aspiration as before. This wash step 
was repeated twice. 80pl PBS (Life Technologies, Fulton, UK) (6.8-7.2pH) was added to 
each well ready for acquisition and analysis upon the Luminex platform. Analysis was 
performed on the Luminex LABScan 100 instrument with the reactivity of the purified 
HLA-A2 antibody calculated from raw fluorescence values within the output csv file 
using HLA fusion (OneLambda, California, USA). The reactivity was normalised for 
background binding levels by correcting for bead reactivity to LABScreen negative 
control serum (OneLambda, California, USA), by dividing the reactivity level of a bead by 
the value of the negative control bead, as per the manufacturers' guidelines.
4.2.3 Determination of the eplet specif icity o f the HLA-A2 antibody using 
HLAMatchmaker.
The OIPAIRABSCREEN version of HLAMatchmaker was utilized for the analysis of data 
generated in 4.2.2 The identity of the HLA antigens coated onto the SAB beads, referred 
to as the panel of HLA antigens, was entered into the OIPAIRABSCREEN program, this 
data was derived from the SAB beads specific lot information, which is supplied with the 
beads. The MFI values of the SAB bead reactivity were transferred from the output.csv 
file generated in 4.2.2 by copying and pasting. A positive cut-off of 1000 MFI was used 
according to the criteria for the detection of clinically relevant HLA antibodies in renal 
transplant patients at St James University Hospital, Leeds. No HLA type of the 
immuniser or self HLA type was included in the analysis as this was unknown. The 
reactive eplets were displayed in the resultant HLAMatchmaker eplet results output 
sheet. The results were manually checked, highlighted and sorted to reveal the reactive 
eplets which were shared by any reactive SAB.
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4.2.4 Structural analysis of eplets and modelling the effect of changing the peptide 
sequence upon eplet structure
The Swiss-PdbViewer (http://spdbv.vital-it.ch/download/binaries/SPDBV_4.10_PC.zip) 
(Guex and Peitsch, 1997) was used to visualise the structure of HLA-A2 with the peptide 
bound within the HLA groove, using HLA-A2 structures obtained from the protein 
database (www.ncbi.nlm.nih.gov/protein). The eplets identified in 4.2.3 via 
HLAMatchmaker were visualised using Swiss-PdbViewer, to determine their proximity 
to the peptide and the peptide binding groove. When an eplet was identified as 
proximal to the peptide, the mutation function of the Swiss-PdbViewer program was 
used to mutate the amino acid within the peptide. Ramachandran plots were used to 
visually assess the orientation of the change, in terms of the formation of appropriate 
torsion angles. Any change leading to improbable torsion angles was not analysed 
further and deleted (Hollingsworth and Karplus, 2010). The impact of altering an amino 
acid via the 'mutation' function upon identified eplets was assessed topographically and 
in terms of electrostatic potential and free energy, as previously described for 
comparing epitopes (Kosmoliaptsis eta l., 2011; Duquesnoy et al., 2013). Electrostatic 
energy and free energy was calculated using the Groningen molecular simulation 
computer (GROMOS596) software which is integrated within the Swiss-PdbViewer 
program using Coulomb calculations (Guex and Peitsch, 1997). Solvent accessibility was 
also calculated using the Swiss-PdbViewer program and mapped directly to the surface, 
for rapid assessment of change of amino acid on solvent accessibility, which is used to 
determine antibody accessibility as described within the HLAMatchmaker system for 
determining epitopes (Duquesnoy, 2011a).
4.2.5 Peptide influence on the ability of an eplet to bind its cognate antibody.
To determine if peptides can influence the ability of antibody to bind to its target, the 
peptides, VMAPRTLIL, LLLSGALAL and ALGFYPAEI identified in chapter 2 as being 
capable of binding to HLA-A2, and utilised in the T2 binding assay (figure 2.12 and 2.14 
peptides 7 ,13  and 19 respectively) were used to determine if any of these peptides 
could affect antibody binding to those eplets close to the binding groove (as identified 
in 4.2.4).
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The HLA-A*02 antibody described in 4.2.2 and 4.2.3 was used in conjunction with a 
w 6/32 mouse monoclonal antibody (Abeam, Cambridge, UK). The w 6/32 antibody is 
specific to an epitope located away from the peptide binding groove, upon residue 121 
of the a-chain, proximal to the p2-microglobulin, which is also argued to form a 
functional portion of the epitope (Trayssac eta l., 2012), and therefore will be 
unaffected by changes within the peptide (figure 4.3). Titrations of the purified HLA- 
A*02 antibody were performed to determine antibody saturation levels, the w 6/32  
antibody was used as per the manufacturers' instructions (volumes and concentrations 
are described below).
The ratio of the fluorescence intensity of w 6/32 (FL-2) to HLA-A2 (FL-1) test antibody 
was calculated and any change in the ratio, when altering the peptide sequence, was 
taken to indicate peptide influence over binding by FILA-A2, this was calculated as FL-1 /  
FL-2, such that an increase in ratio indicated stronger binding, while a reduced ratio a 
decrease in binding. Direct measurement of FL-1 as an indication of FILA-A2 binding was 
not possible, as individual peptides stabilise FILA-A2 at different rates (see fluorescence 
intensity values in figures 2.13 and 2.14), which would skew the data if a measurement 
of the FL-1 fluorescence alone was used.
Peptides ALGFYPAEI, VLLLLSAAL, VMAPRTLIL, and the FIA-1 control peptide 
(VLFIDDLLEA) from the T2 binding assay (section 2.2.8), were used to stabilise the T2 cell 
line. Negative controls of DMSO treated and unstabilised T2 cells were also used (as 
described in section 2.2.8). The only alteration to the assay described within chapter 2 
was the addition of the FILA-A2 antibody purified in 4.2.1 and a subsequent detection 
phase. The FILA-A2 antibody was incubated with the T2 cell line together with the 
mouse anti-w6/32 conjugated to phycoerythin (PE), at saturation conditions (20pl of 
FILA-A2 antibody at 20pg/ml and 5pl of w 6/32 (the antibody was supplied pre-diluted) 
per 1x106T2 cells), and incubated for 30 minutes in the dark, before washing twice with 
serum free R PM I1640 media (Life Technologies, Fulton, UK). To detect the bound HLA- 
A2 IgG antibody, a mouse anti-human IgG FITC conjugated.
An Unpaired t-test was used to assess the influence upon antibody binding using 
GraphPad analysis software (GraphPad software, CA, USA).
140
1 4 1
antibody (BD Pharmingen, Oxford, UK) was added at saturation conditions 
(determined by titration to be 25pl per lx lO 6 cells) and incubated for 30 minutes in the 
dark, before washing twice with serum free R PM I1640 media as before. The washed 
cells were then fixed with 0.5% paraformaldehyde ready for analysis. Analysis was 
performed on a FACSCalibur (BD biosciences) with fluorescence measured on the FL-1 
and FL-2 channels.
4.2.6 Reproducibility o f the assays described in chapter 4
All assays were performed a minimum of 3 times. T2 binding assays and flow
cytometric assays were performed in triplicate and repeated at least 3 times.
142
Purification of HLA-A2 antibody 
by protein G
Determination of purified HLA-A2 
antibody epitope reactivity
Structural analysis of identified 
eplets to determine the location 
of the epitopes on the HLA-A2 
molecule
Structural modelling of the effect 
of changing an amino acid within 
the HLA bound peptide upon 
eplets identified on HLA-A2 which 
engage/are proximal to the 
peptide
Functional analysis of the effect 
of changing the peptide bound by 
HLA-A2
•Assessment of reactivity to HLA-A2 by Luminex single 
antigen beads
• .CSV file from Luminex single antigen beads entered into 
HLA matchmaker via import 
•Determination of epitope reactivity using HLA 
Matchmaker eplet system
•Swiss-PdbViewer utilized to assess location of identified 
eplets upon HLA-A2 molecules obtained from the protein 
database
•Swiss-PdbViewer utilized to change appropriate amino 
acids and measure the effect upon eplets generated
•T2 cells loaded with different peptides and the ability of 
antibody to bind when the different peptides are in place 
measured
Figure 4.4 Flow diagram of the work performed in chapter 4
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4.3 Results
4.3.1 Determining antibody specificity towards HLA-A*02
The reactivity of the antibody donated by Dr David Lowe, and then purified, towards 
HLA-A2 was confirmed by analysis upon SAB, using the Luminex platform. A screen 
shot of the Manhattan graph from the HLA fusion software used is shown in figure 4.5. 
Each column in the graph represents a bead within the assay, and the antigens coated 
onto each bead are listed beneath each column, in rows representing HLA-A, B and Cw 
antigens. Visual inspection of the graph reveals the antibody has reacted with beads 
coated with HLA-A2, 69, and B57, 58 antigens, while the rest of the beads coated with 
antigen remain negative, this data was transferred into the HLA matchmaker software.
4.3.2 Identifying epitope reactivity of HLA-A*02 specific antibody
The measure of reactivity against the beads can be seen more clearly in figure 4.6, 
which shows a condensed version of the output file from the HLAMatchmaker 
software. The positive and negative controls produce a reactivity value of 11,908 and 
7 MFI respectively, demonstrating the validity of the assay. Seven beads show positive 
reactions with the purified HLA-A2 antibody, with highest reactivity being observed on 
the three beads present in the assay which are coated with HLA-A2 antigens, 
specifically HLA-A*02:03, 02:01 and 02:06, which had MFI values of 14,743,14,378.5  
and 13,797 respectively. The HLAMatchmaker software revealed that two reactive 
eplets were present upon these antigens, both the 62GE and 107W eplet. Reactivity 
was also observed for the purified HLA-A2 antibody on the HLA-A*69:01 coated bead, 
which possesses a single eplet shared with the HLA-A2 reactive beads, this being the 
107W eplet, the reactivity was lower than for the HLA-A2 beads being 12,198 MFI. The 
final three reactive beads also shared a single reactive eplet with the HLA-A2 reactive 
beads, this being the 62GE eplet present upon the HLA-B*57:03, 58:01 and 59:01. The 
reactivity on these beads was reduced even further, with MFI levels of 3,827, 3,393 
and 2,495 respectively. These epitopes have been previously observed (Mulder eta l., 
2005).
These results confirm the reactivity of the purified HLA-A2 antibody for the HLA-A2 
antigen, and demonstrate the antibody reactivity is directed against two epitopes, 
identified as the 62GE and 107W eplet.
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4.3.3 Identifying the proximity o f the identified epitopes to the HLA bound peptide 
Using the protein database the crystal structures of HLA-A*02 (PDB no. 3D25) were 
visualised in Swiss-PdbViewer, and the eplets 62GE and 107W were analysed for 
proximity to the peptide binding groove (figure 4.7 [A], [B] and [C]).
This reveals that the 62GE eplet is proximal to the peptide bound within HLA-A2. The 
structural modelling in figure 4.7 [A], showing the 3 dimensional structures of the 
peptide and 62GE, appearing to touch each other. The 62GE eplet is identified as being 
upon the side wall of the a-helical peptide binding groove. The 107W eplet however is 
shown as being distant from the peptide binding groove, shown from the top in figure 
4.7 [B], the 107W eplet is located on the side of the HLA-A2 molecule, on the (3-pleated 
sheet outside, the peptide binding groove.
4.3.4 Assessing the variation in antibody binding due to differential peptide bound by 
HLA-A*02
The proximity of the 62GE eplet to the peptide makes 62GE an ideal candidate for 
assessing if any changes within the peptide can influence the ability of peptide to bind. 
The assessment of the anti-HLA-A2 antibody's ability to bind to HLA-A2 when loaded 
with different peptides is shown in figure 4.8. Whereby, the ratios of FL-1 (anti-HLA- 
A2) and FL-2 (w6/32) MFI were used to demonstrate any change in the ability of the 
anti-HLA-A2 antibody to bind. Comparison of the two negative controls, the DMSO 
control and the unstabilized T2 cells, reveal a consistent ratio of around 6, indicating 
the assay has reproducible results. Comparison of the FL1/FL2 ratios of the T2 cells 
loaded with different peptides shows variation within the ratios (figure 4.8). The HA-1 
peptide, which has a sequence ofVLHDDLLEA, has the highest ratio of around 12, 
indicating the greatest antibody binding was observed when this peptide was bound 
by HLA-A2, while peptide 7, with a sequence of VMAPRTLIL demonstrated the weakest 
antibody binding, with a ratio of 8, peptides 13, VLLLLSAAL and 19, ALGFYPAEI, having 
ratios of around 11 and 10 respectively.
The major difference between the two specific peptides which are associated with the 
strongest (the VLHDDLLEA peptide) and weakest (the VMAPRTLIL peptide) HLA-A2
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antibody binding, in terms of the peptide regions which are proximal to the 62GE 
eplet, is seen in peptide residues 2 and 3. Both of these peptides have V (valine) in 
position 1, while the strongest antibody binding was seen when Leu (leucine) and His 
(histidine) were in positions 2 and 3, while the weakest binding was seen when M et 
(methionine) and Ala (alanine) were in position 2 and 3. In peptides 13 (VLLLLSAAL) 
and 19 (ALGFYPAEI), leucine was also seen in position 2. Therefore all the peptides 
which had L in position 2, demonstrated a greater ability to bind the anti-HLA-A2 
antibody, than the peptide with M et in position 2. To determine if a change between 
Met and Leu at position 2 could be responsible for the difference between the 
antibodies ability to bind, structural modelling of HLA-A2 with peptides which were 
identical except for containing Leu, and then M et at position 2 was performed (figures 
4.9 and 4.10).
4.3.5 Structural modelling o f the effect of changing a single amino acid within the HLA 
bound peptide on an epitope proximal to the peptide binding groove 
The structural modelling of the HA-1 peptide containing L at position 2 is shown in 
figure 4.9. The 62GE eplet consists of both glycine (G or Gly) and glutamic acid (E or 
Glu), these amino acids are highlighted within figure 4.9, while the position of 62GE in 
relation to the L amino acid of the peptide can be seen to be separated by another 
amino acid upon the a-chain, a lysine (K) at position 66. The 62GE eplet does not 
appear to be obscured by this amino acid at position 66, in terms of its accessibility to 
be bound by an antibody. The figure also demonstrates the overall electrostatic 
potential of the HLA-A2 molecule bound with HA-1, with Leu in position 2, for 
comparison to the electrostatic potential when M et is in position 2. The distance 
between the Leu and 62GE is 4.081A while in the modelling of 62GE when M et is in 
position 2 (shown in figure 4.10), the distance is reduced to 3.341A. The modelling of 
Met in position 2 also shows that hydrogen bonds are formed between the 62GE eplet 
and the M et amino acid, no hydrogen bonds were visible when Leu was in position 2.
A comparison of the electrostatic potential and total free energy of the glycine and 
glutamic acid residues, which form the 62GE eplet is shown in table 4.2 for both the 
Met and Leu residues within position 2 of the peptide. The data for the M et residue 
shows a decrease in the total energy (E) on both the Gly and Glu amino acid residues 
within the 62GE eplet, with a reduction in total energy of -0.7777 and -2.108 E
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than -1.6, white 0.00 and blue greater than 1.6. The area circled indicates the 62GE -Leu area. Modelled using Swiss-PdbViewer (Guex & Peitsch,
Modelled using Swiss-PdbViewer (Guex & Peitsch, 1997).
Total Energy 
(E) with Met 
at peptide P2
-15.409
(-0.777)
-30.522
(-2.108)
Total Energy 
(E) with Leu 
at peptide P2
-14.632
-28.414
Electrostatic 
Potential 
(kT/e) with 
Met at 
peptide P2
0.00 (0)
11.61 (0)
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respectively. There was no difference in the electrostatic potential for either of the Gly 
or Glu residues when M et or Leu was in position 2.
To determine if any change between the M et and Leu amino acid residues within 
position 2 of the peptide, altered the accessibility of the 62GE eplet to antibody, their 
solvent accessibility was calculated for comparison (figure 4.11).
The solvent accessibility demonstrates no variation between the molecules when they 
have either Leu or M et in the peptide position 2. The area of the 62GE eplet is 
highlighted within the solvent accessibility structure. A sliding scale of colours is used 
to determine the accessibility of solvent into the molecule, blue indicating a 
completely buried residue while red a total exposed residue.
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accessible are coloured red while blue indicates completely buried residues. The circle indicates the 62GE and Leu/Met area.
4.4 Discussion
The purified HLA-A2 antibody was shown to be specific for both the 62GE and 107W  
eplets. The reactivity within the Luminex assay was not limited to HLA-A2 however, but 
the presence of the 62GE eplet on HLA-B*57:03, 58:01 and 59:01 antigens, explains 
the reactivity of beads coated with these antigens within the assay, as does the 
presence of 107W on the HLA-A*69:01 antigen coated bead. Interestingly the 62GE 
and 107W eplets, which are both present on HLA-A2, being present on separate 
antigens (62GE on B*57, 58 and 59 and 107W on A*69) allows for an indication of the 
strength of reactivity to these individual eplets, which cannot be determined from the 
HLA-A2 reactivity alone. The mean reactivity on the beads which had both 62GE and 
107W eplets is 14,309 MFI, which comprises reactivity to both 62GE and 107W. The 
reactivity on the bead coated solely with 107W however was 12,198, much higher than 
the reactivity seen on those beads with only the 62GE eplet (mean MFI 3,238). This 
indicates that the anti-HLA-A2 antibody most likely consists of two anti-HLA-A2 
antibodies, at two different strengths. The first and strongest being reactive to 107W, 
while the second and weaker reactivity being to 62GE. The addition of the individual 
62GE and 107W reactivity from beads with only one of these eplets present gives a 
value similar to that seen on beads which possess both of these eplets.
Mapping the location of these eplets to the surface of FILA-A2, identifies they are 
located at distinctly different sites on the molecule. The 107W being on the side of the 
molecule and distant to the peptide binding groove, and therefore unsuitable for 
assessing the effect of variation within the peptide upon antibody binding. The 62GE 
eplet however, is shown to be on the a-helical wall of the peptide binding groove, and 
therefore would be an ideal candidate to assess if changes within the peptide bound 
within the binding groove, could affect the ability of the antibody to recognise this 
eplet.
The data showing the ratio of the bound HLA-A2 antibody to the bound w 6/32  
antibody, shows that there is a variation in the amount of HLA-A2 antibody bound, 
when the peptides within the HLA-A2 binding groove are changed. However, as 
mentioned within the introduction to this section, the majority of binding of an
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antibody is derived from the 'hot spot7 area (Duquesnoy, 2011a), identified in this case 
as the eplet 62GE, but further binding energy is also provided by the area surrounding 
the 'hot spot7. Therefore the variability in the HLA-A2 antibody binding HLA-A2, when 
different peptides are present, could be due to antibody contact directly with the 
peptide itself as well as to the 62GE eplet. To clarify this further work is required, 
which could encompass the alteration of a single amino acid residue at a time, within 
the peptide bound to HLA-A2 and measurement of antibody binding. Furthermore the 
use of surface plasmon resonance (SPR) to assess the on/off rates of antibodies, when 
different peptides are present within the HLA-A2 binding groove, could be carried out. 
However what the data presented here does demonstrate is that anti-HLA-A2 antibody 
binding, is affected by different peptides being bound within the HLA-A2 molecule, it is 
the specific mechanism however, which is not fully elucidated here.
Interestingly those peptides which have the highest antibody binding ratios (figure 
4.8), all have Leu at position two of the peptide, which fits the reported binding 
characteristics of the HLA-A2 molecule (Paul, 2013), and is observed as a favourable 
amino acid for the HLA class I molecules pocket B (discussed in section 1.1.19) within 
HLA-A2 molecules. Furthermore, another amino acid which reportedly fits the pocket B 
characteristics is M et amino acid residue, which is observed frequently within this 
position from peptides eluted from HLA-A2, although less so than Leu (Paul, 2013).
The reported observation of M et and Leu, as favoured amino acid residues at position 
2 of peptides bound within the HLA-A2 molecule, combined with the data presented 
here showing that the peptides with Leu in position 2 were able to bind more HLA-A2 
antibody than the peptide with M et at position 2. Highlight these two amino acids as 
interesting candidates for affecting the binding of anti-HLA-A2 antibody.
The structural analysis of peptides with Leu or Met at position 2 (figure 4.9, 4.10, and
4.11), and the relative effect upon the 62GE eplet, revealed some interesting findings.
At the closet point between the Leu and 62GE eplet, the distance is measured as
4.08lA, greater than the 3.0A radius HLAMatchmaker uses to generate its eplets
(Duquesnoy and Marrari, 2009), no bond formation is seen between the 62GE and Leu
residue either, in addition a Lys at position 66 appears above both the 62GE and Leu,
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although the 62GE does not appear to be directly obscured by the Lys at position 66, it 
may prevent some interaction between them. Furthermore to some extent this Lys 
could be expected to shield the Leu residue of the peptide to access by a binding 
antibody, due to its presence above the Leu residue side chain.
Changing the Leu to a Met residue however, results in hydrogen bond formation 
between M et and the 62GE eplet. This formation appears to draw the M et residue 
closer to the 62GE eplet, with a distance of 3.341A from the 62GE eplet. The Lys at 
residue 66 is positioned as before, but this time proximal to the M et residue.
Potentially the formation of the hydrogen bonds between Met and 62GE could 
account for the reduced ability of the 62GE specific, purified HLA-A2 antibody, to bind 
its target by drawing it closer to the Lys residue at position 66 and shielding its access 
to 62GE specific antibody. This seems unlikely as the majority of 62GE still appears to 
remain in an antibody accessible position, however to determine any change in 
accessibility more qualitatively, an assessment of solvent accessible residues was 
performed, which revealed no discernible variation in terms of antibody accessibility 
between both the Leu and M et containing peptides.
In an assessment of the Bw6 and Bw4 epitopes, and their ability to bind antibody, 
Kosmoliaptsis and colleagues (2011), determined the electrostatic potential of Bw4 
and Bw6 epitopes upon various HLA-class I molecules and determined that 'changes of 
critical amino acids that abrogate antibody binding also induce distinct changes in 
epitope electrostatic potential'. These concepts were used to investigate the binding of 
the purified HLA-A2 antibody to the 62GE eplet.
A comparison of the electrostatic potential of the Gly and Glu residues, which form the 
62GE eplet, with Leu and then M et present at position 2 of the peptide, revealed no 
variation within the electrostatic potential. However the electrostatic potential 
calculations performed by the Swiss-PdbViewer utilizes Coulomb calculations, which 
are reportedly less sensitive than the Poisson-Boltzmann calculations (Guex and 
Peitsch, 1997) performed by the DELPHI program used by Kosmoliaptsis eta l., (2011), 
and therefore may not be sensitive enough to measure any change. However the 
additional sensitivity of the Poisson-Boltzmann calculations is derived from their ability
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to consider the influence of buried residues within the protein (Guex and Peitsch, 
1997), which may be of a lesser significance here, since both the peptide bound by 
HLA-A2 and the 62GE eplet are present at the protein surface.
Recently, a measure of total free energy has been shown to influence not only the 
ability of an HLA specific antibody to bind, but also the subsequent ability of this 
antibody firstly to bind Clq, and secondly, to initiate the complement cascade 
(Duquesnoy et al., 2013). It is interesting to note then that the total free energy 
calculated for the Gly and Glu amino acid residues of the 62GE eplet varies dependent 
upon whether Leu or Met is in position 2 of the peptide bound by the HLA-A2 
molecule, with a reduction of total energy when M et is present in comparison to Leu. 
This could be a result of the formation of the hydrogen bonds when M et is present, 
which would require energy, and therefore less energy is available for antibody 
binding. Whether this could explain the reduction in the ability of anti-HLA-A2 
antibody to bind is uncertain, and most likely results from a combination of different 
factors, including reduction in available total energy. An alternative hypothesis could 
also be developed from the Duquesnoy et al., (2013) paper.
Duquesnoy describes the function of other epitopes, which are within a region of 
around 6-15A of the epitope to which the antibody is specific. Clearly this would 
include much of the peptide, which would be expected to fall within a 6-15A region of 
the 62GE eplet (figures 4.9 and 4.10). These epitopes within 6-15A of the 62GE eplet 
are capable of providing variation within free energy, depending upon their 
composition and therefore may influence antibody binding and function. This has not 
been assessed within the structural modelling carried out here, but offers another 
explanation for the variation in HLA-A2 (62GE) antibody binding, observed when the 
peptide loaded onto HLA-A2 is altered within the T2 binding assay.
The impact of the variation in antibody binding as a result of different peptides being 
bound to the HLA molecule is potentially multifaceted, with implications for the  
detection of antibodies by routinely employed methodologies within H+l laboratories, 
as different peptides may be present in different manufacturers solid phase assay HLA 
antibody detection kits (Duquesnoy et al., 2013), while in a clinical context different
159
minor histocompatibility antigens could change the ability of antibodies to bind to 
their target, such that the same antibody could have a different clinical relevance in 
different individuals.
In summary, chapter 4 has highlighted that peptides are not only capable of inducing 
alloreactivity through their influence upon the TCR, but also could affect humoral 
responses through their ability to affect antibody binding to the allograft.
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Current concepts concerning the role of peptides within the processes of T cell 
selection and the establishment of central tolerance, as well as the key role played by 
peptides in the TCR-pHLA interaction are an area of intense research. Peptides are 
also fundamental to the function of HLA molecules and are crucial to their formation 
within the HLA-Class I and Class II processing and presentation pathways. Thus, an 
appropriate response to pathogens while maintaining a tolerance of self, 
fundamentally involves peptides as well as HLA molecules and the TCR.
In the context of allotransplantation, the roles of peptides within allorecognition 
demonstrates a fundamental role for peptides, including mHAGs, within 
allorecognition. Of most interest in the context of this thesis, is the significant 
association of HLA mismatching on the outcome of allotransplantation, and the role of 
peptides derived from the HLA molecules themselves.
The experimental work in chapter 2, investigated the identification of peptides derived 
from HLA molecules, which could have an influence upon the alloresponse, as a 
consequence of their presentation by another HLA molecule. This was achieved by the 
creation of a comprehensive database of peptides predicted to bind to HLA-A*02. Due 
to the differential binding properties of HLA molecules themselves, limiting the 
database to HLA-A*02 was necessary. This produced a database of peptides predicted 
to bind to HLA-A*02 from each of the HLA class I amino acid sequences listed within 
the IMGT/HLA database.
This database was then utilized to identify peptides bound by HLA-A*02, with the HLA- 
A*02 molecules being obtained from the THP-1 monocytic cell line. Through the use of 
MS/MS sequencing and the database of peptides which were predicted to bind to HLA- 
A*02, two peptides, which were derived from the other HLA molecules expressed 
upon THP-1 cells, and were bound and presented by the HLA-A*02 molecule, were 
identified. These were peptides ALGFYPAEI and VMAPRTLIL, encoded for within the 
HLA type present on THP-1 cells (Battle et al., 2012), specifically within HLA-B*15 and 
HLA-C*03 HLA molecules respectively.
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The consequence of this in a transplant setting is that matching for donor and recipient 
HLA-A*02 antigens, while having a mismatch on the donor cells of B*15 and/or HLA- 
C*03 would allow for a recipient's HLA-A*02 restricted T cells, to bind the donor HLA- 
A*02 molecule, complexed with the ALGFYPAEI or VMAPRTLIL peptide, since the 
recipient's TCR would not have experienced the ALGFYPAEI or VMAPRTLIL peptide 
complexed with self HLA-A*02 during development in the thymus, thus it would have 
the potential to form a response.
Significantly HLA-B*15 and FILA-C*03 are not the only HLA molecules to encode 
ALGFYPAEI or VMAPRTLIL, the database of peptides generated within chapter 2 also 
shows that HLA-A*01, A*03, A * l l ,  A*23, A*24, A*30; B*18, B*27, B*35, B*38, B*39, 
B*40, B*41, B*42, B*44, B*45, B*46, B*47, B*48, B*49, B*50, B*51, B*52, B*53, B*54, 
B*55, B*56, B*57 alleles encode for ALGFYPAEI, while HLA-C*01, C*04, C*05, C*06, 
C*08, C*12, C*14, C*16, C*17:02 alleles encode VMAPRTLIL. The significance of this is 
that mismatches of each of these molecules would be expected to generate the same 
HLA-A*02 and ALGFYPAEI or VMAPRTLIL bound peptide. However, if the recipient also 
possessed one of the other HLA molecules which encoded for the peptide, then this 
potential to generate an alloresponse, as a consequence of the peptide, would be null, 
as they would possess an HLA type which included the peptide, and thus T cells 
expressing TCR specific for this self peptide/HLA would have been eliminated in the 
thymus, as self reactive T cells.
These principles can be proposed analogous to Duquesnoy's system of determining 
acceptable mismatches, by the identification of epitopes thoughout an HLA type, 
(Duquesnoy, 2011a), whereby instead of comparing whether a donor and recipient 
share the same HLA molecules, comparison of whether the donor and recipient HLA 
molecules share the same epitopes is assesed via the HLAMatchmaker program, these 
epitopes are not neccessarily on the same HLA molecules. Using this logic to 
demonstrate the significance of the work initiated within chapter 2, an HLA molecule 
could be seen as a group of peptides capable of being bound by other HLA molecules, 
some of these peptides will be shared between HLA molecules and others not, 
allowing the identifcation of permissible peptide mismatches, and identifying potential 
alloreactive peptide mismatches.
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Clearly the work undertaken in chapter 2 can only be seen as the first steps in this 
approach, and a significant amount of further work needs to be performed. In the first 
instance, peptides obtained from HLA-A2 expressed in conjunction with other HLA 
antigens needs assessing, allowing the database of HLA-A*02 encoded alleles, which 
can present peptides obtained from HLA molecules which were not expressed on THP- 
1 to be examined. Subsequent to this work the database needs expanding for the 
prediction of peptides which bind to HLA molecules other than HLA-A2.
To acheive this a significant amount of further work needs to be performed, however 
this is not as insurmountable as it first appears. Due to the knowledge that although 
HLA molecules are extensively polymorphic, the HLA molecules can be thought of as 
being highly polymorphic in specific areas, whilst conserved in others (figure 1.9). This 
has the effect of generating peptides which are of identical sequences from the non 
polymorphic areas, limiting the number of peptides which require analysis. 
Furthermore, many of the polymorphic sites are shared between some HLA alleles, 
indeed the ALGFYPAEI peptide identified within chapter 2 was encoded for by over 25 
groups of HLA class I alleles.
The peptides derived from non-polymorphic areas should not however be dismissed as 
unable to generate alloresponses, as, if these conserved peptides are presented by a 
mismatched HLA molecule, which therefore the recipient has not experienced during 
the establishment of central tolerance, and this presentation produces novel epitopes 
as a consequence of variation in the binding of the peptide, due to different properties 
of the peptide binding groove; then these conserved peptides can also be thought of 
as having an alloreactive potential.
These concepts can bethought of as an extension of the multiple binary complex 
theory, in which, donor peptides which are derived from homologous intracellular 
proteins, which are also present within the recipient, have a different set of peptides 
presented from the same intracellular proteins, due to variation in the recipient and 
donor's HLA binding grooves (Bharat and Mohanakumar, 2007).
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It is most likely that a combination of peptide related alloresponses are responsible for 
direct recognition, rather than the single concept outlined in the multiple binary 
complex theory. This combination would include the peptides generated as described 
by the multiple binary complex theory, with the addition of the presentation of 
peptides derived from mismatched HLA and presented by matched HLA, as described 
in chapter 2, and the presentation of the homologous peptides in a different manner 
to that experienced during central tolerance, due to variation in the peptide binding 
groove. Perhaps a more appropriate collective term for these processes is abating 
negative selection, in which the negative selection process of central tolerance is 
reduced in its amount, degree and intensity. In support of this more comprehensive 
description of the involvement of peptides in direct allorecognition is the obeservation 
that central tolerance can be re-established post transplant by the intrathyminc 
injection of peptides (Oluwole et al., 2001), and more recently that a chimeric state in 
renal transplant recipients by simultaneous HSCT has been shown to be capable of 
providing an environment suitable for renal allograft survival, without maintenance 
immunosuppression (Kawai e ta l., 2008). The proposed mechanism of tolerance 
following chimerism has been suggested to be the elimination of 'reactive cells within 
the thymus which are reactive to donor antigen1 (Kawai et al., 2008). Essentially re­
establishing central tolerance, or described another way, removing the impact of 
abated negative selection by re-establishing it with the presence of donor antigens.
In further work, the impact of the formation of HLA-A*02 molecules complexed with
HLA derived peptides, to which a recipient does not encode any antigens for, should be
examined in a functional setting. The presence of T cells, which are reactive to HLA-
A*02 possessing these specific peptides could be assessed post transplant in peptide
mismatched patients. For example, in a post transplant setting, where the recipient
and donor both possess HLA-A*02 molecules, while the donor also expresses the
VMAPRTLIL peptide encoded for by HLA-C*03 and the recipient does not possess
another VMAPRTLIL encoding HLA allele, the patients' post transplant CD8+ cells could
be stained with HLA tetramers specifically targeting HLA-A*02/ VMAPRTLIL complexes,
allowing any CD8+ positive cells with a TCR reactive to the HLA-A*02/ VMAPRTLIL
complexes to be identified. Once identified, these cells could then be interogated in
terms of their function via intracellular cytokine staining and the cell surface markers
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present. Such work could identify the presence of surface expression of CD69+, an 
activation marker on CD8+ T cells, while the cytokine profiles of these cells, may further 
elucidate the mechanisms of allograft damage. The examination of post transplant 
patients for the non-classical HLA-E molecules complexed with specific peptides using 
tetramers has already been performed within the literature (Allard eta l., 2012) 
validating this approach to some extent.
The leader peptide sequences of HLA are of particular interest, with only one of the 
comprehensive list of leader peptide sequences identified within chapter 2, 
demonstrated as being able to be bound to by HLA-A*02 however. This was confirmed 
both by binding studies using the T2 cell line, as well as it being identified amongst the 
peptides bound to the HLA-A*02 molecule encoded on the THP-1 cell line itself. The 
identification of the leader peptide VMAPRTLIL within chapter 2 initiated the work 
undertaken in chapter 3. As novel functions have previously been reported for leader 
peptides such as VMAPRTLIL, in that they are crucial for the formation of HLA-E and 
their function with NK cell receptors NKG2/CD94 (Petrie et at., 2008).
Given that leader peptides, as shown within chapter 2, can be bound by HLA class I 
molecules (in this case HLA-A*02) and therefore be presented to CD8+ T cells, and that 
they also form a part of a crucial ligand for NK cell receptors. They therefore cross both 
the innate and adaptive immune responses and are an interesting target for 
investigating the role of peptide mismatching within the transplant setting.
The effect of mismatching of HLA class I derived leader peptides was performed within 
chapter 3 via the assessment of the clinical impact of their mismatches within a cohort 
of renal transplant patients. A search of the literature indicates this represents the first 
time a group of endogenously derived peptides had been assessed in such a manner, 
although the need for the assessment of such peptides in the setting of 
allotransplantation has been identified previously (D'Orsonga eta l., 2013). The 
assessment of HLA class I derived leader peptide sequence mismatches, demonstrated 
a striking relationship between a reduction in renal allograft function, as assessed by A 
creatinine, with an increase in the number of mismatches. This function appeared to 
be independent of HLA matching (Battle et al., 2013). Scrutiny of the work within
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chapter 3 reveals several areas for further work. Firstly, the cohort of patients analysed 
here was relatively small, this is of particular significance when data analysis focuses 
on the level of the leader peptide mismatches within specific HLA matched groups, 
such as the ODT matching level. A larger validating cohort of patients should now be 
assessed to validate this data and confirm the findings within chapter 3. By increasing 
the size of the cohort, the confounding influence which affected the work assessing 
the effect of leader peptide mismatches in NHSBT ODT level 3 matched groups may be 
limited.
Secondly, the exact mechanism by which the leader peptide mismatching is exerting 
this effect also needs investigating. In the first instance this work could be performed 
in conjunction with the additional work required from chapter 2. In that tetramer 
staining of post transplant recipient cells for potential HLA leader peptide binding 
targets, specifically HLA-E and mismatched HLA antigens could be performed, and if 
the presence of any cells responding to these specific antigens are identified, then they 
could be interrogated in terms of their function and cytokine profiles, as described for 
the further work outlined within chapter 2. Although the effect of presentation of 
leader peptides via HLA class I molecules directly to CD8+ cells will most likely generate 
alloresponses as described earlier, the evidence within the literature (Tamouza et al., 
2006; Danzer eta l., 2009; Hosseini etal., 2013; Hoare etal., 2008; Battle eta l., 2013) 
already supports the concept of a strong influence of HLA-E bound leader peptide 
mismatching upon the A creatinine levels described in chapter 3.
The literature reports the presence of HLA-E restricted effector memory cells in
patients who are infected with the CMV AD169 virus, which encodes a homologous
leader peptide sequence to maintain HLA-E surface expression, as part of an
immunoevasion strategy (Mazzarino et al., 2005). The effector memory cells being
detected only in patients who possess different leader peptide sequences in their HLA
type to the one CMV is mimicking (Mazzarino et al., 2005), and can thus effectively
target and kill the viral infection. This demonstrates the specificity of the mechanism
by which leader peptides can exert allograft damage, in that instead of CMV
introducing a leader peptide sequence to which a response is formed, the leader
peptides are introduced via the allograft. Essentially the further work using HLA
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tetramers, described above, is similar to that work carried out on CMV infection 
(Mazzarino et al., 2005), except that responses to mismatched leader peptides on the 
allograft would be assessed, instead of mismatched CMV leader peptide immune- 
evasion strategies, in terms of their ability to generate responses.
Considering concepts which relate, instead of to HLA-E presentation to CD8+cells, but 
to the involvement of HLA-E and innate immune responses to allografts. HLA-E 
interaction with CD94/NKG2 receptors, as described in chapter 3, has been shown to 
be affected by the affinity of leader peptides to HLA-E (Hoare et al., 2008). This affinity 
alters the ability to be bound by HLA-E and has a direct effect upon the expression 
level of HLA-E (Vales-Gomez et al., 1999), and therefore changes within peptides which 
have different binding affinities would be expected to alter surface expression of HLA- 
E, and thus alter the ability of HLA-E to interact with the CD94/NKG2 
activating/inhibiting receptors.
It is interesting to note then that the data in chapter 3 demonstrates that A creatinine 
levels increase, when the leader peptide mismatches are amongst those leader 
peptides which are reported to have different affinities for HLA-E, such as HLA-B 
derived leader peptides, while in those reported as having the same affinity for HLA-E, 
such as HLA-A derived leader peptides (Hoare etal., 2008; Lee et al., 1998; Lemberg et 
al., 2001; Vales-Gomez et al., 1999), there appeared to be no change in A creatinine 
levels. This data strongly indicates that the innate responses generated by HLA-E have 
a role within the influence of HLA class I leader peptide derived mismatches and the 
performance of renal allografts, within the first 12 months post transplant (Battle et 
al., 2013). Again this work needs replicating with a much larger cohort of patients, 
however another intriguing observation in the literature, which indicates the affinity of 
leader peptide to HLA-E, may contribute significantly to the results described in 
chapter 3, is the association with the HLA-E*01:03 allele with reduced TRM post HSCT. 
The HLA-E*01:03 is expressed at a much higher level than its counterpart HLA-E*01:01, 
and the explanation for the reduced TRM with HLA-E*01:03, being the increased 
availability of HLA-E*01:03 to bind to inactivating CD94/NKG2 receptors (Hosseini et 
al., 2013). This data then does not directly involve leader peptides but demonstrates
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that expression of HLA-E, which is a function of the leader peptide's ability to bind to 
HLA-E, has an influence upon HSCT outcome.
The work in chapter 3, again highlights the complex nature of peptides in the 
formation of alloresponses, and draws attention to a group of peptides, HLA class I 
derived leader peptides, as an interesting target for further work.
Chapter 4 focused upon another mechanism by which peptides could influence the 
response to allografts, specifically by looking at the role of peptides on the binding of 
HLA specific antibodies to their target epitope. After obtaining and purifying an HLA- 
A*02 specific antibody, analysis of the antibody's ability to bind to HLA-A*02 on theT2  
cell line was shown to vary depending upon the peptide which was bound. Reports 
within the literature demonstrate that antibodies can be peptide specific (Hulsmeyer 
et al., 2004) so perhaps this finding is not surprising. However such a peptide specific 
antibody would have several implications in the setting of allotransplantation. Firstly 
many laboratories supporting transplant programs rely on commercially available kits 
to detect HLA antibodies, within potential transplant recipients, often going to 
transplant without a pre-transplant crossmatch where appropriate. The ability to 
detect any peptide specific HLA antibodies using these techniques is unknown, but 
given that these kits use recombinant HLA as the target antigens (Susal et al., 2013), it 
is likely that the peptides, which are bound to the HLA groove are derived from 
proteins which are not representative of those expressed on the allograft. To some 
degree this would also be true in a crossmatch, as the T and B lymphocytes used in a 
crossmatch, although not expressing recombinant proteins, would not be expected to 
express the same proteins as upon a transplanted kidney or heart. However, the donor 
derived T and B lymphocytes used in crossmatching would be more likely to represent 
donor antigens than the recombinant HLA used within the often used luminex assays 
(Susal etal., 2013).
No such peptide specific antibodies were identified within chapter 4, however the 
observation that changes within the peptide can influence specific antibody binding, 
resulting in a greater or lesser amount of antibody binding, may still be of importance 
in the detection of antibodies within patients awaiting allotransplantation, for example
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a different peptide being bound to the HLA molecules within the test assay's HLA 
antigens, to those expressed upon the transplanted tissue in a recipient means that, an 
antibody has the potential to bind with different affinity in the test to within the 
transplanted tissue. Given that current concepts in the understanding of alloantibody 
reactivity now includes the observation that binding affinity, and available free energy 
of particular epitopes, can affect the ability of an antibody to bind, fix complement and 
activate the complement cascade (Duquesnoy eta l., 2013), then changes within the 
peptides could be expected to induce changes within the antibody functions.
Although the structural modelling undertaken in chapter 4 did not discern the 
functional impact of any observed changes, this work was able to demonstrate that 
peptides induced conformational variation within epitopes (Battle eta l., 2014), and 
also produced a modest variation within the free energy of the amino acids, which 
comprised an epitope proximal to the peptide binding groove, namely 62GE.
The work undertaken in chapter 4 then, allows a greater understanding of the 
potential impact of HLA bound peptides on the ability of HLA antibodies to bind their 
target, while chapter 3 identifies that HLA derived peptides, specifically the HLA class I 
derived leader peptides, have an impact upon renal allograft function in the first 12 
months post transplant when mismatched. These investigations and findings however 
would not have been possible if considerable effort had not been undertaken within 
chapter 2, to establish a database of HLA class I derived peptides, which were capable 
of being bound by HLA-A*02 molecules.
The overall output from this thesis emphasises the potential role of peptides in the 
alloimmune response, with the concept of abated negative selection tentatively 
introduced as a holistic term, for the description of the effect of changing the 
peptidome, through the introduction of novel proteins through transplantation, and 
the variation in presentation of peptides introduced via transplantation. This 
knowledge gives new insights into the matching of HLA types in the context of renal 
transplantation.
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Identified HLA class I epitopes can undergo con- 'S
formational induced variation due to changes ' o '  "
within HLA bound peptides
HLA specific antibodies have a significant im pa rt upon renal 
allotransplantation. Preformed alloantibodies prevent or com­
plicate transplants between otherwise compatible donors and 
recipients 111 and de novo post transplant antibodies are associated 
w ith  poorer overall allograft survival |2|.The identification of such 
antibodies and their subsequent characterisation in terms o f their 
specific target, has been the focus o f much investigation since the 
association o f preformed HLA antibodies and hyperacute rejection 
was first established over 40 years ago 131.
Current concepts in identifying and characterising HLA specific 
antibodies no longer focus upon broad definitions o f antigenic tar­
gets, such as anti-HLA-Al, A2, A3 etc., but instead attempt to define 
the specific epitope target o f the HLA antibody upon each HLA 
molecule |4.5|. This process has further developed the concepts of 
cross-reactive epitope groups (CREG), whereby antibodies demon­
strate reactivity against differing HLA antigens which possess the
same structural motifs or epitopes. Several researchers have pre­
cisely identified the specific epitopes present upon HLA class I and 
class II molecules against which reactivity is directed [4.5|. This 
allows the expected profile o f antigenic reactivity o f an HLA anti­
body elicited by exposure to an individual antigen, to be predicted 
w ith  high confidence, and explains why lim ited exposure can some­
times result in extensive sensitisation.
Most recently this concept has been taken further, showing 
that the electrostatic potential o f epitopes |l>| and their available 
free energy, required to stabilise antigen-antibody complexes, has 
a fundamental role in the consequences o f antibody binding, in 
terms o f the ability to bind Cl q and subsequently activate the com­
plement cascade |7|. A further complexity is introduced by the 
variable nature o f the peptide bound w ith in  the groove o f the HLA 
molecule. In some cases these peptides are also considered to con­
tribute critical contact sites for antibodies and are believed capable 
o f generating their own epitopes 17|.
Our group is particularly interested in the role o f HLA bound 
peptides in the generation o f the alloresponse, be it  cellular or 
humoral. In experimentation to examine how changing the bound
Fig. t .  The interaction of the 62GE epitope and the amino acid at peptide i’2. (A) The 62CE eplet in pink and LEU in red. the distance between these at their closest point 
is shown (in  yellow ) as being 4.081 A. (B) 62GE is shown in pink and MET is shown in red. the distance between the two is shown in yellow (3.341 A). Green dotted lines 
indicate the formation o f hydrogen bounds. The solid green line represents a LYS at position 66 of the o-chain in both (A and B). (fo r  interpretation of the references to color 
in this figure legend, the reader is referred to rhe web version o f this article.)
http; //d xd o i o r  * / 10.1016/l- imlet .2014 04.016 
0165 2 4 7 8 /0  2014 Elsevier B.V. All rights reserved.
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peplide w ould affect the ability of a HLA specific antibody to 
bind to an otherwise identical HLA target, w e observed the vari­
ation reported by other investigators |8 |. However rather than the 
concepts previously postulated for this observation, namely cru­
cial contact sites being present upon the peptide |7 |, we believe, 
through structural modelling in silico, that changes w ith in  the 
nature o f the HLA bound peptide directly influences epitopes which  
are present upon the HLA molecules themselves, via  conforma­
tional induced epitope variation. W e utilised the protein databank 
(PdB) |9| and the PdB-Swissviewer (10) to analyse the introduction 
of specific am ino acid substitutions upon peptides bound w ith in  the 
HLA molecule, and assessed the im pact o f these substitutions upon 
previously defined epitopes proximal to the peptide, in terms of 
electrostatic potential, total energy and any visible conformational 
change. W e identified that the common HLA-A*02:01 encoded epi­
tope 62GE, formed additional hydrogen bonds w ith  the peptide 
when the am ino acid w ith in  peptide position P2 was changed from  
LEU to MET, in a HLA-A2 molecule bound w ith  the HA-1 peptide. 
The position o f the 62GE epitope relative to the P2 peptide am ino  
acid was altered as a result o f this substitution; the distance being 
4.018 A for 62GEand LEU (Fig. 1A), but 3.341 A when MET was in 
position P2 (Fig. IB). Furthermore, the total available energy for 
binding was reduced in the 62GE epitope. The energy loss was 
spread across both am ino acids w ith in  62GE, w ith  a change of 
-1 4 .6 3 2  to -1 5 .4 0 9  total energy for GLY, and -2 8 .4 1 4  to -3 0 .5 2 2  
total energy for GLU. How these changes functionally relate to  the 
ability of antibody to bind to the 62GE epitope requires further elu­
cidation in terms of the effect upon strength o f binding, the ability  
to bind C lq  and to activate the com plem ent cascade. However our 
observation 16,7) does demonstrate that changes w ith in  the bound 
peptide are capable o f altering structural epitopes of HLA w hich  
have been demonstrated as key components of antibody binding 
14-7)
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The relationship of HLA-class I derived leader peptide 
mismatch and renal function within the first 12 months 
post-renal transplant
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Key w o rds : endogenous peptides; human leukocyte antigen class-1 leadei peptides: kidney transplantation
In a recent review  a rtic le , D ’ O rsogna et al. describe the 
latest insights and c lin ica l im p lica tions o f  endogenous- 
peptide-dependent a llo re a c tiv ily  (1). A rg u ing  that T -cc ll 
a llo recogn ition  is h igh ly  lik e ly  to be endogenous peptide spe­
c if ic ,  and that, non-T-ce ll lineage lym phocyte populations, 
such as natural k il le r  (N K ) and B cells, cou ld  also be reliant 
on peptide b inding and presentation in the fo rm a tion  o f  
allorcsponscs. The authors slate that ‘de fin ition  o f  specific 
endogenous peptide targets fo r a llo recogn ition  should be a 
m ajo r focus fo r  transplantation research’ .
We concu r w ith  the authors regarding the im portance 
o f  endogenous peptides in the fo rm a tion  o f  a va riety o f  
alloresponses, and have been assessing the c lin ica l im pact o f  
a group o f  endogenous peptides in the context o f  a llog ra ft 
function  post-renal transplantation.
S p ecifica lly  wc have been assessing the im pact o f  leader 
peptide sequences o f  hum an leukocyte  antigen (H L A )  class I 
molecules. These are re la tive ly  conserved regions o f  the H L A  
class 1 a-chain w h ich tire cleaved fro m  the m olecule at an 
ea rly  tim cpo in t w ith in  H L A  class 1 m olecu le assembly, and 
arc consequently present at a h igh in trace llu la r abundance. 
Wc and others (2) have shown that H L A  class I-de rived 
leader sequences can themselves be presented by H L A  class 
I m olecules, and w ould  thus p rovide a target fo r  C D 8 +  
T  lym phocytes. A d d it io n a lly , H L A  class l-d c r ivcd  leader 
sequences have been shown to  be c rucia l fo r  the fo rm a tion  o f
the C D 94 /N K G 2 activa tin g /inh ib iting  receptors ligand, H L A - 
E (3, 4). These leader peptides, then, arc capable o f  p rov id ing  
an innate and adaptive antigenic dete rm inan t w h ich may fo rm  
a target fo r alloresponses.
In add itional evidence fo r  the im m uno log ica l im po rtance o f  
H L A  class l-dc r ivcd  leader peptides in alloresponses; several 
cy tom egalovirus (C M V ) strains have been shown to em ploy 
an im m uno-evasion strategy by encoding a H L A  class I- 
derived leader peptide hom ologue (.“5). Fu rtherm ore cross­
recognition by C D 8 +  T  cells, responding to a hom ologue 
encoding C M V  strain, to H L A -E  com plcxcd w ith  the H L A  
class l-dc r ivcd  leader sequence has been observed in an 
a llo recogn ition  selling (6).
G iven the remarkable antigenic potential o f  these pep­
tides, w c sought to investigate i f  mismatches o f  H L A  
class l-de rived leader sequences between dono r and recip ­
ient renal transplant pairs in fluenced renal a llog ra ft pe rfo r­
mance w ith in  the first 12 months post-transplant. O u r srudy 
coho rt com prised 139 consecutive renal transplant re c ip i­
ents. M ean age 41.8 (±17 .81  SD ), sex 5 4 F /8 4 M , 50 had 
a n ti-H L A -Ig G  o f  w h ich  three we re dono r specific an tibod­
ies, 77 kidneys were from  donation fo llo w in g  b ra in  stem 
death, 20 cardiac death and 42 were from  liv e  donors. 
National Health Service B lood and Transplant, O rgan Dona­
tion and T ransplantation (N H S B T  O D T ) m atch ing levels 
were 11.5% level I,  28.8%  level 2, 40.3%  leve l 3 and 
19.4% level 4. Mean creatinine levels post-transplant were
A creatin ine  (from  3 to  12 m onths) post tra n sp lan t and  
re la tio n sh ip  to  leader pep tide m ism atch
30
20
0 Leader MM (n45)
1 Leader MM (n54) 
■  2  Leader MM (n33)
3  Leader MM (r>8)
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Figure 1 The relationship o f human leukocyte 
antigen (HLA) class I de rived leader sequence 
m ismatch and A  creatinine post transplant 
Confidence intervals o f 95% are shown.
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Figure 2 Relationship of human leukocyte anti- 
ger). (HLA) class l-derived leader sequence mis­
match upon creatinine within NHSBT ODT match­
ing groups, confidence intervals of 95% aro 
shown.
Effect of leader peptide mismatch within NHSBT ODT matching levels
b  ODT matching
level t (n11)
ODT matching
level 2 (rvtO)
a  ODT matching
lovol 3 (n55)
XW3- 3 loader mm ODT matching 
level 4 (n27)
135 mmol/1 (±60.9SD) at 3 months and 131 mmol/1 (±54.4 
SD) at 12 months. To determine the H LA class I-derived 
leader sequence matching between donor and recipient pairs, 
we utilised the HLA/1GMT database to Identify the encoded 
amino acid sequence of the leader sequence; found at position 
3—11 of the class I a-chain amino acid residues (4), for 
all listed class I  alleles (n  >  6000). Wc then created a key 
allowing a patient, or donor HLA type, to be searched to 
reveal their H IA  class l-dcrivcd leader sequence. In total we 
identified 11 H I .A class T-derived lender sequences fmm the 
HLA/1MGT database. We then compared the level of leader 
mismatch to A  creatinine calculated from 3 to 12 months with . 
outputs as shown in Figure 1.
This identified a striking relationship of leader peptide mm 
with A creatinine, and a statistically significant association 
for 0 leader mm vs 3 leader mm patients (P  =  <0.05).
. Furthermore, as shown in Figure 2 this influence was seen 
within patients and donors grouped according to NHSBT 
ODT HLA matching levels, indicating that our observations 
were not merely a function of coincidental HLA mismatching. 
We believe that this is the first example of the effect of 
multiple endogenous peptide mismatches upon renal allograft 
functional outcome in a clinical setting, and that it provides 
some of. the requirements for the definition of endogenous 
peptides highlighted by D'Qrsogna and colleagues. Work is 
ongoing to further elucidate and characterise the role of leader 
peptides as targets of alloncacljyc responses..
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Molecular characterisation of the monocytic cell line THP-1 
demonstrates a discrepancy with the documented HLA type
Richard Battle1,2, Katherine Poole2, Sarah Haywood-Small1, Brendan Clark2 and.M. Nicola Woodroofe1-
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Dear Editor.
The use of the acute monocytic leukemia cell line, THP-1, 
has been well documented since its establishment was 
reported more than 30 years ago in the IJC1 Since then, the 
THP-1 cell line has been used in countless research papers 
and is now a widely recognized resource as a model of 
monocyte cells within the immunology and . oncology 
research communities.
. Routinely applied good cell culture, practice of THP-1, as 
well as all other cell lines, requires quality assurance of the 
cell line, including assessment of relevant phenotypes and ge­
notypes, state of differentiation and the assessment o f:any 
possible crosscontamination.2 In line with these requirements, 
our recent use of the THP-1 cell line revealed an inconsistency 
with the reported Human Leukocyte Antigen (HLA) type 
. which may have potential consequences for some researchers. ' 
’ • Initially THP-1 was recovered from our bank of frozen 
cell lines and cultured in RPMI 1640 medium (5% Petal Calf. 
Serum (FCS), 200 mM t-Glut, 100 pg/ml Pen/Strep) before 
HLA typing for HLA class I A and B, and the HLA class II 
DR and DQ antigens, via commercially available serological 
typing trays. These serological typing trays represent the con­
temporary equivalent of the assay used .to determine the 
. HLA type of THP-1 when the cell line was established.1 The 
• results of these assays conclusively identified HLA-A2. 
"Weak” reactions against other class I antigens and cfoss- 
rcactivity, particularly between HLA-B5 and B15 antisera, 
confounded the identification of a full HLA-A and B type. 
The HLA dass II antigens were entirely inconclusive.
Since the THP-1 cell line was established in 1980, there 
. l>ave been marked advances within the detection methodolo- 
: gies used to determine HLA types, most notably the devclop- 
. ment of molecular biology-based techniques, such as the 
polymerase chain reaction (PCR). Therefore, to determine a 
conclusive HLA type for the THP-1 cell line, an "in-house” 
PCR using sequence specific primers (PCR-SSP) was per­
formed for HLA-A*, B \ C*. DRB1\ DRB3*, DRB4*, DRB5* 
and DQBl* genes. In addition, an ABO group was deter­
mined using a similar method. Both of these in-house geno- 
typing systems are based on methods which have been previ­
ously published.2'4
Using this assay, we identified the following HLA type for 
THP-1. HLA-A*02; B*15; C*03; DRBl'Ol, DRB1'15; 
DRB5*01/02; DQBl’OS and DQBl*06 (and : ABO blood 
. group genotype BB).
The.reported HLA type for THP-1 is HLA-A2, A9, B5, 
DRwl and DRw2. (The HLA nomenclature system used here 
corresponds to the contemporary system at the time THP-1 
was established in 1980).1
Clearly the HLA dass I type did not correspond to the 
reported HLA type for THP-1, differing at the HLA class 1 A 
and B Iod (to our knowledge IILA-C* has not previously 
been reported for THP-1).
The HLA class II  type corresponded to the original HLA 
type of HLA-DRwl and DRw2, being DRB1*01 and 
DRB1*15. The expressed product of the HLA-DRB1*15 allele 
represents a split of the DR2 antigen and demonstrates the 
increased resolving capabilities of the PCR-SSP assay in com­
parison to the serological technique, (again to our knowledge 
HLA-DQB1* has not previously been reported). In contrast 
.to the reported type, THP-1 appeared to be homozygous at 
the HLA-A, B and C loci by PCR-SSP. . .
.Alterations in the HLA dass I phenotype of malignant 
cells is a frequent event during cancer progression, allowing 
tumor cells to evade the immune system. Indeed, loss of. one 
major histocompatibility complex dass I  haplotype in human 
melanoma cells has been shown not only to allow evasion of 
immunosurvcillance* but also to increase their intrinsic onco­
genic potential1* The mechanisms which lead to HLA class I 
alterations can occur at any Step required for HLA synthesis. 
Most commonly, the,alteration represents a structural defect 
or a regulator)' defect on the transcriptional levd.5 Such alter­
ations would not interfere with the PCR-SSP method used 
here, although a rarer deletion event upon chromosome. 6 
would be undetectable. ' ■
In addition the "missing” class 1 HLA antigens from the 
original report show strong crossreactivity with the confirmed 
HLA type, and most likely account for this discrepancy, 
indeed our serological assay also demonstrated crossreactivity 
at the HLA-B5 and B15 antigens, which were proved errone­
ous by the PCR-SSP. ’
Interestingly, the HLA-B*15 identified within tire haplo­
type HLA-A"02; B*15; C*03, is unusual in itself, corresponding 
to die serological equivalent of B75 (15). The PCR-SSP was ca­
pable of resolving the B*15 allele to B*15;08 or B* 15:11.
A search on die Allele* Frequencies in World Populations 
\vebsite7 for each of these alleles revealed their frequency 
widiin specific populations. Of the two alleles B*15:l 1 
appeared to be the more common, as, although extremely 
rare within the majority of, populations, it is seen in the
k
Asian Pacific Islander population.8 The HLA-B* 15:11 allele 
would therefore correlate with the reported ethnic origin of 
the THP-1 cell line.'
In order to confirm these findings and eliminate the pos­
sibility that our frozen THP-1 cells were incorrectly identi­
fied as such, a frozen vial o f THP-1 cells was ordered from- 
the American- Type Culture Collection (ATCC), ATCC 
Number TIB-202™ The ATCC THP-1 cell line depositor 
was the author of the original paper identifying the develop­
ment of the cell line.1 The ATCC-supplicd THP-1 cells 
were HLA typed as described above, by both serology and 
PCIl-SSP.
The determination of the ATOC-supplied THP-1 HLA type 
confirmed our original findings from our frozen stock supply, 
for both serological and molecular assays. The THP-1 HLA 
type therefore is not, HLA-A2, A9; B5; DRwl and DRw2 as 
reported. Hie correct type being, HLA-A'02; 11*15; C*03; 
DRBrOl, DRB1*15; DRB5‘01/02; DQBl'05, DQB1*06.
This discrepancy is not extraordinary when considering 
• the assay systems originally used to determine the THP-1 
HLA type. Indeed the error rate for HLA-B antigen assign­
ment by serology has previously been demonstrated to be as 
high as 22.5% when compared to DNA based typing.9 
Greater precision has also been shown for PCR-SSP HLA 
typing in comparison to serological typing for both HLA-A10 
and HLA-DR.11
Further HLA typing to determine which HLA-B* 15 allele/ 
s were present on THP-1 was carried out using commercial 
high resolution HLA-A and B typing kits. The results of 
these tests confirmed the presence o f HLA-B*15:11, as the 
frequency data had suggested. The HLA-B*15:11 allele has 
also previously been documented to be hi association with 
C*03:03, as it is here in THP-1.
In conclusion, we present here a revised HLA type for 
THP-1 using molecular-based typing methods, this type 
being HLA-A*02; B*15; C’03; DRBl‘01, DRBI*15; DRB5*01/ 
02; DQB1*05, DQBl*06. The presence of the HLA-B*15:11 
allele was also confirmed within this type.
H ie homozygosity of the HLA class I antigens could per­
haps represent a mechanism by which the leukemic cells 
•evaded detection within the individual from whom the THP- 
1 cell line was established, following a deletion event.5 This 
tumour escape mechanism may have possibly arisen from the 
selective pressure of a patient-specific graft-versws-lcukaemia 
reaction,12 although it is unknown if the patient received a 
haematopoietic stem cell transplant -prior to THP-1 being 
developed from their leukemic cells.1 However, this cannot 
be investigated further due to the lack of normal autologous 
leukocytes.
It should be noted that the revised type presented here 
confirms the utility of THP-1 cells in coculture assays with 
HLA-A*02-cxpressing responder cells, as described recently 
in this journal.15 However, due to HLA restriction, the use of 
THP-1 cells in coculture with HLA-B*05-expressing re­
sponder cells would produce false negative results and there­
fore should be avoided.
Yours sincerely, 
Richard Battle 
Katherine Poole 
Sarah Haywood-Small 
Brendan Clark 
M. Nicola Woodroofe
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